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Metabolic syndrome
Metabolic syndrome (MetS) refers to a cluster of risk factors for type 2 diabetes (T2D), cardiovascular 
disease (CVD) and stroke (Figure 1) that are strongly associated with the Western life style1,2,3,4. This 
life style is a result of the overwhelming and readily available supply of high-energy food that can be 
consumed at relatively low cost in westernized societies and is characterized by excess food intake 
and limited physical exercise. The term syndrome implies a complex etiology and this is confirmed by 
the variety of definitions for MetS that have been formulated over the years (Table 1). 
 The concept of MetS has been recognized for at least 80 years and during this period the syndrome 
has been (re)defined several times. MetS was introduced for the first time in the 1920s by the Swedish 
clinician Eskil Kylin5. Kylin discovered that several individual risk factors for CVD, like hypertension, 
obesity, hyperglycemia and dyslipidemia, tend to cluster. Such individual risk factors are still 
considered part of MetS and involve an increased risk for T2D, CVD and stroke. However, other 
components such as urinary albumin content and different measures for obesity like body mass index 
(BMI) or waist to hip ratio (WHR) can be considered determinants for the diagnosis of MetS. Systemic 
inflammation is widely regarded as associated with MetS, but is not part of any MetS definition. Table 
1 presents four different MetS definitions which were formulated over the last decade. Alternative 
definitions of MetS have been developed, such as the definition of the American Association of Clinical 
Endocrinologists (AACE), and these are more focused on diabetes and insulin resistance6,7,8. Applying 
the different criteria to a single data 
set will lead to different patients being 
classified as MetS
 The International Diabetes 
Federation MetS definition (2006) 
includes central obesity as an essential 
component for the manifestation of the 
syndrome. The obligatory presence of 
obesity in this definition is driven by the 
observed strong association between 
excess energy intake over expenditure 
and MetS. As such, obesity is a clear 
indication that excess energy intake 
has taken place for some period of time 
in an individual.
Energy homeostasis
In the fasting state, the body relies on the production of glucose and lipids by the liver for the supply of 
energy to peripheral organs. The brain requires glucose while skeletal and heart muscle can also utilize 
fatty acids (FA) as substrates for oxidation. Glucose is secreted directly into the blood and FA’s are 
packaged into VLDL particles after secretion by adipose tissue or liver in the form of triglycerides (TG).
 Upon ingestion of a meal composed of lipids and carbohydrates, the body will respond by producing 
a variety of hormones and neuronal signals which cause the system to switch the system from a 




















Fig. 1: Schematic representation of biologically relevant components contributing to the 
metabolic syndrome (MetS): Obesity, Hyperglycemia, Hypertension, Dyslipidemia and Systemic 
inflammation. The latter component is virtually absent in MetS definitions. MetS refers to a 




absorbed in the blood. 
Lipids are converted 
to chylomicrons and 
enter the blood via the 
lymph. The production of 
insulin by the pancreas is 
considered as the most 
metabolically important 
hormone signal. Insulin 
secretion is prompted 
by the relatively rapid 
increase in plasma 
glucose. Insulin represses 
the secretion of glucose 
by the liver and increases 
the uptake of glucose 
by adipose and muscle 
tissue. Insulin also 
represses the secretion of 
VLDL by the liver. 
 From an evolutionary 
perspective, the system 
is exquisitely suited 
to ensure survival of 
prolonged periods of 
chronic food deprivation, 
but seems much less 
suited to deal with chronic over consumption. A chronic excess intake of energy leads to obesity and 
is associated with low grade inflammation, disturbances in both glucose and lipid metabolism and 
high blood pressure. These aspects of MetS are discussed in detail below. In addition to quantity, 
the quality of the food plays a role in the development of pathology. For example, the Mediterranean 
diet has been associated with less pathology presumably due to the increased dietary levels of 
unsaturated FA inherent to a high intake of olive oil and fish9,10. The mechanism of excess of food 
intake leading to MetS is under debate. Although most of the processes that are involved are not 
disputed to play a role in MetS, their relative contribution and the sequence of events leading to 
MetS are the source of the debate. These processes and their overlaps are shown in Figure 1.
Pathophysiology of the metabolic syndrome 
Obesity
A misbalance between energy intake and expenditure is thought to be the cause of the current increase 
in prevalence of MetS11,12. Although obesity may not be the first pathological metabolic consequence of 
excess food intake, its presence does prove that, for a prolonged period of time, there has been higher 
Table 1 Four metabolic syndrome definitions
    WHO (1999)  EGSIR (1999)  ATPIII (2001) IDF (2006)a
Components (N) b  2 + OGTT   2 + IR     3        2 + WC
_ WC (cm)   -     ≥ 94       >102      ≥ 94  
_ WC (cm)   -     ≥ 80       > 88       ≥ 80 
BMI (kg/m2)   > 30 c          -        -
_ WHR    > 0.9 c          -        -
_ WHR    > 0.85 c          -        -
FPG (mmol/L)   -     ≥ 6.0      ≥ 6.1      ≥ 5.6 d,f
AE (_g/min)   ≥ 20   -       -        -
OGTT    < glucose 25% -       -        -
IR    -     > insulin 25% c -        -
SBP (mm Hg)   > 140    ≥ 140      ≥ 135 e     ≥ 130 e
DBP (mm Hg)   > 90    ≥ 90       ≥ 85 e     ≥ 85 e
_ HDL-C (mmol/L)  < 0.9 g   < 1.0       < 1.0      < 1.03 g
_ HDL-C (mmol/L)  < 1.0 g   < 1.0      < 1.3       < 1.29 g
TG (mmol/L)   ≥ 1.7 g   ≥ 2.0      ≥ 1.7      ≥ 1.7 g
WHO; World Health Organization, EGSIR; European Group for the study of Insulin Resistance, IDF; 
International diabetes federation, ATPIII; National Education Control Panel Adult Treatment Panel III. 
a Europids. b Minimal composition of components required for diagnosis MetS. WC; waist circumference, 
BMI; body mass Index, WHR; waist to hip ratio; FPG; fasting plasma glucose, AE; albumin excretion, 
OGTT; oral glucose tolerance test, IR; insulin resistant, SBP; systolic blood pressure, DBP; diastolic blood 
pressure, HDL-C; HDL-cholesterol, TG; total plasma triglycerides., c BMI or WHR, d top 25% of fasting 
insulin values from non-diabetic population, e pharmacological treated hypertensive patients included, 
f pharmacological treated type 2 diabetes patients included, g pharmacological treated dyslipidemic 
patients included. 
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energy intake than is required for expenditure has taken place. Expansion of adipose tissue requires 
an increased influx of FA, but also extensive tissue proliferation and remodeling including precursor 
cell differentiation, extracellular matrix breakdown and neovascularization. Excess adipose tissue is 
also associated with increased effluxes of FA and altered function of the adipose tissue itself. 
 In the definitions of MetS in Table 1, obesity is defined by a threshold BMI or WC. The major difference 
between these two obesity measures is the focus on body composition (BMI) versus central obesity 
(WC) and the corresponding risk for MetS. BMI is the most widely used general measure for obesity 
and is defined by the ratio of weight and squared height (kg/m2). Because BMI involves the total 
sum of bone, fat and muscle mass, it does not make a distinction between specific fat depots. WC 
specifically measures central obesity. Although WC is more region specific than BMI, WC measures 
the total sum of visceral and subcutaneous fat depots and does not distinguish between these two 
functionally different fat depots. Alternatively, body composition can be expressed as waist to hip 
ratio (WHR) and is defined by the ratio between specific fat depots in hip and waist. This measure is 
generally used to distinguish between the benign pear-shaped overweight individuals and the more 
pathogenic apple-shaped overweight individuals. As an isolated measure, WHR does not actually 
represent the level of obesity. 
Adipose tissue
It is generally accepted that adipose tissue functions as an endocrine organ and can respond to 
neuronal and hormonal input by secreting biologically active substances in addition to FA, namely 
adipocytokines or adipokines. Chronic disturbances in the endocrine function of adipose tissue clearly 
play a role in the pathology associated with MetS. In this respect, the different adipose tissue depots, 
such as visceral and subcutaneous fat, are not each other’s equivalent in terms of the production and 
secretion of adipokines13. Visceral fat directly drains on the portal vein, and is thus likely to have a 
much more direct signaling and metabolic relation with the liver in comparison to subcutaneous fat.
The adipokine family can be divided in two types of signaling molecules, namely those with a 
metabolic/immunological function, which include interleukins 1β, 6, 8, 10 or 18, tumor necrosis factor 
alpha (TNF-α) and transcription growth factor beta (TGF-β), and those with an endocrine function, 
which include leptin, retinol binding protein-4 (RBP-4), adiponectin and resistin. All adipokines are 
thought to affect many different tissues throughout the body, including liver, gall bladder, skeletal 
muscle, brain and pancreas. 
 The metabolic/immunological adipokines are, in general, pro-inflammatory and positively 
associated with obesity and trigger a response which results in infiltration of immune cells, such as 
macrophages. Macrophages are involved in the clearance of all forms of debris, including dead cells, 
but are themselves also a source of pro-inflammatory cytokines. Once macrophages are abundant in 
adipose tissue, they maintain the inflammatory state of the adipose tissue in a vicious circle, which 
results in chronic systemic low-grade inflammation. This inflammatory state is far less severe than 
pathogen-induced inflammation14,15. 
 The adipokines with endocrine function do not only affect the liver, skeletal muscle and pancreas, 
but also the central nervous system (CNS)16. The adipokine leptin affects the arcuate nucleus in the 
brain, which is involved in the regulation of appetite and energy expenditure. Increased plasma 
leptin functions as a signal of increased adipose tissue mass. As such leptin is, potentially, an ideal 
weight loss hormone. However, obesity is associated with leptin resistance limiting the use in 
13
weight reduction17,18. The adipokines resistin and adiponectin are negatively associated with adipose 
tissue mass and insulin sensitivity, whereas RBP-4 is positively associated with adipose tissue mass 
and insulin sensitivity19,20,21,22,23,24. The precise role of the adipokines resistin and adiponectin in the 
development of obesity and insulin resistance remains to be fully characterized. The role of RBP-4 
in the manifestation of T2D seems to involve a secondary mechanism25. Still, in animal intervention 
studies it has been shown that modulation of adipokine levels can determine the development of 
insulin resistance24,16. Although pharmacological interventions in patients that improve insulin 
sensitivity clearly ameliorate plasma adipokine levels, interventions that are directly aimed at 
adipokines have yet to be performed26.
Hyperglycemia 
Hyperglycemia is defined by elevated levels of fasting plasma glucose. The threshold values of 
these levels vary between the different MetS definitions (Table 1). Hyperglycemia is thought to be 
characterized by insulin resistance (IR). IR is defined as an impaired response of a specific process or 
organ to insulin. In a normal physiological state, insulin suppresses glucose production by the liver 
and increases glucose uptake by peripheral organs such as muscle and fat. As a consequence of IR, 
plasma insulin levels increase to achieve normal plasma glucose levels27. 
 Many physiological and pathological processes have been identified that can modulate the 
response of cells to insulin and thus affect insulin sensitivity. These processes include nutritional 
status, circadian rhythms, inflammation, ER stress and intracellular lipid levels28,29,30,31. A current 
important challenge lies in the understanding of the integration of these (patho) physiological 
processes in the development of insulin resistance. 
 Hyperglycemia is generally defined as T2D when fasting plasma glucose levels consistently rise 
up to 7 mmol/L. T2D is a specific risk factor for retinopathy, neuropathy and nephropathy32. The 
progression of insulin resistance to diabetes is thought to result from the chronic nature of the 
triggers that induce insulin resistance. It seems more than likely that as time progresses, some of 
these triggers exacerbate as a consequence of aging-induced changes, i.e. hormonal status and 
physical activity. At some point, the insulin resistance may fail to be compensated by increased insulin 
secretion, resulting in failure of the glucose homeostasis and thus in hyperglycemia. Since high levels 
of glucose are cytotoxic, the hyperglycemia will contribute further to the overall deterioration of the 
system. Eventually, this vicious cycle may progress to pancreatic beta-cell deterioration, at which 
point the diabetic state has become irreversible. 
 It should be noted that the threshold levels for fasting hyperglycemia in the various definitions 
of MetS (5.6-6.1 mM/L, Table 1), are all below the accepted level that is considered to be minimal for 
treatment (>7.0 mM/L). 
Dyslipidemia 
The dyslipidemia associated with MetS is defined by hypertriglyceridemia and low HDL-cholesterol levels. 
Both have been identified as risk factors for cardiovascular disease33 and especially hypertriglyceridemia 
is a target for drugs aimed at CVD prevention. These drugs include fibrates, which act mainly via the 
nuclear receptor PPAR-alpha. Similar to hyperglycemia, the level of hypertriglyceridemia required for 
MetS diagnosis is well below the level required for pharmacological intervention.
general introduction
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The lipids TG and cholesterol are transported via lipoproteins in the blood. After a meal, food derived 
TG and cholesterol are packaged into chylomicrons in the intestine and secreted via the lymph into 
the circulation. The main fate of the TG in chylomicrons is lipolysis in peripheral muscle and storage 
in fat. In the fasting state, TG and cholesterol are transported from the liver to the periphery via 
very-low-density-lipoprotein particles (VLDL). Once chylomicrons and VLDL are depleted of TG, 
their remnants are cleared by the liver. A fraction of VLDL remnants progresses to be metabolized in 
cholesterol-rich LDL particles. LDL particles are specific transporters of cholesterol to the periphery 
and LDL cholesterol is a well defined risk factor for CVD. A separate lipoprotein, HDL, is responsible 
for cholesterol transport from the periphery to the liver, which is referred to as reverse cholesterol 
transport. High levels of HDL cholesterol are associated with low levels of CVD34,35.
 From epidemiological studies it is well known that plasma TG and HDL-cholesterol are highly 
correlated inversely. The enzyme Cholesterol-Ester Transfer Protein (CETP) balances the levels of 
TG and HDL-cholesterol and is thus responsible for the mutual exchange of TG and cholesterol ester 
between apoB-containing lipoproteins (chylomicrons, VLDL and LDL) and HDL. It has been suggested 
that CETP activity explains some of the high TG levels and low HDL levels, observed in persons with 
MetS36.
It has recently been hypothesized that hepatic insulin resistance of glucose and lipid metabolism 
may be differentially affected in persons with MetS. In individuals with MetS, insulin-mediated 
suppression of hepatic glucose output may be decreased, but insulin-mediated stimulation of de 
novo lipogenesis may be increased. This will result in increased hepatic lipid accumulation, increased 
VLDL production and thus ensuing hypertriglyceridemia37,38.
Hypertension
Hypertension is characterized by chronically elevated systolic (SBP) and/or diastolic (DBP) blood 
pressure. The diagnosis hypertension can be subdivided in two types: primary hypertension, which 
involves an unknown cause or origin and secondary hypertension, which involves a known cause 
or origin. Threshold values for hypertension within the different MetS definitions differ slightly 
(Table 1). For diastolic blood pressure this threshold range between 85-90 mm Hg and for systolic 
blood pressure the threshold ranges between 135-140 mm Hg. The increased blood pressure found in 
persons with MetS is in general of unknown cause (primary hypertension). Similar to the previously 
discussed MetS traits, the threshold for hypertension in the definition of MetS is well below the level 
that requires pharmacological treatment.
 The exact cause for the increased blood pressure associated with MetS is not known but there is 
evidence suggesting that genetic predisposition plays an important role. However, it has also been 
suggested that MetS components hyperglycemia, dyslipidemia and low grade systemic inflammation 
affect the functioning of the vascular endothelium. A dysfunctional endothelium will not properly 
respond to physiological stimuli that increase NO production, an important signaling molecule 
involved in vascular contraction-relaxation and subsequent hypertension39. Such mechanism may 
occur independently of a joint genetic etiology.
 Alternatively, mild hypertension may be involved in the etiology of MetS in that hypertension can 
contribute to the presence of MetS as an independent risk factor. Especially when hypertension is 
the consequence of endothelial dysfunction not directly associated with MetS (i.e. genetic factors 
or smoking), this endothelial dysfunction may, in turn, affect blood supply to organs and thus affect 
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tissue function. Insulin sensitivity of the blood supply to adipose tissue, muscle and liver is an 
important regulator of glucose and fat fluxes.
Inflammation
Low grade systemic inflammation and/or hepatic inflammation are generally not included in 
MetS definitions. However, in addition to the inflammation associated with adipose tissue as 
discussed above, hepatic inflammation is also strongly associated with MetS14,15. Markers such as 
C-reactive protein, several hepatic enzymes like alanine aminotransferase (ALAT) and aspartate 
aminotransferase (ASAT) and cytokines like IL-6 can serve as determinants (biomarkers) of the 
inflammatory state40. Hepatic inflammation associated with MetS but not due to excessive alcohol 
intake is termed non-alcoholic steatohepatitis (NASH). NASH is thought to be a consequence of 
hepatic lipid accumulation. NASH is also characterized by hepatic insulin resistance. As discussed 
above, the differential insulin resistance of hepatic glucose output and hepatic de novo lipogenesis 
may explain the development of NASH in individuals with MetS. This explanation is attractive in its 
simplicity, but remains to be thoroughly investigated and confirmed. For example, the specific triggers 
that lead from lipid accumulation to inflammation remain to be fully characterized. Moreover, the 
role of immune cells, such as macrophages, in relation to the inflammatory state of the hepatocyte 
remains to be characterized.
 As discussed above, the low grade systemic inflammation has been hypothesized to present a 
continuous insult to the endothelium, leading to endothelial cell dysfunction and abnormal blood 
pressure regulation. The loss of cell function can also extend to the endothelial barrier. When the 
endothelial barrier function is compromised, LDL and other potentially harmful substances may 
enter the sub-endothelial space more easily and trigger an inflammatory response. The chronic 
accumulation of LDL, subsequent oxidation of LDL and uptake by invading macrophages leads to foam 
cell formation, which is considered the first step in the development of an atherosclerotic plaque. As 
such, chronic low grade inflammation, hypertension and dyslipidemia all represent chronic triggers 
for the development of atherosclerosis34,41,42.
Epidemiology of the metabolic syndrome and its components
Prevalence of MetS
The prevalence of MetS has increased dramatically over the last decades in societies with a Western 
lifestyle. In the US, studies have shown that the prevalence of MetS in adults and, in particular, in 
adolescents and female adults was growing constantly over the years 1984 to 2000. In this time 
frame, the prevalence of MetS in adults ranged from approximately 25% to 30%, and in it adolescents 
ranged from approximately 4% to 9%, with a higher prevalence in males than in females43,44,45. In 
Europe, studies in the general Caucasian population of the prevalence of the metabolic syndrome 
are scarcer and quite diverse due to different study methods. For example, the prevalence of MetS 
among healthy French families ranged from approximately 7% to 9%46, whereas the prevalence in an 
urban and rural German population ranged from 20% to 40%47. Although consistent and comparable 
information about the increase of the prevalence of the metabolic syndrome in European is scarce, 
there is no doubt that the prevalence of metabolic components such as obesity and hyperglycemia 
general introduction
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is increasing in Europe48,49,50. The macro-economic consequences but also individual morbidity and 
mortality associated with an increase in the prevalence of MetS, are substantial51,52.
Prevalence of overweight and obesity
In westernized countries the prevalence of overweight and obesity has increased dramatically over 
the last few decades53,54,55,56. A particularly worrying development is the rise in the manifestation of 
overweight and obesity in young children and adolescents57. In 2002, the prevalence of overweight 
(BMI ≥ 25 kg/m2) or obesity (BMI ≥ 30 kg/m2) in young US children, adolescents and adults, exceeded 
the astonishing level of 60%. In a time span of approximately 25 years, a 25% increase of overweight 
was seen in children from age 6 to 11 58. In the period 1997-2001, the prevalence of European obese 
children between 13 and 17 years old ranged, in general, from 10 to 15%. However, in Greek children 
the prevalence of obesity was much higher, at 22 to 30%59,57. 
 The prevalence of overweight and obesity in the Dutch population is carefully monitored by 
the “Centaal Bureau voor Statistiek” (CBS; http://www.cbs.nl) and by the “Rijksinstituut voor 
Volksgezondheid en Milieu” (RIVM; http://www.rivm.nl). These studies are cross sectional and 
prospective and include males and females, children and adolescents. Figure 2 illustrates the cross 
sectional increase of the prevalence of overweight in the Dutch population between 1987 and 2007. 
The mean prevalence of overweight in Dutch adults (>20 years old) increased from 33% in 1983 to 
45% in 2007. 
 The prevalence of overweight (BMI>25 kg/m2) and/or obesity (BMI>30 kg/m2) in Dutch men and 
women (age> 20 years old) rose with 10% in the timeframe of 1981 to 2007. In general, the prevalence 
in men is approximately 10% 
higher than in women. The 
prevalence of obesity alone in 
this timeframe rose from 4% 
to 10% in women and from 
6% to 12% in men. In Dutch 
adolescents, a similar increase 
of the prevalence of overweight 
is seen. Especially in children / 
adolescents (age > 8 years old) 
the prevalence of overweight 
increased by approximately 10% 
between the years 1997 and 2004 











Fig. 2: Prevalence of overweight in Dutch population in the periods between 1987-1989 and 2004-
2007. Prevalence adjusted for gender and age. source: CBS 
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Prevalence of hyperglycemia
The prevalence of hyperglycemia as entity in general populations is mainly monitored by the 
prevalence of diabetes mellitus (fasting plasma glucose > 7mM/L). However, within MetS an 
impaired glucose metabolism is diagnosed using a variety of measurements (see Table 1). There are 
large differences in the definition of impaired glucose metabolism between the four MetS definitions. 
The WHO uses the oral glucose tolerance test (OGTT), whereas the EGSIR includes fasting plasma 
glucose or the top 25% of fasting insulin values from the (non-diabetic) population. Both the NCEP 
ATPIII and IDF use fasting plasma glucose levels, though with different thresholds. The choice of 
such a parameter is a matter of availability (within clinics), cost-efficiency and personal preference. 
The outcome of epidemiological studies of the presence of impaired glucose metabolism and MetS 
are affected by these methodological differences.
 The increase of the prevalence of hyperglycemia or T2D is as dramatic as the increase of the 
prevalence of obesity58,60. In 2007 the incidence of diagnosed T2D in the general US population 
was 5.9%. It should be noted that about 2% of the population was estimated to be suffering from 
undiagnosed diabetes (source: National Diabetes Information Clearinghouse: NCDIC; http://diabtes.
niddk.nih.gov/DM/PUBS/statistics).
 The prevalence of hyperglycemia (fasting plasma glucose > 6.1, T2D included) was monitored in two 
cross-sectional Dutch cohorts, the MORGEN and PREVEND studies61. The prevalence of hyperglycemia 
ranged between 5%-20% in men and 3%-9% in women. The age of the individuals in these studies 
ranged from 28 to 59 years old. The overall incidence of T2D in 2007, as monitored by the RIVM (http://
www.rivm.nl), was approximately 4.5%. The incidence of T2D in the Dutch population has increased in 
the last decade. Between 1990 and 2007, the incidence of T2D increased by approximately 50% in men 
and 40% in women. However, it should be noted that in addition to the increase of obesity, the increase 
in average age of the Dutch population also contributes to this increase of the prevalence of T2D.
 Although T2D is typically a late onset disease, the increasing incidence of T2D is also seen in young 
children and adolescents57. The prevalence of T2D or other rare forms of diabetes among US children 
ranged between 1-2%. In the last decade however, several reports have indicated an increase of 
incidence of up to 50% of newly identified non immune-mediated diabetes in US young children62. 
In Europe the increase in the prevalence of T2D in children is limited63. Recently a prevalence of T2D 
or impaired glucose tolerance of 2.5% was reported in German children with a low socioeconomic 
status64. 
Prevalence of dyslipidemia 
Two of the 5 traits defining the metabolic syndrome are dyslipidemias, namely high TG and low HDL-
cholesterol. These traits are not independent, since high TG and low HDL are strongly correlated. This 
correlation may be caused by the activity of the enzyme Cholesteryl Ester Transfer Protein (CETP), 
as discussed above65,36. The prevalence of HTG (> 1.7 mM/L) in the MORGEN and PREVEND studies, 
ranged between 13% in women and 24% to 29% in men (age ranging from 28 to 59 years old)61. The 
prevalence of low HDL-cholesterol (men <1.0 and women <1.3 mM/L) ranged between 28% and 36% 
in the MORGEN and PREVEND studies61. 
 Both high TG and low HDL are classical risk factors for CVD and stroke66. However, the other 
classical lipid risk factor for CVD and stroke, LDL-cholesterol, is not part of the definition of the 
general introduction
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metabolic syndrome. This is due to the independent association of LDL cholesterol with CVD/stroke 
risk. High levels of plasma LDL-cholesterol do not consistently cluster with other components of 
MetS, such as obesity and insulin sensitivity. In some cases, a specific genetic cause (Familial Hyper 
cholesterolemia; FH) lies at the basis of this particular impairment67.
Prevalence of hypertension
Similar to T2D, hypertension is a late onset and common disease in the general population. 
Hypertension in the general adult US population shows a prevalence of approximately 25 up to 36% 
(SBP ≥ 140 mm Hg and DBP ≥ 90mm Hg or use of medication, reported from 1988 to 1998)68,44. This 
prevalence of hypertension in general USA adults increased up to 41% in the period between 1999-
200044. In general, other countries show lower percentages of hypertension68,69. The prevalence of 
hypertension (according to NCEP ATPIII, see Table1) in the MORGEN and PREVEND studies, ranged 
between 42% and 44% in men and from 21% to 26% in women (age ranging from 28 to 59 years old)61.
 Analogous to hyperglycemia, dyslipidemia and hyperglycemia, many hypertensive patients are not 
aware that they are suffering from elevated blood pressure. 45% of US adults in the period between 
1988 and 1993 were not aware of their elevated blood pressure. Hypertension develops gradually 
and eventually does result in overt problems in the patient. Since anti-hypertension medication is 
generally prescribed life long and may have unwanted side-effects, a large proportion of patients 
does not adhere to therapy; 29% of US adults suffering from hypertension in the period between 1988 
and 1993 did not adhere properly to therapy68,70. 
Approaches in genetic epidemiology
Introduction to genetic epidemiology
Genetic diseases can be divided in disorders with a monogenic inheritance pattern and disorder 
with a complex inheritance pattern. Monogenic disorders show autosomal or X-linked dominant or 
recessive inheritance patterns. Complex disorders are characterized by inheritance patterns where 
only some of the mutation carriers are affected. This is referred to as reduced penetrance. In complex 
disorders, environmental variables or additional genetic factors contribute to the manifestation of 
the disease. For the genetic part, this means that multiple genes and interactions may contribute to 
the disease according to a threshold model. 
 An example of a monogenetic x-linked recessive disorder is Duchenne muscle dystrophy (DMD). 
DMD is characterized by a progressive dystrophy of skeletal muscles and eventual respiratory or 
heart failure. The genetic basis of this neuralmuscular disorder lies, in general, in a disrupted reading 
frame in the dystrophin gene (Xp21) caused by nucleotide insertions or deletions of variable length. 
Such disruption of the reading frame results in a truncated (dysfunctional) or absent dystophin 
protein71. An example of a complex disorder is the disease hyperlipidemia (HLP) type III, which is 
characterized by elevated plasma levels of VLDL triglyceride and cholesterol. In the last 3 decades, 
researchers have found that patients suffering from HLP type III were predominantly homozygote 
carriers of the apoE2 protein variant. Since homozygosity of this variant is mainly present in healthy 
controls, this metabolic disorder is characterized by a reduced penetrance. Functional analyses 
indicated that apoE2 has a defect in binding to the hepatic LDL receptor and is thus poorly cleared 
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from the circulation72,73,74. In addition, a number of rare variants of apoE have been identified that 
contribute to the expression of type III HLP or HTG75,76. Family analyses of these variants revealed 
clear co-segregation of disease and variant and these variants were completely absent from healthy 
controls. This provided convincing evidence for causation of disease, which was confirmed by in vivo 
analyses in transgenic mouse models77,78. Thus, monogenic disorders are completely or predominantly 
caused by variations in one single gene. In contrast, complex disorders result from joint effects of 
multiple genetic -and environmental causes with each factor having only a minor contribution to the 
expression of the disease79. 
 In general, two methods are available for the identification of loci involving monogenetic or complex 
diseases and these are illustrated in 
Figure 3. Linkage analysis is a family 
based method and was the first robust 
method in genetic epidemiology. The 
second method is association analysis 
which is based on cases and controls 
or quantitative trait analysis. Both 
methods are described below with 
regard to their design and statistical 
power in the following sections. 
Linkage analysis 
Early techniques which made large scale genotyping possible enabled a novel strategy for the 
identification of disease loci, namely large scale linkage analysis. This type of analysis is based on 
the characterization of a large number of short tandem repeats (STRs) or micro-satellites distributed 
over the genome. At present, large genotyping platforms involving SNPs are also used in linkage 
analysis, as described in the section below. 
 Linkage analysis focuses on chromosomal regions that are transmitted to diseased offspring more 
often than expected. Linkage analysis is based on the fact that particular loci do not show independent 
inheritance patterns. This means that between such loci the probability of recombination approaches 
0 within a family of closely related subjects. This phenomenon of linked loci is also called linkage80. 
Linkage analysis is thus a family-based approach where the segregation of the disease within the 
families can be linked to a specific chromosome region (locus). Linkage analysis was and still is a 
robust method to identify novel disease loci. After determining the chromosomal location of the causal 
gene, these loci often contain multiple interesting genes with regard to the disease of interest. The 
most interesting genes overlap or involve a certain pathway which is impaired in the disease. These 
are called “candidate genes”. The method for validation or replication of the involvement of such 
candidate genes in the disease is described in the section “validation and replication”. In addition, 
new pathways not implicated earlier in the disease may also be discovered. Linkage analysis can 
be performed with a relatively small number of samples and genotypes. Nevertheless, information 









Fig. 3: Two main types of cohorts with regards ro feasible typs of analyses in genetic 
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Genome wide association 
Family based genome wide linkage analysis is especially powerful for the detection of association of 
rare genetic variants with rare diseases, since large chromosomal regions are linked to the disease. 
Traditionally, genetic association has been used for fine mapping of the linked region. Moreover, the 
last decade (genome wide) genetic association was also used. The basic underlying assumption is 
the “common disease – common variant” (CD-CV) hypothesis. This hypothesis involves the idea that 
a prevalent disease in the general population (common) is caused by many common genetic variants. 
Thus, according to the CDCV hypothesis, proposed in the last decade of the 20th century, common 
prevalent diseases like hypertension, CVD or T2D, might be caused by (multiple) common variants 
in genes throughout the general population81. Discovery of novel loci using linkage analysis is not 
suitable in CDCV because different 
genes may be involved in the same 
family. Thus, for the search for 
common variants, causing common 
disease, preferably large cohorts 
with extensive genotype data are 
used. Within such large cohorts, 
cases and controls can be selected for 
binary association or alternatively, 
quantitative trait analyses can be 
performed. The statistical power 
(see section statistical power) of the 
two study designs, linkage analysis 
and genome wide association, are 
illustrated in Figure 4. 
To find novel loci according the CDCV hypothesis, extensive genotyping is necessary and the available 
techniques have evolved rapidly in recent years. Extensive genotyping techniques are based on micro-
array technology. Two major companies, Affymetrix and Illumina, have developed micro-arrays, 
among which SNP-arrays. At present, SNP micro-arrays involving 6K to 1000K SNPs are available. 
The SNPs present on the Illumina SNP arrays are based on their tag property. This implies that these 
SNPs were selected because each SNP covers a relatively large region in linkage disequilibrium (LD). 
Such tag property of the SNPs is of less importance in the Affymetrix design. By contrast, Affymetrix 
SNP arrays also contain known “coding” mutations.
 Since it is likely that common variants are associated with small effects, large cohorts are needed 
to achieve sufficient statistical power. Therefore, in Genome Wide Association studies (GWAs), the 
aim is to accumulate the highest achievable number of genotypes of as many subjects as possible. 
When GWAs results in novel loci, the “candidate gene” approach is generally chosen to search for and 
validate the causal variant82. 
Allele frequency
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A classical method in genetic research of disease is the “candidate gene” approach. Candidate genes 
can be selected after indication obtained through several different methods, namely by means of: (1) 
linkage analysis, (2) GWAs or by (3) selecting a gene / protein according to its biochemical characteristic 
in the disease process or pathway. In general, fine mapping of the gene of interest is performed 
using sequencing analysis. Replication of a candidate gene is, mostly, performed using association 
analysis. This association analysis can be performed using SNPs and is based on the fact that most 
genetic variants causally related to the trait are expected to be more or less prevalent in patients 
than in controls, depending on whether they increase or decrease the risk of disease. However, also 
the SNPs close to the causal ones are expected to be increased or decreased in patients, when SNPs 
are close to each other. This phenomenon is called linkage disequilibrium (LD).
 Thus causal mutations can be identified using SNP analysis or sequencing analysis. Mutations that 
cause overt changes in protein function (i.e. reading frame shifts leading to stop codons) provide 
strong proof for being the cause of a genetic disease. Less overt changes that nevertheless lead 
to protein dysfunction (i.e. missense mutations) can be identified by comparing the prevalence of 
the variants in patients versus controls. Putative dysfunction of the proteins encoding these genes 
can subsequently be characterized in vitro in material (i.e. blood cells) derived from patients versus 
healthy controls. Finally, a SNP that is located in a gene desert may very well influence the expression 
of a gene in the region (cis regulation) or elsewhere (trans regulation).
Alternative Study cohort
Most association studies are conducted in the general population. Alternatively, the design of a study 
can be based on a genetically isolated population. In short, this design is a mix between a family 
based cohort and a general cohort. It requires an extensive and more expensive collection procedure 
of study subjects, as in most cases a pedigree confirmation is required to rule out possible admixture 
with the general population. The statistical power of association analysis in such genetically isolated 
populations or founder populations is thought to be much stronger due to the fact that it is based 
on a limited gene pool83,84,82. This limited gene pool is a result of a limited number of founders in 
combination with a fast expansion of the population. Furthermore, a genetically isolated population 
is characterized by minimal immigration, due to social, geographical or religious reasons. Genetically 
isolated populations are liable to genetic drift. Genetic drift is defined by the phenomenon that rare 
genotypic variants disappear or, vice-versa, that rare variants become overrepresented with regard 
to the general (out bred) population. Common genetic variants are, however, generally not affected 
in genetically isolated populations and their frequencies are expected to be similar to those in the 
general population83.
Statistical power in association studies
To perform linkage analysis or GWAs with sufficient statistical power, the study cohort must be of 
sufficient size and this requires significant effort and finances. Statistical power represents the 
measure of confidence to detect an (genetic) effect in a particular number of samples. However, the 
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problem with both linkage analysis and GWAs is the enormous number of tests which might result 
in false positive signals; type I errors. Statistical methods generally use a 95% confidence interval, 
which implies that five percent of the associations that are found are actually type I errors. When 
performing a single test, the 5% probability of finding a false positive result is acceptable. However, 
when performing half a million tests such as in GWA, the amount of false positive results will be 
large.
 To address the multiple test correction issue in GWAs, methods like the method of Bonferroni are 
used to overcome the problem of accumulating type I errors85,86. In brief, the method of Bonferoni 
decreases the probability of a true finding by dividing the confidence (represented by the P-value) by 
the number of independent tests performed. This method is, however, a very stringent multiple test 
correction which might result in a high probability of type II errors; or false negatives. Therefore, other 
multiple test correction methods, like the method of Benjaminii – Hochberg, have been developed. 
This correction method also reduces the number of false positive associations, but also takes into 
account the possibility of false negative findings85,86. 
Meta-analysis of association studies
To validate GWAs results and tackle the remaining probability of both false positive and false negative 
associations, meta-analyses are performed87. Meta-analysis is a statistical method to compare and 
strengthen similar observed candidate loci for disease associations in different studies/cohorts. Meta-
analysis is capable of detecting in several different study cohorts consistent, yet small significant 
associations, but is also capable of excluding single significant false positive associations88. Meta-
analysis is now generally accepted as a powerful tool in genetic epidemiology and the application of 
meta-analysis in the field of genetic epidemiology is widely used. Large international consortia have 
been formed over the last years, resulting in studies exceeding 30.000 samples. Meta-analysis on 
such large number of samples resulted for example in the discovery of several new loci associated 
with T2D and obesity and several quantitative traits such as plasma lipids89,90,91,92. 
 Three common problems in meta-analysis are (1) the use of different types of cohorts, (2) 
inconsistency in phenotyping and (3) inconsistency in genotyping. The use of different types 
of cohorts in GWAs meta-analysis, at least with regard to ethnicity, should be avoided or at least 
carefully monitored since population specific genetic associations might unjustly be disregarded. 
Differences in (the accuracy of) phenotyping might also result in false negative findings. For example, 
in a meta-analysis of plasma glucose GWAs, consistent use of information about the fasting state of 
the samples and the use of glucose lowering medication should be included in each individual GWA. 
Genotypic inconsistencies between cohorts are for example caused by the use of different genotyping 
platforms. In this respect, the design of two major suppliers of genome wide genotyping platforms, 
Illumina and Affymetrix, are totally different. 
 To overcome the problem of missing SNPs, the statistical tool of imputation was developed93,94. 
Imputation is based on the fact that most genetic variants are more or less in LD with nearby genetic 
variants. Based on the genetic data of Hapmap, which involves about 2.500.000 genetic variants, 
differences in genetic variants between platforms can be filled in using estimation of the missing 
genetic variants95. This way, different platforms (cohorts) can be forced towards similarity in genetic 
variation and thus be used in meta-analysis. 
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Outline thesis
In this thesis several aspects of metabolic syndrome are addressed. The focus involves questions 
concerning the genetics of obesity, TG and cholesterol and hyperglycemia. Since we hypothesized 
that obesity is the most important trigger of metabolic impairment, the MetS definition in this 
thesis was chosen to include the obesity measure waist circumference as an essential component. 
In the study described in chapter 2, the heritability of the metabolic syndrome was addressed and 
compared to the heritability of its individual components. Since the individual components of MetS 
were shown to be more heritable than MetS itself, the studies described in chapter 3 and 4 focused 
on the genetics of the individual MetS component plasma TG. For this purpose, a candidate gene 
approach was employed using HTG patients and healthy controls. The involvement of a series of 
candidate genes was confirmed. The study described in chapter 5 followed a similar approach to that 
used in the studies described in chapter 3 and 4. Several candidate genes were studied in patients 
suffering from hyperlipoproteinemia (HLP) type III, which is characterized by elevated levels of 
total plasma cholesterol and plasma TG. HLP type III is characterized by APOE2 homozygosity. 
Contributing genetic factors in the (metabolically stressed) APOE2/2 environment were confirmed. 
Plasma adiponectin, an adipose tissue secreted hormone (adipokine), has been suggested to be a 
biomarker for MetS. In chapter 6 we describe a study which particularly aimed to determine the 
effect of menopause on the discriminating accuracy of adiponectin to predict MetS. Especially low 
levels of plasma adiponectin in postmenopausal women were found to be a risk for MetS. However, 
the discriminating accuracy of adiponectin for the presence of MetS was exceeded by BMI in men and 
pre –and post menopausal women. Since plasma adiponectin levels are very well correlated with 
MetS components or related traits, the study described in chapter 7 addressed the question whether 
these correlations are caused by a genetic overlap (genetic correlation). The genetic correlation 
was mono-laterally validated with regard to the adiponectin gene (ADIPOQ). Chapter 8 describes a 
study towards finding novel loci associated with adiponectin or loci that are possibly involved in the 
genetic overlap between adiponectin and MetS components or related traits. This study followed 
a genome-wide association (GWA) approach. The results of this GWA were used in a joined analysis 
with two other cohorts in a meta-analysis. In addition, a selected proportion of SNPs was submitted 
for replication in several cohorts. Chapter 9 provides a general discussion by reviewing all previous 
chapters in the thesis. Furthermore, chapter 9 includes suggestions and proposals for future analyses 
towards unraveling genetic and environmental factors involved in the expression and manifestation 
of metabolic risk factors. 
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Abstract
 Background: Metabolic syndrome (MetS) is defined by a combination of abnormalities that are 
all individual risk factors for the development of type 2 diabetes and/or cardiovascular disease. The 
etiology of MetS includes both an environmental and genetic component. We studied prevalence and 
heritability of MetS and its individual components in a Dutch genetic isolate.
 Methods: The Erasmus Rucphen Family study (ERF) consists of some 3000 genealogically 
documented individuals from a Dutch genetic isolate. Data on waist circumference (WC), blood 
pressure (BP), high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and fasting plasma 
glucose values (FPG) are available. MetS was defined according to the International Diabetes
Federation (IDF) (2003) and National Cholesterol Education program Adult Panel III (NCEP ATPIII) 
criteria. Variance component analysis was applied to extended family data to test for evidence of 
heritability. 
 Results: The prevalence of MetS in the ERF cohort ranged from 23-37% depending on MetS 
definition and gender considered. Low HDL-C and high WC are the main contributors to MetS. The 
heritability of MetS corrected for sibship effect was 10.6% (P = 0.01) according to IDF and 13.2% (P = 
0.07) according to NCEP ATPIII criteria. In addition, the heritability of individual components of MetS 
were analyzed and found to range from 21.9 to 42.9%. The highest heritability was found for HDL-C 
(42.9%, P < 0.0001) and WC (37.8%, P < 0.0001). In addition, WC, SBP, HDL-C and TG, showed low 
to moderate genetic correlation (RhoG) between genders, whereas FPG and DBP showed absolute 
genetic correlation between genders.
 Conclusion: Although the prevalence of MetS was high, the heritability of MetS in the ERF 
population was found to be moderate. The high heritability of the individual components of MetS 
indicates that the genetic dissection of MetS should be approached from its individual components.
Introduction
In populations that have adopted the Western life style, risk factors for type 2 diabetes (T2D) and 
cardiovascular disease (CVD) are strongly increased. These include high blood pressure (BP), low 
plasma high density lipoprotein cholesterol (HDL-C), elevated values of plasma triglyceride (TG), 
increased waist/hip ratio (WHR) or body mass index (BMI) and elevated levels of fasting plasma 
glucose (FPG). The combined presence of several of these risk factors has been termed the Metabolic 
Syndrome (MetS) or Syndrome X. Several definitions of MetS have been formulated over the years1,2.
 MetS as entity has proven to help clinicians in risk estimation for CVD and T2D. The question we 
raise in the present study is whether this entity is also of use in genetic research. Clustering of obesity 
and other cardiovascular risk factors might be explained by a common genetic origin, thus combining 
factors into a single outcome, as defined by MetS, may improve the power of gene discovery. 
However, recently the interest in defining gene specific endo-phenotypes in genetic research, in which 
syndromes are decomposed in traits with a homogeneous genetic origin, has increased. This approach 
does not favor gene discovery in MetS as entity, but favors studies of individual components. As the 
heritability of a trait is one of the main determinants of the power of gene finding, we compared this 
parameter in MetS and its individual components.
 In the present study, we determined the prevalence of MetS and estimated the heritability of MetS 
and its individual components (by means of a general polygenic model, a polygenic household model 
31
Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: 
The Erasmus Rucphen Family (ERF) study.
and polygenic gender model, respectively) in a Dutch genetically isolated population with extensive 
phenotypic and genealogical information. As in all isolated populations, our isolate is characterized 
by genetic drift and founder effect3. Genetic drift reduces the genetic variation. In recent simulation 
studies of genetic isolation, it was shown that rare variants may disappear completely or become 
common but it is unlikely that common alleles disappear4. Thus, genetically isolated populations 
will provide insight in both common and rare genetic variants that predispose to common complex 
diseases such as the metabolic syndrome5,6.
Subjects and methods 
In the present study, we used data of the Erasmus Rucphen Family study (ERF) which is embedded 
in a rural isolated population (Genetic Research in Isolated Populations; GRIP). This young, genetic 
isolate in the southwest of the Netherlands was founded in the mid-eighteenth century. Minimal 
immigration and/or marriages occurred between surrounding settlements due to social and religious 
reasons. This population experienced a fast expansion, at the moment this region counts roughly 
20.000 inhabitants. The ERF population includes 3,000 individuals, who were not selected based on 
health information, but rather comprises of living descendants of 22 couples with at least 6 children 
baptized in the community church around 1850-1900 (approximately a total of 150 founders). Details 
about the genealogy of the population are described elsewhere6,4,3. The study protocol was approved 
by the medical ethics board of the Erasmus MC Rotterdam, the Netherlands. All investigations were 
carried out in accordance with the Declaration of Helsinki. 
 Plasma concentrations of triglyceride (TG), high density lipoprotein – cholesterol (HDL-C), fasting 
plasma glucose (FPG), diastolic and systolic blood pressure (DBP and SBP), waist circumference (WC), 
anti-diabetic (insulin, oral hypoglycemic) treatment, antihypertensive treatment and lipid lowering 
agents were determined as described previously5,6,7.
 We applied two different MetS definitions (table 1) in our study, namely the definition formulated 
by the National Cholesterol Education program Adult Panel III (NCEP ATPIII) and the definition 
formulated by the International Diabetes Federation (IDF).
 SPSS 11.0.1 (SPSS, Chicago, IL, USA) was used for selection, descriptive and regression analysis. 
For the prevalence of MetS according to the IDF definition, the Caucasian WC threshold values 
of >94 cm for males and >80 cm for females were used8. Correlations between components were 
based on transformed data. Pearson correlation coefficients were used to examine the association 
of MetS components and age, to confirm the presence of important cluster of traits within the MetS. 
Gender differences were evaluated by means of the Chi squared algorithm or Student’s T-test. 
Heritability estimates were calculated using the SOLAR software version 2.05 (http://www.sfbr.org/
solar/4.0.7.doc/00.contents.html). The individual components, WC, HDL-C, S/DBP, and TG showed 
a small deviation from a normal distribution within the ERF population, of which the software is 
extremely sensitive. Therefore heritability estimates of these components were based on the log 
normal transformed values. SOLAR’s tdist function was used when traits remained to show some 
kurtosis. Where necessary, traits were multiplied with a factor (suggested by the software) for an 
optimal trait standard deviation.
 The polygenic model was applied for all traits (MetS as binary trait, individual components as 
quantitative traits) which is assuming that an infinite number of genetic factors with a small additive 
effect contribute to the trait variance. In family based heritability estimations, the shared environment 
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within one household and shared genetic dominant effect between sibs within one household, may 
inflate the outcome of the heritability estimate. Therefore we corrected our heritability estimations 
for sibship effect (S). This shipship effect is an estimate of phenotypic similarity, induced by the 
progeny of the same parents. Thus, the sibship effect is a combination of effects induced by sharing 
early childhood environment and dominant genetic variation. Detailed description of calculation of 
heritability estimates was described by others4,6. To estimate the effect of gender specific heritability 
and the genetic correlation of a trait between genders (RhoG), bivariate polygenic analysis (trait + 
gender, covariates: age and inbreeding coefficient) was applied on all individual traits of the MetS9,10.
Results 
Threshold values for MetS definitions according to the IDF and the NCEP ATPIII are given in table 1. 
Values for WC; HDL-C; TG; FPG; DBP and SBP were available for 2860 individuals. Table 2 shows the 
mean demographic characteristics of the study population. The mean age of the 1286 males was 49.4 
years old (range 17.6 to 86.5) and the mean age of the 1574 females was 48.3 years old (range from 16.7 
to 86.1). 
The prevalence of MetS 
was 36.8% in males 
and 31.0% (P = 0.01) in 
females according to 
the IDF MetS definition 
and 26.7% in males 
and 22.8% (P = 0.02) 
in females according 
to the NECP ATPIII 
definition. As expected, 
the prevalence of MetS 
strongly correlated with 
age. We divided the 
population in six age groups: younger than 30 years old (N=294), 30-40 years old (N= 534), 40-50 
years old (N=657), 50-60 years old (N=686), 60-70 years old (N=505) and 70 years old or older (N=184). 
Figure 1a illustrates the gender specific percentages within each age group of the prevalence of MetS 
according to the IDF definition. Figure 1b represents the same graph for the NCEP ATPIII definition. 
Using the IDF definition, in the group of 30-40 years old and using the NCEP ATPIII definition, in the 
groups of 30-40 and 40-50 years old the prevalence of MetS was significant higher in males compared 
to females. 
According to the IDF definition of MetS, WC plus a minimum of any two other components are 
necessary for the expression of MetS. In contrast, the NCEP ATPIII definition does not require WC 
as an essential component for MetS expression. In this study, we investigated which combination 
of components contributed most to both the prevalence of the IDF MetS and NCEP ATPIII MetS. 
Table 3 represents all possible combinations of components in both genders, which can contribute 
to the expression of MetS. In these calculations, the blood pressure component was combined (BP = 
Table 1: Metabolic syndrome definitions
    IDF (2003)a ATPIII (2001)
male waist circumference (cm)  ≥ 94   >102 
female waist circumference (cm) ≥ 80   > 88 
Fasting plasma glucose (mmol/L) ≥ 5.6 b,c  ≥ 6.1
Systolic blood pressure (mm Hg) ≥ 130 c  ≥ 135 c
Diastolic blood pressure (mm Hg) ≥ 85 c  ≥ 85 c
male HDL-Cholesterol (mmol/L) < 1.03 c  < 1.0 
female HDL-Cholesterol (mmol/L) < 1.29 c  < 1.3 
Triglycerides (mmol/L)  ≥ 1.7 c  ≥ 1.7
a Europids
b included previously diagnosed type 2 diabetes patients
c included treatment patients.
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SBP and/or DBP). For calculation within the IDF MetS, in total 11 combinations are possible with the 
components WC, HDL-C, TG, FPG and BP. Six of these combinations consisted of three components 
(for example WC + HDL-C + TG), four consisted of four components and one contribution included 
all components. For calculation within the NCEP ATPIII MetS in total 16 combinations are possible 
with the components WC, HDL-C, TG, FPG and BP. Ten of these combinations consisted of three 
components, five consisted of four components and one combination included all components. To 
determine the most prevalent contributions of combinations of the traits to MetS according to both 
definitions in the ERF population, we calculated Pearson correlations for all MetS components and 
age. These data are presented in table 4. Three main clusters of components contributing to MetS 
can be observed (bold in table 3). For males, these clusters are the same for the two definitions, [WC 
/ HDL-C / BP] and [WC / HDL-C / TG / BP]. For females differences in composition of these clusters 
was observed between both definitions. The main female clusters according the IDF definition are 
[WC / HDL-C / BP] and [WC / HDL-C / TG / BP], but for the NCEP ATPIII definition [HDL-C / TG / BP] 
and [WC / HDL-C / TG / BP] contribute the most to the prevalence of MetS. Significant correlations 
between individual components (bilateral) were more prevalent in females than in males (table 4). 
Table 2: Demographic characteristics of the ERF population
Trait  
    Mean ± SE     Mean ± SE Mean ± SE      P-value a
    total       males females  
N    2860      1286  1574 
Medication lipids   366(12.8)      193(15.0) 173(11.0)        < 0.01
Medication DM   137(4.8)      74(5.8)  63(4.0)        < 0.05
Medication hypertension  492(17.2)      241(18.7) 251(15.9)        < 0.05
Age (years)   48.8 ± 0.27     49.4 ± 0.40 48.3 ± 0.36       < 0.05
Waist circumference (cm)  87.7 ± 0.25     94.2 ± 0.33 82.3 ± 0.32       < 0.001
Fasting plasma glucose (mmol/L) 4.7 ± 0.21      4.84 ± 0.034 4.51 ± 0.026     < 0.001
Systolic blood pressure (mm Hg) 140.1 ± 0.38     143.6 ± 0.512 137.2 ± 0.538     < 0.001
Diastolic blood pressure (mm Hg) 80.4 ± 0.19     82.05 ± 0.276 79.0 ± 0.248      < 0.001
HDL-Cholesterol (mmol/L)  1.3 ± 0.007     1.13 ± 0.009 1.40 ± 0.009      < 0.001
Triglycerides (mmol/L)  1.3 ± 0.146      1.49 ± 0.025 1.23 ± 0.016       < 0.001
a Difference between genders, P value by t-test. Value presented as N (%) or mean ± standard error.





















































Figure 1 Prevalence (%) of the metabolic syndrome (MetS) in age groups <30 years, 30–40, 40–50, 50–60, 60–70, and >70 years in the MetS subgroup 
of the Erasmus Rucphen Family population according to two different MetS definitions. Panel A: International Diabetes Federation (IDF). Panel B: US 
National Cholesterol Education Program Adult Panel III (NCEP ATPIII). *P<0.05; **P<0.001.
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WC in females correlates with all other components. HDL-C and TG are correlated in both genders. 
The BP components showed a somewhat lower correlation with WC and no correlation with HDL-C 
in females. 
For both MetS definitions, we estimated the heritability in the ERF population (N=2488). Furthermore, 
we estimated the contribution of the sibship effect (early childhood environmental factors and 
genetic dominant effects) for both definitions. Table 5 illustrates the heritability estimates without 
consideration of the sibship effect (S) and table 6 illustrates the heritability estimates with 
consideration of the sibship effect. For both estimations, with and without sibship effect (S), the 
covariates we included were: gender, age and inbreeding coefficient. The heritability of the IDF-
defined MetS, even when corrected for sibship effect, still reached significance (P = 0.01) whereas 
the heritability of the NCEP ATPIII-defined MetS was not but borderline significant (P = 0.07). In 
addition to the heritability of MetS definitions, we also estimated the heritability of the individual 
components of MetS in the ERF population (N=2488). SOLAR’s analysis of covariance is not sensitive 
for altered trait values due to (limited) medication use (data not shown). Because all traits showed 
some skewness or extra kurtosis, these heritability estimates were based on natural log transformed 
data (table 5) and were necessary, t-distribution modeling was applied. In addition, we estimated 
the contribution of the sibship effect to the heritability of each component (table 6). This sibship 
effect inflated the heritability of all traits, with exception of HDL-C. 
Table 3: Contribution (%) of possible combinations of individual components to MetS expression (both IDF 
MetS and NCEP ATPIII MetS). 
Parameter combination IDF MetS (%)  NCEP ATPIII MetS (%)
   male a female b  male c female d
1 WC / HDL-C / TG  3.6 4.7  4.7 5.2
2 WC / HDL-C / FPG  0.6 0.2  0.6 0.3
3 WC / TG / FPG  0.2 0.0  0.0 0.0
4 WC / TG / BP  10.3 5.9  4.7 7.6
5 WC / HDL-C / BP  27.3 40.8  31.5 14.0
6 WC / FPG / BP  3.8 3.1  1.9 1.7
7 HDL-C / FPG / BP  - -  2.2 3.8
8 HDL-C / TG / BP  - -  11.7 24.5
9 HDL-C / TG / FPG  - -  0.0 0.3
10 TG / FPG / BP  - -  0.0 2.3
11 WC / TG / FPG / BP 4.7 1.0 0.8  2.6
12 WC / HDL-C / FPG / BP 0.0 0.0  6.1 5.2
13 WC / HDL-C / TG / BP 26.4 22.3  25.9 22.2
14 WC / HDL-C / TG / FPG 11.8 10.9  0.0 0.9
15 HDL-C / TG / FPG / BP - -  2.8 3.2
16 WC / HDL-C / TG / FPG / BP 11.4 11.1  7.0 6.1
WC, waist circumference; HDLC, high density lipoprotein cholesterol; TG, triglycerides; FPG, 
fasting plasma glucose; BP, blood pressure; IDF, International Diabetes Federation; NECP
ATPIII, National Cholesterol Education program Adult Panel III.
 - , combination not represented by definition.
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Table 7 represents gender specific heritability estimates and the genetic correlation of a trait between 
genders (RhoG), for all individual MetS traits. Inclusion of the sibship effect in this model was not 
appropriate (overmodelling). The lowest significant genetic correlation between genders (RhoG) 
was observed for WC and SBP (RhoG WC = 69.9 + 14.0%, RhoG SBP = 61.5 + 19.4%), whereas absolute 
genetic correlation between genders was observed for FPG and DBP (both RhoG = 100.0%). Both lipid 
traits, HDL-C and TG, showed moderate genetic correlation between genders (RhoG – HDL-C = 82.5 + 
12.6%, RhoG – TG = 85.5 +17.5%)
Discussion
The prevalence of MetS in this Dutch genetic 
isolate according the IDF definition is 36.8% in 
males and 31.0% (P < 0.01) in females. According 
to the NECP ATPIII definition the prevalence of 
MetS was 26.7% in males and 22.8% (P < 0.02) 
in females. The two most important clusters 
of individual components, contributing to the 
manifestation of MetS (in both genders and 
both definitions) were [WC / HDL-C / BP] and 
[WC / HDL-C / TG / BP]. Another important 
cluster according the NECP ATPIII definition, in 
females was [HDL-C / TG / BP]. The heritability of 
MetS in our genetically isolated population was 
10.6% ± 5.3% according to the IDF definition 
(p=0.07) and 13.2% ± 6.0% according to the 
NECP ATPIII definition (p<0.05). The heritability 
of the individual components ranged from 21.9% 
(DBP) to 42.9% (HDL-C). Low significant genetic 
correlations between genders were 
Table 4: Pearson correlation coefficients all components in ERF MetS (IDF) subjects   
male n =473 a Age HDL-C WC TG FPG SBP  
   SBP FPG TG WC HDL-C Age female n =488 a
HDL-C   0.09  0.40 **  0.06 -0.04  0.16 ** -0.01 -0.05 DBP
WC   0.03 -0.08  0.22**  0.04  0.12 **  0.06  0.50 ** SBP
TG  -0.16** -0.11**  0.06  0.16**  0.29 ** -0.00  0.20 ** FPG
FPG   0.19**  0.03  0.13**  0.02  0.15 ** -0.12 **  0.10 * TG
SBP   0.30**  0.15 **  0.07 -0.03  0.17 ** -0.16 **  0.04 WC
DBP   0.01  0.13 **  0.10*  0.16**  0.04  0.10 *  0.18 ** HDL-C
HDL-C, high density lipoprotein cholesterol; WC, waist circumference; TG, triglyceride; FPG, fasting
plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; IDF, International Diabetes
Federation. a Above diagonal (in italics) represents female correlation values.
*P<0.05, **P<0.01.
Table 5: Heritability of IDF and NCEP ATPIII MetS 
definitions and its natural log transformed individual 
components in ERF population.
Parameter h2 (%)a SEM P-valueb
n  2488  
IDF   14.3 4.8 <10-06
ATPIII  19.2 5.6 <10-06
ln WC  40.5 4.2 <10-06
ln FPG  28.2 4.0 <10-06
ln SBP  27.9 3.9 <10-06
ln DBP  27.0 3.9 <10-06
ln HDL-C  42.9 4.1 <10-06
ln TG  30.8 3.9 <10-06
IDF, International Diabetes Federation; NCEP ATPIII, National 
Cholesterol Education program
Adult Panel III; WC, waist circumference; FPG, fasting plasma glucose; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high 
density lipoprotein cholesterol TG, triglyceride. a Heritability based 
on polygenic model without consideration of the sibship effect (S), 
covariates: gender, age and inbreeding coefficient 
b P values were derived using the likelihood ratio test.
*P<0.05, **P<0.01.
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observed for WC and SBP (RhoG: 69.9% and 61.5% respectively) Absolute genetic correlation between 
genders was observed for FPG and DBP (RhoG both 100.0). Moderate genetic correlation between 
genders, were observed for HDL-C and TG (RhoG: 82.2% and 85.5% respectively).
 Although our genetically isolated population was not selected on disease phenotype, the population 
in general suffers from mild overweight (mean WC male = 94.2 ± 0.33 cm and mean WC female = 82.3 
± 0.32 cm) and mildly elevated blood pressures (mean SBP male = 143.6 ± 0.5 mm Hg, mean DBP male 
= 82.05 ± 0.3 mm Hg). It cannot be excluded that these phenotypic profiles are the consequence 
of enrichment of (rare) pathogenic alleles due to genetic drift associated with genetically isolated 
populations. Moreover, the ERF cohort is from a rural region, of which has been shown to be enriched 
in unfavorable metabolic profiles as compared to urban regions11.
 Relatively little information is available on the prevalence of MetS in Dutch populations. In a 
Dutch familial hypercholesterolemia (FH) patient population, a prevalence of 31% of MetS was found. 
Table 7: Heritability of gender specific natural log transformed individual components in ERF population.
 h2 (%)a SE P b h2 (%)a SE P b RhoG a SE P b
 Female N =1397   Male N = 1091   
ln WC 53.7 6.6 <10-06 37.6 8.2 <10-05 69.9 14.0 0.03
ln FPG 34.4 6.5 <10-06 25.4 6.1 <10-04 100.0 - -
ln SBP 42.9 6.6 <10-10 20.3 7.5 < 0.01 61.5 19.4 0.05
ln DBP 42.6 6.7 <10-09 14.7 4.6 < 0.01 100.0 - -
ln HDL-C 53.0 7.1 <10-13 42.0 7.7 <10-07 82.2 12.6 0.16
ln TG 35.6 6.7 <10-06 31.7 7.4 <10-04 85.5 17.5 0.41
WC, waist circumference; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein 
cholesterol TG, triglyceride.
a Heritability and RhoG (% shared genetics between genders) based on polymod model, RhoE (% shared environment between genders) forced to 0, 
covariates: age and inbreeding coefficient. b P values were derived using the X2 test.
Table 6: Heritability of IDF and ATP MetS definitions and its log normal transformed 
individual components in ERF population. 
Parameter h2 (%)a SE P-valueb S (%)c SE P-valueb
n  2488     
IDF  10.6 5.3 < 0.05 9.05 6.2   0.07
ATPIII  13.2 6.0  0.07 15.89 7.4 < 0.05
ln WC  37.8 4.6 <10-06 5.6 3.4 < 0.05
ln FPG  22.7 4.7 <10-06 9.6 3.6 < 0.01
ln SBP  25.4 4.3 <10-06 7.8 3.3 < 0.01
ln DBP  21.9 4.6 <10-06 2.7 3.3   0.20
ln HDL-C  42.9 4.1 <10-06 0.0 - -
ln TG  28.3 4.4 <10-06 4.1 3.3   0.10
IDF, International Diabetes Federation; NCEP ATPIII, National Cholesterol Education program
Adult Panel III; WC, waist circumference; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HDL-C, high density lipoprotein cholesterol TG, triglyceride.a Heritability based on polygenic household 
model with consideration of the sibship effect (S), covariates: gender, age and inbreeding coefficient.
b P values were derived using the likelihood ratio test.
*P<0.05, **P<0.01.
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This study also reported, in a population suffering from CVD or other vascular disease, a prevalence 
of MetS ranging from 41-58%12. Data on two populations in the Southwest of Germany11 showed a 
notably higher prevalence of MetS in rural as compared to urban populations, (urban 10%-15%, rural 
20%-25%). Others13 reported the prevalence of MetS in different ethnic groups. A Hispanic cohort 
(enriched for T2D) had a very high prevalence of MetS (73%). Overall, the prevalence of MetS in the 
Western world is estimated to vary between 10-35% (depending on age)14,15,16. Thus, the prevalence 
of MetS in the ERF population is relatively high. The higher prevalence of MetS according to the IDF 
definition as compared to the NCEP ATPIII definition is caused by the less stringent threshold values 
of the IDF definition. The significant difference in prevalence of MetS between genders is clearly a 
consequence of differences of prevalence in the first three age groups, < 30, 30-40 and 40-50 years 
old (figure 1). Women in the pre-menopausal period are apparently protected from MetS, as also 
reported by others17.
 In this study, we calculated the contributions to the total prevalence of MetS of all different 
combinations of individual components. The two most important contributors, for both genders, to 
the IDF MetS were [WC / HDL-C / BP] and [WC / HDL-C / TG / BP] (bold in table 3). The three most 
important contributions to the NCEP ATPIII MetS were [male WC / HDL-C / BP], [female HDL-C / TG / 
BP] and [both genders WC / HDL-C / TG / BP]. (bold in table 3). These findings were partly confirmed by 
Pearson correlation analysis of all traits, age included (table 4). In male IDF MetS subjects, a clear 
and significant correlation was found between HDL-C, TG and both BP components. In female IDF 
MetS subjects, HDL-C mainly correlated with WC and TG. The clustering of TG, HDL-C and WC is in 
line with previous findings18,19,20. The early metabolic syndrome definition was mainly determined by 
insulin resistance. Interestingly, FPG, is virtually absent in the most important clusters, contributing 
the most to MetS in our population. The result that FPG not only plays a minor role in MetS clusters, 
but also shows a relative moderate heritability estimate (22.7 %) in comparison with for example 
HDL-C, is in concert with findings of others. Apparently the environmental contribution to alterations 
in FPG seems to be prominent. 
 A heritability of 24% for MetS (NCEP ATPIII) in a Caribbean-Hispanic population has been reported 
by Lin et al21. Factor analysis in this study suggested two clusters of components: A lipid / obesity / 
plasma glucose cluster and a second blood pressure cluster. The first cluster showed the highest 
heritability (44%). Bayoumi et al reported a heritability of MetS (binary trait) in healthy Omani Arab 
families (N=1277) of 38%. Individual components as HDL-C and BMI showed the highest heritability 
in these families22. 
 The heritability of MetS in our genetic isolated population was moderate (IDF = 10.6% ± 5.3%, 
NCEP ATPIII = 13.2% ± 6.0%) in comparison with data of others. However, our estimates of heritability 
of MetS were based on a complex pedigree structure, far more complex than a family pedigree. 
This complex pedigree structure allowed us to correct for the sibship effect, which should be a 
standard procedure to avoid substantial inflation of the heritability estimate due to early childhood 
environment (household-effect) and dominant genetic factors. 
 In the present study, the heritability estimations for the individual components of MetS were based 
on quantitative values. The heritability estimation found for individual components of MetS, ranged 
from 21.9% ± 4.6% for the DBP component to 42.9% ± 4.1% for the HDL-C component. Interestingly, we 
did not find evidence for a contribution of the sibship effect to this trait, which suggests a dominant 
role for strong genetic factors causing variation in plasma HDL-C values. The heritability of our MetS 
individual traits correspond well with findings of others in general populations (Omani Arab families) 
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and genetically isolated populations as the Hutterite population and Sardinian population. The 
Sardinian population is a large genetically isolated population which has already been useful in the 
identification of genes involved in several Mendelian disorders. Pilia et al found that, in a Sardinian 
cohort, the heritability of the MetS individual traits: fasted serum glucose, HDL-C, TG and WC was 
31.8%, 47.1%, 29.6%, and 31.2% respectively23. The Hutterite population lives on nine communal 
farms (colonies) in South Dakota, USA and involves participants which are descendants of only 64 
Hutterite ancestors who were born in the mid-eighteenth century. Abney et al24 and Ober et al25, both 
reported on the heritability in the Hutturite population. They found heritabilities of 37% for plasma 
TG, 45% for SBP and 21% for DBP. 
 Gender specific genetic architecture (heritability) of several individual MetS traits and several 
MetS related traits (such as plasma insulin, BMI and low density lipoprotein cholesterol, LDL-c) was 
reported by Weiss et al9 and Pan et al10 in the genetically isolated Hutterite population. The latter 
concluded that the individual MetS traits SBP and TG showed significant X chromosome effects, 
HDL-C showed a non-X chromosome gender effect and DBP showed no significant gender effects. 
The majority of our findings are in concert with these conclusions of Pan et al. Gender specific genetic 
architecture (genetic correlation or Rho G between genders) was found for the individual MetS traits 
WC, SBP, HDL-C, and TG whereas for FPG and DBP no evidence was found for differences in the genetic 
architecture between genders (RhoG = 100%).
 Our findings suggest that genetic dissection of MetS as compound syndrome has a low power 
and should be approached by studying the genetics of the individual traits of MetS21. However, the 
observation that a limited set of clustered risk factors are the predominant contributors to MetS 
indicates that these clusters may have a common genetic origin. The power of genetic dissection 
using limited sets of risk factors is compromised by the limited number of subjects in the sub-
selection. Alternatively, the interaction between clustered components within MetS can be studied 
by means of an epistasis model to study gene-gene interactions in the whole population26. 
 Difference in the genetic architecture between genders is striking. Our findings and findings of 
others9,10 indicate that these differences seem to be common in quantitative traits. Four of six of our 
MetS individual traits: WC, SBP, plasma HDL-C and plasma TG, show large to moderate differences 
in genetic architecture between genders. These findings indicate that analyses for novel loci should 
imply gender specific analysis
 In conclusion, the present study on the prevalence and heritability of MetS and the individual 
components in a Dutch genetically isolated population provides a good basis for future genetic 
analyses to identify genetic risk factors for individual components contributing to MetS.
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Abstract
 Objective: The recently discovered apoAV is hypothesized to affect triglyceride metabolism by 
stimulating the lipolysis of triglycerides in VLDL and chylomicrons. We set out to determine the 
association between increased serum TG levels, plasma apoAV levels, and polymorphism of the APOA5 
gene, with specific emphasis on the APOA5 S19W variation. This mutation alters the endoplasmic 
reticulum signal peptide and is hypothesized to impair apoAV secretion into the circulation.
 Methods and Results: Two haplotype-tagging APOA5 polymorphisms, APOA5 S19W and APOA5 
–1131T>C and plasma apoAV levels were determined in a previously characterized population of 
patients with severe hypertriglyceridemia (HTG). As compared to a random control population, the 
allele frequencies of the APOA5 S19W and –1131T>C rare variants were significantly increased in HTG 
patients. Furthermore, the HTG population exhibited markedly elevated plasma apoAV levels that 
were positively correlated with serum TG levels. Plasma apoAV levels were positively correlated with 
occurrence of the APOA5 S19W rare variant.
 Conclusions: The increased allele frequencies of the APOA5 S19W and –1131T>C rare variants in 
the HTG population are in agreement with previous reports. Our data show a positive correlation 
between apoAV and TG levels. Moreover the finding of a positive association between apoAV levels 
and the APOA5 S19W rare variant is in disagreement with the hypothesis that this variant is poorly 
secreted. 
INTRODUCTION
The recently identified apolipoprotein (apo) AV1,2 has been shown to affect triglyceride (TG) levels 
in mouse models. Serum TG concentrations in mice were 4-fold increased upon deficiency of the 
endogenous APOA5 gene and were decreased by 65% by overexpression of the human APOA5 gene 
1. Adenovirus-mediated transfer of murine APOA5 to mice resulted in a dose-dependent reduction of 
serum TG3,4. Thus, in these animal model studies, plasma apoAV levels are negatively correlated with 
serum TG levels.
 In a large number of human populations, polymorphisms in the APOA5 gene have been associated 
with variation in serum TG level (for reviews see5-7). Moreover, deficiency for apoAV has been associated 
with HTG8-10, confirming the TG-lowering activity of apoAV. The APOA5 gene is localized in a gene 
cluster containing APOC3, APOA1 and APOA4, characterized by a high level of linkage disequilibrium. 
Single nucleotide polymorphisms (SNPs)  in the APOA5 gene fall into three common haplotypes: 
APOA5*1, with common alleles at all sites; APOA5*2, with rare alleles of -1131T>C, -3A>G, 751G>T, and 
1891T>C; and APOA5*3, distinguished by c.56C>G (S19W)11,12. 
 ApoAV is a 39 kDa protein (343 amino acids) that may enhance LPL mediated TG hydrolysis, most 
likely in concert with heparin sulphate proteoglycans3,13,14. The APOA5 S19W mutation is located in 
the endoplasmic reticulum signal peptide and is hypothesized to decrease the apoAV secretion rate 1. 
Recent studies using a secreted alkaline phosphatase as reporter protein for signal peptide function 
are in agreement with this hypothesis15.
 In the current study, we have screened a severely hypertriglyceridemic population for the frequency 
of the most common APOA5 haplotype tagging SNP’s, -1131T>C for APOA5*2 and S19W for APOA5*3. 
In addition, we have determined the plasma apoAV levels and correlated these levels with serum TG 
levels and APOA5 haplotype tagging SNPs. We find an increased frequency of the APOA5 –1131C>T 
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and APOA5 S19W rare variants in the HTG population and markedly elevated plasma apoAV levels. 
Moreover, the apoAV levels are positively associated with serum TG levels. These data do not support 
the previously reported negative association between plasma apoAV and TG levels16,17 and presumed 
secretion defect of the APOA5 S19W rare variant.
MATERIALS AND METHODS
Patient and control population recruitment
Hypertriglyceridemic subjects were recruited from our lipid clinic meeting the following criteria: 
serum triglyceride >3.8 mmol/L, VLDL-cholesterol >1 mmol/l, LDL-cholesterol < 4.5 mmol/L and 
no apoE2/E2 phenotype18,19. The diagnosis was based on the means of two fasting blood samples 
obtained after a step one diet of the NCEP for at least 8 weeks. Patients with renal-, liver- or thyroid 
disease and/or alcohol consumption >40g/day were excluded. 29 (21%, N=139) HTG patients had 
type II diabetes. The random control panel include a total of 175 anonymous subjects. Data on 
age, body mass index and lipid levels of random control subjects were not available. The random 
control population consisted of 100 anonymous blood donors, blood supplied by Sanquin (Leiden, 
the Netherlands) and 75 anonymous subjects of a population-based study among 2018 randomly 
selected 35-year-old men20 (Table 1). Informed consent was given by each participant and the study 
was approved by the Medical Ethics Committee of the LUMC. All blood samples were collected after 
an overnight fast. Serum was obtained after centrifugation at 1500 g for 15 min at room temperature. 
Lipids and lipoproteins were measured after ultracentrifugation using standard methods21. 
Genetic analysis
 Identification of the polymorphisms was performed using PCR followed by restriction enzyme 
analysis. The following SNPs were analyzed: APOA5 c.56 C>G (S19W) and APOA5 –1131T>C (SNP3)12,22. 
For amplification of the APOA5 S19W fragment (c.56 C>G) the following primers were used: 5’-CCA GAA 
GCC TTT CCG TGC CTG GGC GGC-3’ (sense) and 5’-TGT AAA ACG GCC AGT - AAA AGG AAA A-CGG CCG-
GTG CTC ACC TGG GCT GCT CTT C-3’ (antisense). The penultimate base in the forward primer (sense) 
was changed to a C to create a Eco521 recognition site in the common allele. This recognition site was 
also introduced in the reverse primer (antisense), which served as a digestion control. To establish 
an optimal visualization, the 3’ primer also was elongated with a 5’ additional M13 tail. Fragments 
of 24, 156 and 27 bp represented the Ser-19 allele and the fragments 24 and 184 bp represented the 
Trp-19 allele. 
 The primers for amplification of the APOA5 -1131T>C SNP were as follows: 5’-CCC CAG GAA CTG GAG 
CGA AAT T-3’ (sense) and 5’-TGT AAA ACG GCC AGT AAA AGG AAA AGG AAA AGG TTA AGA TTG ATT 
CAA GAT GCA TTT AGG AC-3’ (anti-sense). The penultimate base in the forward primer (sense) was 
changed to a T to create a Tru1 recognition site in the common allele. This recognition site was also 
introduced in the reverse (antisense) primer, which served as a digestion control. To establish an 
optimal visualization, the 3’ primer also was elongated with a 5’ additional M13 tail. Fragments of 21, 
168 and 36 bp represented the –1131T allele and the fragments 36 and 189 bp represented the –1131C 
allele.
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Analysis of plasma apoAV levels
Total plasma apoAV levels were measured by means of a sandwich ELISA assay 23. A subset of the 
population, representing individuals from all tertiles with respect to serum TG and apoAV levels 
(as determined by ELISA) was analyzed by semi-quantitative Western blot analyses as previously 
described2.
Statistical analysis
For both polymorphisms and haplotypes, the Hardy-Weiberg equilibrium was calculated using the 
gene-counting method and differences were assessed by chi-squared analysis. P-values lower than 
0.05 were considered as significant differences. Differences in sex were evaluated with Chi-squared 
analysis. Data in table 1 are expressed as mean ± SD. Data in figure 1,2 and 3 are expressed as mean ± 
S.E.M. Since total TG and apoAV levels showed non-Gaussian distributions, the mean differences of 
these parameters between groups were calculated by means of Mann-Whitney analysis. Association 
analysis between the TG concentration and apoAV concentration was performed by subdividing TG 
levels in quartiles (3.80-6.31, 6.53-9.42, 9.45-15.71 and 16.64-82.14 mmol/L resp.) All statistical analyses 
were performed with SPSS for windows 11.0.1 (SPSS, Chicago, IL, release November 2001).
RESULTS
Frequency of APOA5 haplotype-tagging SNP’s  in HTG and control population
The occurrence of 2 common haplotype-tagging APOA5 SNPs, APOA5 -1131 T>C (haplotype APOA5*2) 
and APOA5 c.56C>G (S19W, haplotype APOA5*3) were determined in 141 patients with severe HTG 
and 175 control individuals (random control panel) (for population characteristics, see Table 1). 
Allele frequencies for both 
polymorphisms in the HTG 
and random control subjects 
were in Hardy-Weinberg 
equilibrium. Allele frequency 
of the rare APOA5 -1131 T>C 
SNP is 5.9% in the control 
population versus 23.5% in 
the HTG population (P<0.05). 
Similarly, allele frequency of 
the rare variant of the APOA5 
S19W is 4.4 % in the control 
population versus 19.1 % in 
the HTG population (P<0.05). 
Thus, both the APOA5 –1131T>C 
and APOA5 S19W rare variants 
are significantly increased in 
the HTG population.
Table 1: Characteristics of patients with hypertriglyceridenia and controls
        HTG   N  RCP       N
Male         119 (84.4 %) 141  171 (97.7 %)     175
Female        22 (15.6 %) 141  4 (2.3 %)       175
Age        53.9 ± 10.7 141 
range        26-78  
BMI (kg/m2)       27.7 ± 3.4  141 
Total triglycerides (mmol/L) 14.3 ± 13.8 141 
VLDL-triglycerides (mmol/L) 12.0 ± 12.3 132 
apoAV (ng/ml)       965.2 ± 1391.8 129 
Total cholesterol (mmol/L)  8.8 ± 3.9  141 
HDL-C (mmol/L)      0.68 ± 0.20 137 
VLDL-C (mmol/L)      5.0 ± 4.1  132 
LDL-C (mmol/L)      2.8± 1.5  132 
HOMA index       14.0 ± 16.7 135 
RCP indicates random control panel; N indicates total number of subjects with available data 
about respective parameter; Age, body mass index, lipid levels, HOMA index and apoAV levels are 
presented as mean ± SD
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Association between plasma apoAV, TG levels and 
APOA5 polymorphisms
Plasma apoAV levels in the HTG population were 
determined by sandwich ELISA. ApoAV levels in a selected 
set of individual sera were confirmed by an independent 
ELISA and also by semi-quantitative Western Blot analyses 
(data not shown). All replicate data were in near perfect 
concordance. Average plasma apoAV concentration in the 
HTG population was 0.97 ± 1.39 ug/ml, which is 4 to 5–fold 
increased as compared to reported apoAV levels in normal 
individuals16,17,23. 
 Twenty HTG patients were taking antihypertensive 
medication. The apoAV levels were not significantly 
different between the treated and untreated groups of 
patients. Association studies were performed between 
APOA5 polymorphic variants and plasma apoAV and TG 
levels. Figure 1 shows that there is a significant positive 
correlation between presence of the APOA5 S19W rare 
variant and plasma APOA5 levels (P<0.05). No association 
was found between presence of the APOA5 –1131T>C rare 
variant and plasma APOA5 levels. 
 Neither the APOA5 S19W nor the APOA5 –1131T>C rare 
variants were correlated with serum TG levels (Fig. 2). The 
plasma apoAV levels were positively correlated with serum 
TG levels. The apoAV level in the lowest quartile of serum 
TG level (up to 6.31 mmol/L) is significantly different from 
the apoAV levels in all subsequent quartiles of serum TG 
level (Fig. 3).
DISCUSSION 
Here, we show that the frequencies of the APOA5 S19W 
and -1131T>C variant allele carriers are about four times 
higher in patients with severe hypertriglyceridemia than in 
the control population, indicative for a causal association 
of the APOA1/C3/A4/A5 locus with this complex lipid 
disorder. Plasma apoAV levels are approximately 5-fold 
increased as compared to normal controls16 and positively 
correlated with serum TG levels and the APOA5 S19W rare 
variant. The increased frequencies of the APOA5 S19W and 
-1131T>C rare variants in the HTG population are in line 
with previous reports, that have demonstrated a positive 

























































































































Fig.1. Association between the APOA5 S19W and APOA5 
−1131T>C polymorphisms and plasma apoAV level in 
HTG patients. ApoAV concentration is expressed as mean 
±S.E.M. Data are shown for all individuals characterized 
for the parameters involved. Differences between non-
carriers and carriers of the rare variants were evaluated 
with Mann-Whitney analysis. *P < 0.05 as compared with 
S19W 11/−1131 T>C 11; S19W 11/−1131 T>C 12; S19W 
11/−1131 T>C 22. †Haplotype definitions as described by 
others 6,12,26,28.
Fig.2. Association between the APOA5 S19W and 
APOA5−1131T>C polymorphisms and serum TG level 
in HTG patients. Triglyceride concentration is expressed 
as mean ±S.E.M. Data are shown for all individuals 
characterized for the parameters involved. Differences 
between non-carriers and carriers of the rare variants 
were evaluated with Mann-Whitney analysis. ÜHaplotype 
definitions as described previously 6,12,26,28.
Fig.3. Association between the serum TG concentration and 
plasma apoAV concentration in HTG patients. The HTG 
populationwas divided in quartiles based on TG concentration. 
ApoAV levels are expressed as mean ±S.E.M. Data are shown 
for all individuals characterized for the parameters involved. 
Differences between groups were evaluated with Mann-
Whitney analysis. Significant differences are expressed as: *P 
< 0.05; **P < 0.01; ***P < 0.001.
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various populations24-27 (for reviews see 5-7). Somewhat surprisingly, within the HTG population itself, 
the correlation between TG levels and presence of the APOA5 S19W or APOA5 -1131C>T rare variants 
was not significant (Fig. 2). However, since a trend seems present, this may be a power problem due to 
the size of the population. In addition, the lack of correlation may be caused by the selection criteria 
used for inclusion of patients in the HTG population. Half of the HTG population is characterized by 
TG levels of more than 9 mmol/L (upper two quartiles of the population (Fig. 3). It is more than likely 
that especially these quite extreme HTG patients will have mutations in additional genes causing the 
high TG levels that will be dominant over the effects associated with the APOA5 variants.
 The increased average apoAV levels in the presence of HTG and the positive correlation between 
apoAV levels and TG levels indicate that, at least in these patients, the presumed LPL-stimulatory 
activity of apoAV does not normalize circulating TG levels. This observation contrasts with a study in 
Japanese indivuals that demonstrated a negative correlation between plasma apoAV and serum TG 
levels16 and with two other independent studies which both found that apoAV deficiency is associated 
with HTG in humans8,9. Interestingly, individuals that are heterozygous for apoAV deficiency have a 
highly variable phenotype8,9, indicating that additional factors may be necessary for the expression of 
apoAV-associated hyperlipidemia. The observation that the phenotypes of apoAV overexpression and 
apoAV-deficiency in mice are so clear cut, could indicate that these factors are skewed in a species-
specific manner as to emphasize the role of apoAV. The identity and role of these putative modifiers 
remain to be established.
 Several explanations could be invoked to explain the positive correlation between apoAV and 
TG levels and some of these may be affected by species-specific modifiers. First, the disturbance 
in TG metabolism in a large fraction of the HTG patients is dominant over the presumed apoAV TG-
lowering effect. For example, if more potent inhibitors of lipolysis are up-regulated. It is possible 
that apoAV may actually even be up-regulated as a consequence of the HTG, but to no avail. Analysis 
of the production and turn-over rate of apoAV should clarify this issue. Second, the increased plasma 
levels of apoAV are a consequence of the altered lipoprotein structure present in HTG. If apoAV has 
for example a higher affinity for large-sized TG-rich particles, the observed increase in plasma apoAV 
levels is a symptom of  HTG23. Third, apoAV could be up-regulated as an indirect consequence of HTG. 
It is conceivable that apoAV may have an as yet unknown function in liver homeostasis. For example, 
it is unknown what the mechanism is underlying the up-regulation of APOA5 expression after partial 
hepatectomy2. It should be noted that plasma apoAV levels did not correlate with SAA levels and 
thus presumably not with liver dysfunction per se (data not shown). Independent of the explanation 
underlying the increased apoAV levels in HTG patients, it is obvious that in the majority of individuals 
of this HTG population, the TG-lowering effect of apoAV is not sufficient to normalize TG levels.
 The analyses of APOA5 variant allele frequencies and correlations with apoAV and TG level were 
performed under the assumption that the APOA5 S19W and APOA5 -1131T>C rare variants are allele-
tagging variants. Although we have not performed a haplotype analysis in the HTG population, this 
assumption seems reasonable since the APOA5 haplotypes are in Hardy-Weinberg equilibrium in 
the HTG population. Moreover, the haplotype structure has been confirmed in numerous population 
studies6,12,26,28.  Since we have not studied other polymorphic sites in APOA1/C3/A4/A5 locus, we cannot 
draw conclusions on the causality between the presence of the APOA5 S19W and APOA5 -1131T>C rare 
variants and HTG or apoAV level. However, it is of interest to note that the APOA5 S19W variant allele 
is characterized by presence of the most common (wild type) variants of other SNP’s in the APOA1/C3/
A4/A5 locus12,26,28. The APOA5 S19W variation occurs in the signal peptide for co-translational transport 
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into the endoplasmic reticulum. Computer modeling of this variation indicated a conformational 
change and in vitro analysis using a secreted alkaline phosphatase as reporter demonstrated that the 
variant signal peptide resulted in 50% less efficiently secretion as compared to the wild type form 15. 
Therefore, the positive correlation between the presence of the APOA5 S19W rare allele and serum 
apoAV levels is unexpected.
 This study was designed to test the hypothesis that apoAV levels are negatively correlated with 
HTG. The positive correlation between plasma apoAV levels and TG levels on the one hand and apoAV 
levels and the APOA5 S19W rare variant on the other hand provide evidence against (1) a dominant 
role for apoAV in reducing serum TG levels in HTG patients and, (2) a secretion defect associated with 
the APOA5 S19W variant. These observations illustrate that the postulated role of apoAV as dominant 
gene determining serum TG levels in humans may require adjustment.
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Introduction
Occasionally severe hypertriglyceridemia (HTG) may develop or exacerbate in females during 
pregnancy or use of exogenous estrogens1-3. Estrogens might increase production of triglyceride-rich 
very low density lipoproteins (VLDL) by the liver impair lipolysis of triglycerides through reduction 
of the concentration of lipoprotein lipase and hepatic lipase4,5. These effects might be induced as a 
result of a decrease of insulin sensitivity by estrogens6,7.
 Recently, a new apolipoprotein designated AV (apoAV) was discovered which is associated with 
VLDL-production in the liver and might stimulate lipoprotein lipase (LPL) in hydrolyzing triglycerides 
in fatty acids8. APOA5 is closely linked to a well-studied apolipoprotein cluster located on chromosome 
11q23, which involves the genes APOA4, APOC3 and APOA1. ApoCIII plays an important role as inhibitor 
of lipoprotein lipase (LPL) in hydrolyzing triglycerides in fatty acids8. Several reports have shown that 
deficiency for apolipoprotein AV (apoAV) in humans is associated with HTG9,10. 
Methods and Results
Here, we report a patient deficient for apoAV, yet having a variable TG phenotype. The study was 
approved by the medical ethical committee of our institution. A healthy 31-year old woman was 
referred to our Lipid clinic for HTG, detected by routine medical examination. She had no physical 
complaints, rarely consumed alcohol and used an oral anticonceptive, ethinylestradiol/desogestrel, 
for more than four years. No abnormalities were detected by physical examination. Her body mass 
index (BMI) was 23 kg/ m2. 
 Laboratory examination showed HTG: plasma-TG 19.4 mmol/L, elevated VLDL-cholesterol and 
VLDL-TG and low HDL-cholesterol (data not shown). Her apoE phenotype was E3E2. The apoAV, 
determined by ELISA11,12, was not detectable. She was advised to adhere to a diet low in fat (National 
Cholesterol Education Program 2). During the 
diet, her plasma TG did not normalize (6.0 – 13.3 
mmol/L). However, after she stopped with the 
oral anticonceptive medication her plasma TG 
normalized 1.8 mmol/L. During her pregnancy, 
plasma TG increased to 54.0 mmol/L and 
normalized after delivery (Figure 1). Since then, 
plasma TG have remained normal (data not 
shown). The plasma apoCIII levels determined 
by ELISA11,12 decreased from 37.5 mg/dl in the 
presence of HTG to 9.3 mg/dl in the normo-
triglyceridemic state (Table 1).
Sequence analysis revealed that the patient was homozygous for a novel mutation in the APOA5 gene: 
c.161 + 5G (guanine) >C (cytosine). Computational splice site analysis13 indicated that the c. 161 +5G>C 
variant severely decreased its binding capacity as donor splice site in intron 3 (SC35 weight matrix; 
fold change = -3.2), which suggests a splicing defect. Both parents of the apoAV-null patient were 
heterozygous for the same variant. Her parents did not show any alterations in plasma lipid levels nor 
plasma apoAV and apoCIII levels (Table 1), except for a mild combined hyperlipidemia (T-cholesterol 




























Fig.1. The variable plasma triglyceride phenotype of the apoAV deficient 
patient over a time span of 26 months; stop intake oral anticonceptive at 0 
months, start pregnancy at 11 months, delivery at 20 months.
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6.7 mmol/L and TG 3.9 mmol/L) of the obese (BMI 
30.2 kg/m2) mother of the proband. 
 The following additional SNPs in the APOA5-
APOC3 locus were analyzed in proband and parents: 
APOA5 S19W (rs3135506), APOA5 SNP3 (rs662799) 
and APOC3 Sst-1(rs5128), using PCR followed by 
restriction enzyme analysis14. Interestingly, the 
c.161 + 5G>C variant is linked to the rare alleles 
of the APOA5 SNP3 and APOC3 Sst-1 variants and 
the patient is thus homozygous for both rare variants (Table 1). These data indicate that apoAV-
deficiency alone was not sufficient for the induction of HTG in this patient. Exogenous estrogens and 
hyperestrogenemia of pregnancy may be the additional factor causing HTG in the presence of genetic 
susceptibility. 
Discussion
Whether the genetic susceptibility in the patient is defined by the APOA5 splice mutation (and 
associated apoAV-deficiency) or the presence of the linked variants APOA5 SNP3 and/or APOC3 Sst-1 
cannot be concluded from these analyses. However, it is intriguing to note that many of the patients 
with null-mutations in APOA5 described to date, are carriers of TG-raising alleles in the APOA5-APOC3 
gene locus (reviewed by Talmud15). 
 Thus, the patient described here confirms the notion that expression of HTG in apoAV-deficiency 
requires the presence of additional genetic and/or environmental factors.
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ABSTRACT
Type III hyperlipoproteinemia (HLP) is mainly found in homozygous apolipoprotein (APO) E2 (R158C) 
carriers. Genetic factors contributing to the expression of type III HLP were investigated in 113 hyper- 
and 52 normolipidemic E2/E2 subjects, by testing for polymorphisms in APOC3, APOA5, HL and LPL 
genes. In addition 188 normolipidemic Dutch controls (NDCP) and 141 hypertriglyceridemic (HTG) 
patients were genotyped as well. 
 No associations were found for four HL gene polymorphisms and two LPL gene polymorphisms 
and type III HLP. The frequency of the rare allele of APOC3 3238 G>C and APOA5 -1131 T>C (in linkage 
disequilibrium) was significantly higher in type III HLP patients compared with normolipidemic E2/
E2 subjects, 15.6% vs. 6.9% and 15.1% vs. 5.8% respectively (P<0.05). Furthermore, the frequencies 
of APOA5 c.56 G>C polymorphism and LPL c.27 G>A mutation were higher in type III HLP patients, 
though not significant. Some 58% of the type III HLP patients carried either the APOA5 -1131 T>C, c.56 
G>C and/or LPL c. 27 G>A mutation as compared to 27% of the normolipidemic APOE2/2 subjects (odds 
ratio 3.7, 95% confidence = 1.8 – 7.5, P<0.0001). The HTG patients showed similar allele frequencies 
of the APOA5, APOC3 and LPL polymorphisms, whereas the NDCP showed similar allele frequencies 
as the normolipidemic APOE2/2. Patients with the APOC3 3238G>C / APOA5 -1131 T>C polymorphism 
showed a more severe hyperlipidemia than patients without this polymorphism. 
Polymorphisms in lipolysis genes associate with the expression and severity of type III HLP in 
APOE2/2.
INTRODUCTION
Patients with type III hyperlipoproteinemia (HLP) are characterized by elevated levels of total 
cholesterol and triglycerides due to high plasma levels of chylomicron and very low density 
lipoproteins (VLDL) remnants enriched in cholesterol esters and APOE.1,2
 APOE, a major constituent of chylomicron and VLDL remnants, serves as a ligand for the receptor-
mediated uptake of these particles by the liver.3 In type III HLP, APOE mutations lead to an impaired 
clearance of remnant lipoproteins by hepatic lipoprotein receptors. There are three common 
genetic variants of APOE: APOE2 (Arg158   Cys), APOE3 (Cys112; Arg158) and APOE4 (Cys112   Arg). 
These isoforms are encoded by three co-dominant alleles that are located at one single gene locus 
on chromosome 19. In comparison to the other two isoforms, APOE2 has less than 1% binding 
capacity for the hepatic low density lipoprotein receptor (LDLR).4 Most type III HLP patients (> 90%) 
are homozygous carriers of APOE2 (Arg158    Cys).4 In Caucasian populations, APOE2 homozygosity 
occurs with a frequency of about 1%, whereas the frequency of type III HLP is about 1 to 7 per 5000.5,6 
A minority of the APOE2 homozygous subjects will develop type III HLP, indicating that type III HLP 
is a multifactorial disorder requiring additional genetic and environmental factors for its clinical 
manifestation.4,7,8 It has been suggested that contributors to the expression of type III HLP include 
factors causing (1) an overproduction of lipoproteins, (2) an impaired lipolysis of lipoproteins or (3) an 
impaired hepatic uptake of remnants.4,9 Insulin resistance is associated with high triglyceride levels 
caused by an increased VLDL production.10,11 Earlier we found an association of high insulin levels with 
the expression of type III HLP.6,12
 Several groups studied genetics factors that may contribute to the expression of type III HLP. 13-16 
However, in the present study we have studied a larger type III HLP cohort. In addition, we used a 
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normolipidemic APOE2 homozygote cohort as control group. Mutations in genes involved in lipolytic 
conversion, such as LPL (lipiprotein lipase), HL (hepatic lipase) and APOC3 have been associated with 
hyperlipidemia (for reviews see references).17-20 In addition, Zhang et al.13 observed an increased 
allele frequency for the LPL N291S mutation in type III HLP patients when compared with the general 
population. SNPs in the APOA5 gene (11q23) were found to be strongly associated with plasma 
triglyceride levels.21,22 
 Data from family studies on type III HLP indicate that one or more genes are possible additional 
genetic factors predisposing to type III HLP.4 However, from these studies it was not evident which 
additional genes were involved or the study population was very small. In the present study, a 
significant population of both normolipidemic and hyperlipidemic E2/2 subjects was collected to 
determine additional genetic risk factors contributing to the expression of type III HLP in APOE2 
homozygotes. For comparison, these genetic risk factors were also typed in hypertriglyceridemic 
(HTG) patients 23,24 - they partly match their elevated VLDL/TG phenotype with type III HLP patients – 
and a normolipidemic Dutch control panel (NDCP). 
METHODS
Subjects
The study population consisted of 167 unrelated homozygous carriers of APOE2 (Arg158    Cys). Type 
III HLP patients were defined as having total cholesterol and triglyceride levels ≥ 90th percentile, 
VLDL cholesterol/triglyceride ratio > 0.3 (mg.dL-1/ mg/dL) and/or VLDL cholesterol/VLDL triglyceride 
ratio of > 0.8 (mmol/L/mmol/L) whereas normolipidemic E2/2 subjects had total cholesterol and 
triglyceride levels < 90th percentile according to the age- and sex-related percentile levels of the 
Prospective Cardiovascular Münster Study (PROCAM).25 Ultracentrifuge data were not available from 
24 HLP type III patients. Two HLP APOE2 homozygotes were excluded from the analysis because 
their plasma triglyceride levels were normal. 
 In total, 102 type III HLP patients and 9 normolipidemic E2/2 subjects were recruited from the 
outpatient Lipid Clinics of the University Medical Centers of Leiden, Nijmegen, Amsterdam and 
Rotterdam. Ten unrelated carriers (two type III HLP patients and eight normolipidemic E2/2 subjects) 
were detected during a population-based study among 2018 randomly selected 35-year-old men.26 
Forty-four E2/2 subjects (9 type III HLP patients and 35 normolipidemic E2/2 subjects) were collected 
from the Rotterdam Study, a prospective cohort study of 6870 healthy participants aged 55 years and 
older, investigating determinants of chronic diseases .27
 In this study we included 113 type III HLP patients and 52 normolipidemic E2/2 subjects. Clinical 
data and blood samples from type III HLP patients were collected before lipid-lowering medication. 
One normolipidemic E2/2 subject and one type III HLP patient with a history of pancreatitis were not 
included in the study. 
 The selection of the 141 hypertriglyceridemic (HTG) patients was described earlier.23 The 188 
normolipidemic Dutch controls (NDCP) were selected on APOE genotype, and total plasma cholesterol, 
triglycerides and HDL levels, between the 25th and 75th percentile. Informed consent was given by 
each participant and the study was approved by the Ethics Committee of our hospital. 
 Vascular disease was defined as the presence of coronary artery disease (angina pectoris, 70% 
stenosis on coronary arteriography, myocardial infarction, coronary by-pass or percutaneous 
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transluminal coronary angioplasty) and/or cerebrovascular disease (stroke or transient ischaemic 
attack) and/or peripheral vascular disease. Hypertension was defined as systolic blood pressure of ≥ 
160 mm Hg, or diastolic blood pressure of ≥ 90 mm Hg, or the use of medication for hypertension.28 
Less than 20% of the Type III HLP patients were treated with antihypertensive medication: 11% 
with a bètablocker and/or diuretic and 8% with other antihypertensive drugs. About 6% of the 
normolipidemic subjects were treated with antihypertensive medication. Four patients received 
anti-diabetic medication.
 Hyperinsulinemia was defined as fasting insulin concentrations ≥ 100 pmol/L. The diagnostic 
criterion for diabetes mellitus was fasting blood glucose ≥ 7 mmol/L. Smoking was defined as the 
consumption of at least ten cigarettes per day. The non-smokers also included ex-smokers, who 
stopped smoking for at least one year. Alcohol consumers were defined as subjects with alcohol 
consumption of two or more grams per day.
APOE phenotyping and genotyping
APOE phenotypes were determined by isoelectric focusing of delipidated serum samples and after 
cysteamine treatment followed by immunoblotting with a polyclonal anti-APOE antiserum as 
described.29 The results were confirmed by APOE genotyping.30
Lipid and lipoprotein analysis
With the exception of the sampling of 38 E2/2 subjects originating from the Rotterdam Study, all 
blood samples were collected after an overnight fast. Serum was obtained after centrifugation at 
1500 g for 15 min at room temperature. Total serum cholesterol and triglyceride levels were measured 
enzymatically, using commercially available kits. Serum HDL-C concentration was measured after 
precipitation of VLDL and LDL with phosphotungstic acid and MgCl2.
31 Three milliliters of serum 
was ultracentrifuged for 15 hours at 232000 g at 15°C in a TL-100 tabletop ultracentrifuge. The 
ultracentrifugate was divided in a density (d) < 1.006 and 1.006 < d < 1.25 g/mL fraction, designated as 
the VLDL and IDL+LDL-HDL fraction, respectively.
Serum insulin and glucose measurements
Insulin and glucose concentrations were only measured in fasting blood samples. The insulin 
concentration was determined by a radioimmunoassay (Ins-Ria-100, Medgenix). The antibody of 
this assay cross-reacts with proinsulin (40%) but not with C-peptide (< 0.001%).32 Serum glucose was 
determined by the automated hexokinase method of Hitachi 747, Boehringer Mannheim-Hitachi.
DNA analyses
Genomic DNA was isolated from leucocytes according to Miller et al.33 The following mutations or 
polymorphisms were indentified with PCR followed by restriction enzyme analysis as previously 
described: The 3238 C>G (Sst-1; rs5128) 34 polymorphism in 3’-UTR of exon 4 of the APOC3 gene, LPL 
c.27 G>A (D9N; rs1801177), LPL c.1342 C>G (S447X; rs328) 35, LPL c.874 A>G (N291S; rs268) 13, HL c.219 
G>A (V73M; rs6078), HL –480 C>T (rs8192701) 36, HL c.1005 A>G (L334F; rs3829462) 37 and HL c.609 C>G 
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(T202T; rs6084) 38 in respectively the LPL and HL gene. Analysis of both the APOA5 polymorphisms 
-1131 T>C (SNP3; rs662799) in the APOA5 promoter region and the c.56 G>C (S19W, rs3135506) in exon 3 
of the APOA5 gene, were analyzed as described earlier.23 
Statistical analyses
Differences between groups were tested with the X2 test for dichotomous and categorical variables 
and the unpaired Student’s t-test for continuous variables. As total cholesterol, total triglyceride and 
plasma insulin levels showed non-Gaussian distributions, these parameters were logarithmically 
transformed before analysis. Untransformed levels are shown in the tables. 
 For each polymorphism or mutation, the Hardy-Weinberg equilibrium was calculated using 
the gene-counting method and differences were assessed by X2 test. The X2 test or Fisher’s exact 
test were applied to compare genotype and allele frequencies between type III HLP patients, 
normolipidemic E2/2 subjects, NDCP and HTG patients. A logistic regression model was used to 
examine the association between the presence of a mutation and the occurrence of type III HLP. The 
strength of the association was estimated as the odds ratio (OR) with 95% confidence intervals (95% 
CI). P-values lower than 0.05 were considered significant. Selection of all SNPs in this study was based 
on literature data, describing association of these SNPs with lipid phenotype. Therefore adjustment 
for multiple testing was not applied (replication). Statistical analyses were performed with SPSS 
statistical software (version 14.01; SPSS, Chicago, IL). Linkage disequilibrium (LD) estimations in the 
APOC3/A5 region were estimated using Haploview 3.32.39
RESULTS
Baseline characteristics of the study populations
The mean age of type III HLP patients was lower and their BMI was higher compared with 
normolipidemic E2/2 subjects (Table 1). The prevalence of vascular disease was increased in type III 
HLP patients, whereas no differences in the occurrence of hypertension, diabetes mellitus and the 
number of smokers and alcohol consumers were found between the groups. Furthermore, type III HLP 
patients had significantly higher total triglyceride and insulin levels compared with normolipidemic 
E2/2 subjects, whereas HDL-C was decreased. Characteristics of the normolipidemic panel (NDCP) 
and hypertriglyceridemic (HTG) patients are summarised in Table 1. 
Genotype and allele frequencies
Table 2 shows the genotype distributions and allele frequencies of polymorphisms in the APOC3, 
APOA5, and the LPL genes in the type III HLP patients, normolipidemic E2/2 subjects, NDCP and 
the HTG patients. The genotype or allele frequencies of all HL polymorphisms and a subset of the 
analyzed LPL polymorphisms did not differ significantly between the study populations and are not 
shown in Table 2. These include: HL -480 C>T, HL c. 219 G>A, HL c.1005 A>G, HL c.609 C>G, LPL c.874 A>G 
and LPL c.1342 C>G. All polymorphisms, in all groups, were in Hardy-Weinberg equilibrium. 
 Distribution of the genotypes of the APOC3 3238 G>C, APOA5 -1131 T>C and LPL c.27 G>A 
polymorphisms differed significantly between the normolipidemic E2/2 subjects and the type III HLP 
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patients (Table 2). Distribution of the genotypes of the APOC3 3238 G>C, APOA5 -1131 T>C and LPL c. 27 
G>A, but not the APOA5 c.56 G>C polymorphisms, differed significantly between NDCP and type III 
HLP patients. We observed a significant difference in genotype frequency between HTG patients and 
type III HLP patients for the APOA5 -1131 T>C polymorphisms but we did not observe such difference 
for the APOC3 3238 G>C, APOA5 c.56 G>C and LPL c.27 G>A polymorphisms.
 The frequency of the minor allele of the APOC3 3238 G>C polymorphism and the (in LD) APOA5 
-1131 T>C polymorphism were increased in type III HLP patients and the HTG patients (15.6% and 
15.1% in the type III HLP, 21.7% and 23.5% in the HTG patients, vs. a mean NDCP / normolipidemic 
APOE2 homozygotes of ~7.2 and ~6.1%, respectively). The APOA5 c.56 G>C polymorphism showed a 
significantly increased frequency of the minor allele in type III HLP patients (11.8%) and in HTG patients 
(18.7%) when compared with the mean minor allele frequency of the NDCP / normolipidemic APOE2 
homozygotes (~6.2%). A significant enrichment of the minor allele of the LPL c.27 G>A mutation was 
observed among type III HLP patients and HTG patients (respectively, 6.2% and 4.8%), compared 
to the other study populations (NDCP and normolipidemic APOE2 homozygotes respectively, 2.6%, 
and 1.0%). LD estimation within the tightly linked cluster of the APOC3/A5 region, confirmed earlier 
findings of others that the APOA5 -1131 T>C and APOC3 3238 G>C polymorphisms are in strong LD (D’ = 
0.8), whereas the APOA5 c.56 G>C and -1131 T>C polymorphisms are not. 
Table 1 Clinical and biochemical characteristics of type III HLP patients, normolipidemic E2/2 subjects, normal 
Dutch controls and hypertriglyceridemic patients 
       Type IIIHLP      Normo       NDCP       HTG 
              N         N          N          N
Male       76 (67%)    113   32 (62%)  52  90 (48%)   188  119 (84)    141
Female       37 (33%)    113   20 (39%)  52  97 (52%)   188  22 (16%)   141
Age mean (years)     50.4 **    113   64.0    52  41       187  53       141
Age range (years)     27-80     113   27-80    52  6-78     187  26-78     141
Body mass index (kg/m2) 26.9 ± 3.8*   113   25.3 ± 4.0  49  -       -   -       -
Vascular disease     46 (41%)*   113   7 (15%)   39  -       -   -       -
Hypertension      31 (27%)    113   14 (26%)  42  -       -   -       -
Diabetes mellitus     11 (10%)    113   5 (10%)   40  -       -   -       -
Smokers      45 (40%)    112   19 (39%)  43  -       -   -       -
Alcohol consumers    78 (75%)    105  29 (78%)  30  -       -   -       -
Total cholesterol (mmol/L) 11.0 ± 3.5a,**   113   5.7 ± 1.0   52  5.1 ± 0.72a   188  8.8 ± 3.89  141
Total triglycerides (mmol/L) 6.7 ± 4.7a,**   113   2.0 ± 0.7  47  1.1 ± 0.35a   188  14.3 ± 13.80a 137
HDL-C (mmol/L)     1.0 ± 0.3 **    113   1.4 ± 0.3  48  1.3 ± 0.23a   188  0.7 ± 0.20  137
Glucose (mmol/L)     5.4 ± 1.2    100  5.2 ± 0.8  14  -       -   -       -
Insulin (pmol/L)     157.2 ± 138.0**  74   62.5 ± 41.4  14  -       -   -       -
Type III HLP: type III hyperlipidemic patients; normo: normolipidemic E2/2 subjects; NDCP: normal Dutch control panel; HTG: 
hypertriglyceridemic patients. N, total number of subjects with available data about the respective parameter. Body mass index and plasma 
parameters are presented as mean ± SD. 
a Selection criterion.
*   P < 0.05 , significantly different from normolipidemic E2/2 subjects.
** P < 0.001, significantly different from normolipidemic E2/2 subjects. 
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Association of APOC3 3238 G>C, APOA5 -1131 T>C, APOA5 c.56 G>C and LPL c.27 G>A with 
type III HLP
Association between polymorphisms and the expression of type III HLP was tested by logistic 
regression analysis using a dominant model (i.e. 1/1 vs. 1/2 + 2/2). Table 3 shows the association of the 
APOC3 3238 G>C polymorphism (OR = 2.7, 95% CI 1.1 – 6.7, P = 0.03), the APOA5 -1131 T>C polymorphisms 
(OR = 3.1 95% CI 1.2 – 8.0, P = 0.02), the APOA5 c.56 G>C polymorphism (OR = 2.4, 95% CI 0.9 – 6.7, P = 
Table 2 Genotype and allele frequencies
            APOE2 homozygotes  
Genotype  / Allele frequencya  Type III HLP, N (%)   NORMO, N (%)   NDCP, N (%)  HTG, N (%)
APOC3 3238 G>C    
GG        78 (69.6)         44 (86.3)  *      123 (83.9) **    71 (61.7)
GC        33 (29.5)         7 (13.7)       23 (15.4)     38 (33.0)
CC        1 (0.9)          0 (0.0)       1 (0.7)      6 (5.2)
1        189 (84.4)         95 (93.1) *        273 (92.6) *    180 (78.3)
2        35 ( (15.6)         7 (6.9)        25 (7.4)      50 (21.7)
95 % CI        1.11 – 1.20         1.02 – 1.12      1.05 – 1.12     1.16 – 1.27
APOA5 -1131 T>C    
TT        75 (70.8)         45 (88.2)  *       127 (88.2) **    67 (58.3) *
TC        30 (28.3)         6 (11.8)       16 (11.1)      42 (36.5)
CC        1 (0.9)          0 (0.0)       1 (0.7)      6 (5.2)
1        180 (84.9)         96 (94.1) *       270 (93.7) **    176 (76.5) *
2        32 (15.1)         6 (5.9)        18 (6.3)      54 (23.5)
95 % CI        1.10 – 1.20         1.01 – 1.10      1.03 – 1.09     1.18 – 1.29
APOA5 c.56 G>C    
GG        84 (79.2)         46 (90.2)      114 (85.1)      85 (67.5)
GC        19 (17.9)         5 (9.8)        20 (14.9)     35 (27.8)
CC        3 (2.8)          0 (0.0)       0 (0.0)      6 (4.8)
1        187 (88.2)         97 (95.1)       248 (92.5)     205 (81.3)
2        25 (11.8)         5 (4.9)        20 (7.5)      47 (18.7)
95 % CI        1.01 – 1.16         1.01 – 1.10      1.04 – 1.1     1.14 – 1.24
LPL c.27 G>A    
GG        100 (88.5)         51 (98.1) *      144 (94.7) *     103 (90.4)
GA        12 (10.6)         1 (1.9)         8 (5.3)      11 (9.6)
AA        1 (0.9)          0 (0.0)        0 (0.0)      0 (0.0)
1        212 (93.8)         103 (99.0) *     296 (97.4) *     217 (95.2)
2        14 (6.2)          1 (1.0)        8 (2.6)      11 (4.8)
95 % CI        1.03 – 1.09        0.99 – 1.03     1.01 – 1.04     1.02 – 1.08
95% CI: 95% confidence interval; type III HLP: type III hyperlipidemic patients; normo: normolipidemic E2/2 subjects; NDCP: normal Dutch 
control panel; HTG: hypertriglyceridemic patients. 
a 1 represent common allele frequency, 2 rare allele frequency.
 *  Significant different genotype / allele frequency (P< 0.05) with type III HLP.
 ** Significant different genotype / allele frequency (P< 0.01) with type III HLP. 
Differences between genotype or allele frequencies are based on linear-by-linear association.
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0.12) and the LPL c.27 G>A mutation (OR = 6.6, 95% CI 0.8 – 52.1, P = 0.07) with the occurrence of type 
III HLP. 
 The APOA5 -1131 T>C and APOC3 3238 G>C polymorphisms (in LD) showed a similar significantly 
increased risk on the occurrence of type III HLP. A significant association between the APOA5 c.56 
G>C polymorphism and the LPL c.27 G>A mutation and expression of type III HLP was not seen. 
However, the association (Table 3, cumulative) of carrying a rare allele of either APOA5 c.56 G>C, -1131 
T>C, APOC3 3238 G>C polymorphisms or LPL c.27 G>A mutation (OR = 3.7, 95% CI 1.8 – 7.5, P < 0.0001) 
and the expression of type III HLP was significantly increased. 
 To investigate the effect of the polymorphisms on plasma lipid levels, type III HLP patients were 
divided in carriers and non-carriers of the polymorphisms. Type III HLP patients with the APOC3 3238 
G>C polymorphism and (in LD) the APOA5 -1131 T>C polymorphism showed increased levels of total 
cholesterol compared with their counterparts without the polymorphism (Figure 1). Total triglyceride 
levels were significantly increased in carriers of the APOA5 -1131 T>C polymorphism compared with 
non-carriers, whereas the increased levels of total triglyceride levels in the APOC3 3238 G>C carriers 
did not reach statistical significance (Figure 2). To further determine the association of the different 
cholesterol-rich lipoprotein fractions with genetic variation, we also investigated the effect of the 
polymorphisms, APOC3 3238 G>C, APOA5 -1131 T>C and c.56 G>C, and LPL c.27 G>A on plasma HDL and 
VLDL cholesterol (Figure 3). We observed no effect of the polymorphisms on plasma HDL cholesterol 
(data not shown) whereas carriers of rare variants of both APOC3 3238 G>C and APOA5 -1131 T>C, 
showed a significant association with plasma VLDL cholesterol levels. Evaluation of the association 
of the APOA5 c.56 G>C, APOA5 -1131 T>C, APOC3 3238 G>C and the LPL c.27 G>A variants with plasma 
lipid levels in the NDCP did not reveal any significant associations. The effect of the polymorphisms 
on plasma lipid (TG) levels in the HTG patients has been described previously.23,24
Table 3 Association of genotypes with the expression of type III HLP
    Type III HLP, N (%)  Normo, N (%)  OR (95% CI)   P-value
APOC3 3238 G>C    
1/1    78 (69.6)      44 (86.3)     2.7 (1.1– 6.7)   0.03
1/2 + 2/2    34 (30.4)      7 (13.7)  
APOA5 -1131 T>C    
1/1    75 (70.8)      45 (88.2)      3.1 (1.2–8.0)   0.02
1/2 + 2/2    31 (29.2)      6 (11.8)  
APOA5 c.56 G>C    
1/1    84 (79.2)      46 (90.2)     2.4 (0.9–6.7)  0.12
1/2 + 2/2    22 (20.8)        5 (9.8)  
LPL c.27 G>A    
1/1    100 (88.5)      51 (98.1)      6.6 (0.8– 52.1)  0.07
1/2 + 2/2      13 (11.5)      1 (1.9)  
Cumulative ¥     
non-carrier   48 (42.5)      38 (73.1)     3.7 (1.8 – 7.5)    < 0.0001
Carrier    65(57.5)      14 (26.9)  
Type III HLP: type III hyperlipidemic patients; normo: normolipidemic E2/2 subjects. OR, odds ratio; 95% CI: 95% confidence interval. 1/1: ho-
mozygous for the common allele; 1/2: heterozygous for the common and rare allele; 2/2: homozygous for the rare alelle. ¥ Cumulative: non-carrier 
represents non-carrier of the rare allele of either the APOA5 C.56 G>C , SNP3, APOC3 -1131 T>C or LPL c.27 G>A and carrier represents carrier of the 
rare allele of either the APOA5 C.56 G>C , SNP3, APOC3 -1131 T>C or LPL c.27 G>A.
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DISCUSSION
The clinical manifestation of type III HLP, in addition to defective hepatic clearance of remnant 
lipoproteins in E2/2 subjects, may be caused by impaired lipolysis.4,9,40 Several groups reported 
about LPL and proteins involved in LPL activity, as apoCIII and apoAV in type III patients. 13-16 In 
accordance with this hypothesis we replicated in the largest type III cohort reported thus far, 
associations for polymorphisms in proteins involved in the lipolytic conversion of lipoproteins: the 
3238 G>C polymorphism in the APOC3 gene (in LD with APO5 -1131 T>C polymorphism) and the c.27 G>A 
mutation in the LPL gene. Our results show that the APOC3 3238 G>C/ APOA5 -1131 T>C polymorphism 
exacerbates the hyperlipidemic phenotype of type III HLP patients, while the LPL c.27 G>A mutation 
has no additional effect on plasma lipid levels.
 In an earlier study, we found an interaction between hyperinsulinemia and the APOC3 3238 
G>C polymorphism, associated with severe hyperlipidemia in APOE2 homozygotes.12 By increasing 
the number of E2/2 subjects, data from the present study demonstrate that the APOC3 3238 G>C 
polymorphism per se is also an important contributor to type III HLP expression. The APOC3 3238 G>C 
polymorphism is strongly associated with elevated plasma triglyceride levels.41 In accordance, our type 
III HLP patients carrying the APOC3 3238 G>C polymorphism showed a more severe hyperlipidemia, 
i.e. higher VLDL-cholesterol levels and a tendency of higher triglyceride levels than non-carriers. 
The molecular mechanism underlying the 
association with HTG is still unclear. The APOC3 
3238 G>C polymorphism is located in the 3’-UTR 
of the APOC3 gene and could be a causal variant 
by acting on mRNA stability which results in 
increasing apoCIII plasma levels. However, 
it is also possible that the APOC3 3238C>G 
polymorphism itself is not responsible for the 
triglyceride-raising effect. Other mutations 
within the APOA1-C3-A4 gene cluster, located 
near the APOC3 3238 G>C polymorphic site, could 
be candidates for being the causative mutations 
leading to HTG. Two polymorphisms located 
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Fig.3. Effect of the APOC3 3238 G>C, the APOA5 -1131 T>C and APOA5 c.56 
G>C, and the LPL c.27 G>A polymorphisms on VLDL-cholesterol levels in 
type III HLP patients. N represents number of type III HLP patients.
*P < 0.05.
Fig.1. Effect of the APOC3 3238 G>C, the APOA5 -1131 T>C and APOA5 c.56 
G>C, and the LPL c.27 G>A polymorphisms on plasma cholesterol levels in 
type III HLP patients. N represents number of type III HLP patients. 
*P < 0.05.
Fig.2. Effect of the APOC3 3238 G>C, the APOA5 -1131 T>C and APOA5 c.56 
G>C, and the LPL c.27 G>A polymorphisms on plasma triglyceride levels in 
type III HLP patients. N represents number of type III HLP patients. 
*P < 0.05.
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at positions –482 and –455 in the promoter region of the APOC3 gene showed substantial linkage 
disequilibrium with the 3238 G>C polymorphism, as reported by others.41-43 However, we found in a 
much smaller subgroup of our type III HLP patients, no evidence of an association between these 
polymorphisms and increased triglyceride levels 12, whereas Miller et al. suggested an association 
with these two APOC3 polymorphisms and the metabolic syndrome. 40 Functional studies to elucidate 
the exact role on apoCIII protein levels of each of these three polymorphisms should be performed.
 The LPL c.27 G>A mutation leads to an increased bridging of LDL and monocyte adhesion and is also 
associated with elevated levels of plasma triglycerides and reduced plasma HDL-cholesterol levels.44 
In our type III HLP patients, a tendency towards increased plasma cholesterol and triglyceride levels 
was observed in LPL c.27 G>A carriers, but this did not reach statistical significance, possibly due to 
the size of our groups. In Caucasians, the –93T  G transition in the LPL gene promoter is in linkage 
disequilibrium with the LPL c.27 G>A mutation.18,45 However, several studies have reported that the 
triglyceride-raising effect was solely attributable to the presence of the LPL c.27 G>A mutation.45 
 Data from genetic association studies on type III HLP are limited due to the low prevalence of 
APOE2 homozygosity in the population. To circumvent this problem, most studies have compared the 
allele frequency of mutations in type III HLP patients to that of the general population. Zhang et al.13 
found an increased allele frequency for the LPL N291S mutation in type III HLP patients compared 
with the Dutch population. However, this approach does not include the possibility that the mutation 
is also more prevalent in normolipidemic APOE2 homozygotes. Conversely, Evans et al16 showed that 
the LPL mutations D9N, in particular N291S and S447X (c.27 G>A, c.874 A>G and c.1342 C>G resp.) were 
not associated with type III HLP. 
 Comparison of the Dutch population frequency for the HL -480 C>T mutation (19%) with that 
of our type III HLP patients (31%) revealed that the mutation was significantly more prevalent in 
patients (P < 0.001).36 However, the fact that we did not find such a difference between patients and 
normolipidemic E2/2 subjects indicates that the LPL c.874 A>G and the HL -480 C>T mutations are not 
major contributors to the expression of type III HLP (data not shown).  Moreover, also no association 
with type III HLP was found for HL c. 219 G>A, HL c.1005 A>G, HL c.609 C>G and LPL c.1342 C>G. 
 To further study the patient and population prevalences of the APOA5, APOC3 polymorphisms and 
the LPL c.27 G>A mutation, two additional populations were screened: the NDCP and HTG patients. 
The prevalences of the APOC3 3238 G>C/APOA5 -1131 T>C polymorphism, APOA5 c.56 G>C and the LPL 
c.27 G>A mutation in the NDCP cohort are similar to those observed in the normolipidemic APOE2 
homozygote individuals. This indicates that the normolipidemic APOE2 homozygotes were not a 
selected sub-population. In contrast, the prevalences of the APOC3, APOAV and LPL mutations in the 
HTG patients are similar to those of the type III patients, indicating that these polymorphisms are 
universal risk factors for hypertriglyceridemia.
 Earlier studies have reported frequencies for the rare variant of the c.56 G>C polymorphism in type 
III patients.14,15,46 In our type III patients, the rare variant of APOA5 c.56 G>C polymorphism is far less 
frequent (11.8%) than reported thus far. In addition, 4.9% of the normolipidemic APOE2 homozygotes 
still was carrier of the rare allele of the APOA5 c.56 G>C polymorphism. Moreover, we found no 
association between plasma triglyceride and cholesterol levels and the c.56 G>C polymorphism in 
hyper- and normolipidemic FDs. The fact that this association is not present and the frequency of the 
c.56 C-allele is somewhat increased in the type III HLP population suggests that the APOA5 c.56 G>C 
polymorphism is a weak contributor to the clinical manifestation of type III HLP. The mechanism how 
this variant acts remains to be solved. It has been suggested that the APOA5 c.56 G>C polymorphism 
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alters the signal peptide which results in a decreased secretion of apoAV protein. However, such 
correlation between APOA5 rare variant carriers and plasma apoAV, was not found in a cohort of HTG 
patients. 23
As reported by others, our data show that the APOC3 3238 G>C and APOA5 -1131 T>C polymorphisms 
show a high linkage disequilibrium. 41,47 Fifteen percent of type III HLP patients are carriers of the 
APOA5 -1131 T>C polymorphism and 15.6% are carriers of the APOC3 3238 G>C polymorphism. In the 
present study we did not aim to elucidate a causal role of each polymorphism. 
 In total 58% of type III HLP patients vs. 27% of normolipidemic APOE2 homozygotes are carrier 
of the APOC3 3238 G>C/APOA5 -1131 T>C polymorphism, APOA5 c.56 G>C and/or the LPL c.27 G>A 
mutation, indicating that these mutations could partly explain the expression of type III HLP. 
Additional genetic and environmental risk factors remain to be identified. Earlier, we found that 
hyperinsulinemic APOE2 homozygotes have an increased risk for type III HLP.6 It is likely that the 
suppression of VLDL-production by insulin in these hyperinsulinemic patients is reduced, resulting 
in chronically elevated VLDL-production.10 Another possible mechanism is through an interaction 
between insulin and genes involved in the lipolysis of lipoproteins. Several studies support the 
hypothesis that insulin is involved in the regulation of the APOC3 gene. The presence of the APOC3 
–455 and –482 polymorphisms may abolish the insulin responsiveness of the APOC3 promoter.48,49 
Since the APOC3 3238 G>C polymorphism in E2/2 subjects is almost exclusively found in combination 
with the presence of the –455 and –482 promoter variants, it seems possible that in E2/2 subjects, 
who are carriers of the 3238 G>C polymorphism, the loss of insulin regulation results in overexpression 
of the APOC3 gene and, as a consequence, in overt hyperlipidemia.12,34 In addition, insulin is a major 
regulator of LPL activity. The combination of high insulin levels and decreased LPL activity, as found 
in carriers of LPL mutations, may further exacerbate the expression of HTG.50
 In conclusion, our data indicate that the APOC3 3238 G>C, APOA5 -1131 T>C and to a lesser extent 
the LPL c.27 G>A mutation associate with the elevated plasma TG phenotype of type III HLP patients, 
whereas APOA5 c.56 G>C is perhaps a weak modifier. 
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Objective: Plasma adiponectin is negatively correlated with metabolic syndrome (MetS) components 
obesity and insulin sensitivity. Here, we set out to evaluate the effect of menopause on the association 
of plasma adiponectin with MetS.
Design: Data on plasma adiponectin and MetS were available from 2256 individuals participating 
in the Erasmus Rucphen Family study. Odds ratios for MetS were calculated by logistic regression 
analysis using plasma adiponectin quartiles. The discriminative accuracy of plasma adiponectin for 
MetS was determined by calculating the area under the receiver-operator curve (AUC). Analyses were 
performed in women and men, pre- and postmenopausal women and younger and older men.
Results: Virtually all determinants of MetS differed significantly between groups. Low plasma 
adiponectin showed the highest risk for MetS in postmenopausal women (OR = 18.6, 95% CI = 7.9 
– 44.0). We observed a high discriminative accuracy of age and plasma adiponectin for MetS in 
postmenopausal women (AUC = 0.76), but also in other subgroups (AUC from 0.67 – 0.87). However, 
in all groups, the discriminative accuracy of age and BMI for MetS was not exceeded by age and 
plasma adiponectin. 
Conclusions: Low plasma levels of adiponectin are associated with increased prevalence of MetS, 
especially in postmenopausal women. Age and BMI have similar discriminatory accuracies for 
presence of MetS when compared to age and plasma adiponectin. Thus, we conclude that the 
association of plasma adiponectin with MetS is significantly affected by menopause but challenge 
the additional value of adiponectin for the discriminatory accuracy for presence of MetS.
Introduction
The prevalence of obesity and the metabolic syndrome (MetS) is increasing dramatically in populations 
with a western lifestyle1-3. Central obesity, dyslipidemia, impaired fasting plasma glucose (FPG) and 
hypertension are important components of MetS4. Given the increased morbidity and mortality 
associated with MetS, research has focused on associations of specific biomarkers with the (early) 
onset and progression of MetS2,5,6.
 Obesity plays a key role in the aetiology of MetS and related diseases. Adipose tissue functions 
as an endocrine organ which responds to changes in metabolic conditions by secreting biologically 
active substances also known as adipocytokines or adipokines7,8,9. Specifically, the visceral fat depot, 
which has rapid access to the systemic circulation via the portal vein, is thought to play an important 
role in adipokine secretion and MetS and related disorders10. Many groups have suggested that 
plasma adipokines are potential biomarkers for MetS, in particular plasma adiponectin11,12.
 Adiponectin is secreted form adipose tissue and is present in plasma in various multimeric forms. 
Plasma adiponectin levels have been shown to differ largely between genders13. In humans, plasma 
adiponectin levels are negatively correlated with obesity and type two diabetes (T2D)14,15,16. In mouse 
models, adiponectin has been shown to play a role in energy homeostasis by regulating insulin 
sensitivity of the liver17. Adiponectin is suggested to have an important role in vascular endothelium 
as modifier of monocyte adhesion by affecting anti-inflammatory properties. In addition, adiponectin 
has also been implicated in regulation of vasodilatation, via the endothelial NO synthase (eNOS) 
pathway18. 
 Gender and age effects in the expression of MetS have been previously demonstrated19. 
Furthermore, it was shown that MetS is more prevalent in men than in premenopausal women19,20. 
After menopause, women experience a substantial increase in dyslipidemia and other MetS related 
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risk factors, leading to a risk profile comparable with that seen in men21,22. Thus, differences between 
pre- and postmenopausal women with regard to the prevalence of MetS and plasma adiponectin 
have been reported independent from each other. It has been suggested that plasma adiponectin is 
a promising biomarker for MetS11,12. However, within the general population the effect of menopause 
on the association of plasma adiponectin with MetS is not clear. Furthermore, it is not clear to what 
extent menopause affects the association between plasma adiponectin and MetS.
 The present study aims to elucidate the effect of menopause on the association of plasma 
adiponectin with MetS. In addition, we investigate the discriminatory accuracy of plasma adiponectin 
for presence of MetS as a measure for a MetS biomarker. Analyses were performed overall and in 
subgroups: pre- and postmenopausal women and younger and older men (stratified on the mean age 
at halt of menstruation of women).
Methods
Study population
We used data of the Erasmus Rucphen Family (ERF) study. This population was embedded in an 
isolated population (Genetic Research in Isolated Populations, GRIP). The ERF population includes 
individuals who were not selected based on health information, but comprises living descendants of 
22 couples, who had at least 6 children baptized in the community church between 1850 and 1900. 
Details about the genealogy of the population are described elsewhere23,24,25. The study protocol was 
approved by the medical ethics board of the Erasmus MC Rotterdam, the Netherlands. A written 
informed consent was obtained from each participant and all investigations were carried out in 
accordance with the Declaration of Helsinki. 
Data collection
Blood of participants was obtained in the fasted state. Total plasma insulin was analyzed with the INS-
Irma kit of DIAsource ImmunoAssays (formerly Bio-Source; Nivelles, Belgium; cat #: KIP1254), total 
plasma adiponectin with the Human adiponectin RIA kit (cat#: HADP-61HK) of Linco Research (St. 
Charles, MO, USA) and total plasma CRP with the US C-reactive protein ELISA (cat.# DSL-10-42100) of 
Diagnostic Systems Laboratories (Webster, TX, USA), Inc. All measurements were performed conform 
the manufactures protocol. The distribution of plasma CRP level was skewed, therefore upper plasma 
CRP levels exceeding three times the standard deviation of the mean were removed from the analyses. 
Menopause was defined by halt of menstruation whether it be naturally, due to medication or due to 
surgical intervention. Insulin sensitivity was based on the homeostasis model assessment insulin 
resistance (HOMA-IR; glucose* insulin divided by 22.5). Assessment of the following study variables 
have been given earlier by others26,23,27,19: Medication use; glucose lowering, lipid lowering or anti-
hypertension treatment, body mass index (BMI), MetS (International Diabetes Federation – 2006, 
europids); waist circumference (WC, men ≥ 94 cm, women ≥ 80 ), fasting plasma glucose (FPG, ≥ 5.6 
mmol/L, previously diagnosed/treated type 2 diabetes patients included), HDL-cholesterol (HDL-C, 
men < 1.03 mmol/L, women < 1.29 mmol/L, treated patients included), total plasma triglycerides (TG, 
≥ 1.7 mmol/L, treated patients included), systolic blood pressure (SBP, ≥ 130 mm Hg, treated patients 
included), diastolic blood pressure (DBP, ≥ 85 mm Hg, treated patients included).
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Statistical analyses
Women were stratified in two groups according to menopause. The mean age of premenopausal 
-and postmenopausal women was 37.8 and 60.2 years respectively and the mean age at halt of 
menstruation was 46.8 years. In order to be able to exclude an age effect in our analyses, we divided 
the men in two groups, younger -and older men, using the mean age at halt of menstruation of 
women. Younger men were defined by an age limit of < 46.8 years, older men by an age limit of > 
46.8 years. Continuous variables did show some deviation from a normal distribution. Analysis of 
mean differences between groups was tested using analysis of variance (ANOVA) statistics using log 
normal transformed continuous variables or chi-squared statistics (categorical variables). All further 
analyses were based on the log normal transformed trait values with exception of the correlation 
analysis, which was performed using Spearman’s correlation method. Odds ratios (OR) were 
calculated using binary logistic regression analyses, using quartiles of plasma adiponectin level, age 
and BMI as independent variables. Plasma adiponectin cut off values for these quartiles were 18.3 
mmol/L, 11.1 mmol/L, 7.9 mmol/L and 4.7 mmol/L for group 1 to 4 respectively. The group with highest 
plasma adiponectin levels (18.3 mmol/L) was taken as reference group. The discriminative accuracy 
for MetS was based on predicted probabilities (binary logistic regression) according four different 
models; model 1: age; model 2: age and BMI; model 3: age and plasma adiponectin; model 4: age, 
BMI and plasma adiponectin. Predicted probabilities were calculated in pre –and postmenopausal 
women, total women, younger –and older men and total men. The binary logistic regression in 
total women and total men included next to independent variables also interaction terms of the 
stratification component (menopause or younger and older men) with each independent variable 
within the respective model. For example, in the total female group the first model (1) included age 
and age*menopause, the second model (2) age, BMI, age*menopause and BMI*menopause, the 
third model (3) age, adiponectin, age*menopause and adiponectin * menopause and the final model 
(4) included age, BMI, adiponectin, age*menopause, BMI*menopause and adiponectin*menopause. 
The discriminating accuracy is the extent to which test results can discriminate between individuals 
who will develop the disease and those who will not28. The area under the receiver operating 
characteristic curve (AUC) is commonly used to quantify this discriminative accuracy of a predicting 
model29. The AUC is the probability that the test correctly identifies the diseased individual from a pair 
of whom one is affected and one is unaffected, and ranges from 0.5 (total lack discrimination) to 1.0 
(perfect discrimination)28. Analysis of the data was performed using SPSS 14.01 software. Statistical 
tests were not independent, which was a equirement for multiple test correction (e.g. Bonferoni). 
However, as we performed a considerable amount of statistical tests, only P-values below 0.01 were 
assumed significant.
Results
Characteristics of the study population are described in Table 1. Data on plasma adiponectin, insulin 
and CRP levels were obtained for 2256 individuals. The population included 695 premenopausal and 
581 postmenopausal women and 418 younger and 549 older men (stratified on mean age of onset 
menopause in women). The prevalence of MetS was 17.0% in premenopausal women, 43.2% in 
postmenopausal women, 22.2% in younger men and 48.5% in older men. All measurements, with 
exception of age and HDL-cholesterol, differed significantly (P< 0.05) between women and men (data 
77
not shown) and between pre- and postmenopausal women and between younger and older men.
 Spearman’s correlation coefficients between plasma adiponectin and MetS, MetS individual traits 
and MetS related traits are presented in Table 2. Correlation coefficients of plasma adiponectin 
level with MetS were -0.23, -0.37 in respectively pre- and postmenopausal women and -0.19, -0.22 
in respectively younger and older men. We observed significant correlations of plasma adiponectin 
with each of the individual components of MetS with exception of diastolic blood pressure in all four 
groups. Correlation coefficients of plasma adiponectin level with MetS related traits: BMI, fasting 
plasma insulin level, HOMA-IR and plasma CRP level ranged from -0.11 to -0.34 (P < 0.01). Correlation 
coefficients differed in general more than 0.10 between pre- and postmenopausal women, whereas 
no difference was observed between younger and older men.
 The presence of MetS was higher in subgroups with lower plasma adiponectin levels, indicated 
by the higher OR presented in Figure 1. The highest OR for the presence of MetS was observed for 
postmenopausal women in the lower plasma adiponectin quartile (OR = 18.6, 95% CI=7.9–44.0) which 
differed significantly from that seen in the premenopausal women (OR = 4.5, 95% CI=1.7–7.4). We did 
not observe such extreme differences in OR’s between the two male groups. 
 To assess the value of adiponectin as biomarker for MetS, we analyzed the AUC as a measure of 
discriminative accuracy according to several models (Table 3). The AUC of age for MetS (model 1) 
Table 1: General characteristics of the study population
         Women                Men
         Premenopausal   Postmenopausal   Younger   Older
         (n=695)      (n=581)       (n=418)    (n=549)
Age (yr)         37.8 ± 9.6      60.2 ± 8.3 **   36.0± 7.8   59.5 ± 8.0 ***
Metabolic syndrome and its individual components
Metabolic syndrome % (n)   17.0 (118)       43.2 (251) ***    22.2 (93)   48.5 (266) ***
Waist circumference (cm)    78.4 ± 11.3     86.1 ± 11.5 ***  90.5 ± 10.8  96.9 ± 11.2 ***
Glucose (mmol/L)       4.2 ± 0.8      4.7 ± 0.8 ***    4.5 ± 0.8   5.0 ± 1.1 ***
HDL-cholesterol (mmol/L)    1.4 ± 0.4      1.4 ± 0.4      1.1 ± 0.3   1.2 ± 0.3
Triglycerides (mmol/L)     1.1 ± 0.6      1.4 ± 0.7 ***    1.4 ± 0.9  1.6 ± 0.9 *
Systolic blood pressure (mm Hg)  126.7 ± 15.2     147.4 ± 21.8 ***   136.9 ± 12.6 148.2 ± 20.0 ***
Diastolic blood pressure (mm Hg)  76.5 ± 9.6      80.9 ± 9.4 ***   78.8 ± 9.8  84.0 ± 9.2 ***
Metabolic syndrome related traits
Body mass index (kg/m2)   25.5 ± 5.0      27.8 ± 4.7 ***    26.9 ± 4.1  27 .6 ± 4.0 ***
Insulin (_U/ml)        12.2 ± 5.5      13.6 ± 7.4 ***    13.9 ± 9.8  13.9 ± 8.1
HOMA-IR        2.3 ± 1.3      2.9 ± 1.9 ***    2.9 ± 2.5   3.2 ± 2.3 
Adiponectin (mgl/L)      11.9 ± 5.3      12.9 ± 6.2 *    7.7 ± 3.8   8.2 ± 4.4 *
C-reactive protein (mg/L)   5.7 ± 4.6      6.3 ± 4.7 **     4.0 ± 3.6   5.9 ± 4.4 ***
Medication
Glucose lowering % (n)    0.9 (6)       3.4 (20) ***     0.0 (0)    4.9 (27) ***
Lipid lowering % (n)      3.2 (22)       18.9 (110) ***    3.6 (15)    23.5 (129) ***
Blood pressure lowering % (n)   8.1 (56)        31.2 (181) ***     5.3 (22)    32.6 (179) ***
HDL: high density lipoprotein; HOMA-IR: Homeostatic model assessment-Insulin resistance. Values presented as mean ± SD for continuous 
variables and percent (number) for categorical variables. Plasma was taken in fasted state. Differences were calculated within gender group only, 
* P < 0.05, ** P < 0.01, *** P < 0.001. Significance of continuous variables based on ANOVA, for non-continuous variables based on Chi2. 
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ranged from 0.55 (95% CI= 0.50 – 0.60) in older 
men to 0.71 (95% CI= 0.68 – 0.74) in total women. 
When the discriminatory accuracy for presence 
of MetS was based on age and BMI (model 2) 
AUC’s ranged from 0.80 (95% CI= 0.76 – 0.83) in 
postmenopausal women to 0.92 (95% CI= 0.90 – 
0.95) in younger men. In the third model, which 
included age and adiponectin (model 3), AUC’s 
ranged from 0.67 (95% CI= 0.64 – 0.71) in older 
men to 0.87 (95% CI= 0.85 – 0.89) in the total 
female group. Finally, when age, adiponectin and 
BMI all (model 4) were included, we observed 
the largest AUC’s, ranging from 0.84 (95% CI= 
0.81 – 0.87) in postmenopausal women to 0.92 
(95% CI= 0.90 – 0.95) in younger men. 
Discussion
Low plasma adiponectin is associated with obesity and insulin resistance15,30 and plasma adiponectin 
has been proposed as a biomarker for MetS16,31. Large differences in mean plasma adiponectin 
and correlation coefficients with Mets and MetS associated traits have been reported between 
genders13,32,33. Our observations confirmed a significant difference in plasma adiponectin level and 
Fig.1. Odds ratio of adiponectin quartiles for presence of the MetS. Bars 
represent OR ± 95% confidence interval in pre- and postmenopausal 
women and younger men (<46.8 years old) and older men (>46.8 years 
old). * P < 0.01, Odds ratio based on logistic (binary) regression adjusted 
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Table 2: Spearman’s correlation coefficients of plasma adiponectin levels with MetS, MetS individual 
components and MetS related traits.
         Women                 Men
         Premenopausal   Postmenopausal    Younger  Older
         (n=695)      (n=581)        (n=418)  (n=549)
Age         -0.03       0.07         -0.14 **  0.12 **    
Metabolic syndrome and its individual components
Metabolic syndrome     -0.23 ***     -0.37 ***      -0.19 ***  -0.22 ***
Waist circumference      -0.30 ***     -0.38 ***      -0.18 ***  -0.24 ***
Glucose         -0.09 *      -0.22 ***      -0.13 **  -0.07
HDL-cholesterol        0.33 ***      0.42 ***        0.29 ***    0.31 ***
Triglycerides        -0.19 ***     -0.34 ***       -0.18 ***  -0.17 ***
Systolic blood pressure    -0.03       0.00         -0.14 **  -0.08
Diastolic blood pressure    -0.01       0.01         -0.09   -0.06
Metabolic syndrome related traits
Body mass index       -0.26 ***     -0.30 ***       -0.17 ***  -0.21 ***
Insulin         -0.27***     -0.33 ***       -0.18 **  -0.19 ***
HOMA-IR        -0.26 ***     -0.34 ***       -0.19 **  -0.18 ***
C-reactive protein       -0.11 **     -0.25 ***      -0.08   -0.14 **
HDL: high density lipoprotein; HOMA-IR: Homeostatic model assessment-Insulin resistance. Values presented as Spearman’s correlation 
coefficient, * P < 0.05, ** P < 0.01, *** P < 0.001.
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virtually all aspects of MetS between genders and within gender subgroups (Table 1). As large mean 
differences are also observed between the male groups (stratified on mean age of onset menopause 
in women), age seems significant contributor to variation in plasma adiponectin. 
 We further questioned whether menopausal status, independent from age, affects plasma 
adiponectin levels and its association with MetS and associated traits. The spearman’s ρ correlation 
coefficients for plasma adiponectin levels with MetS, MetS individual components and associated 
traits were different in women before and after menopause (Table 2). Furthermore, we observed 
higher correlation coefficients in postmenopausal women and we observed that correlation 
coefficients varied to a much lesser extent between both male groups. These findings indicate that 
menopausal status, independent of age, had a large effect on the correlation of plasma adiponectin 
with MetS, MetS individual components and MetS associated traits (with exception of diastolic 
blood pressure).
 The correlation of plasma adiponectin with MetS was further investigated by determining the 
OR for MetS in pre- and postmenopausal women and younger and older men. It is well known 
that age and body composition strongly influence the manifestation of MetS and that obesity is 
strongly associated with plasma adiponectin levels. Therefore, we included in addition to age, BMI 
as covariates in the logistic regression. Although an effect was seen in premenopausal women and 
both male groups, our analysis showed that the OR of MetS in the lowest adiponectin quartile was 
the highest in postmenopausal women (OR = 18.6 95% CI = 7.9 – 44.0, figure 1). Because in men 
such high OR was not observed, these data indicate that the risk for MetS was especially high for 
postmenopausal women, independently of age. 
 Our data showed a moderate discriminative accuracy for the presence of MetS, expressed as 
AUC, of age alone (Table 3, model 1). As obesity is an essential component of MetS, our data further 
confirmed the high discriminative accuracy for the presence of MetS of age and BMI (Table 3, model 
2). As the AUC of age alone was lower compared to the AUC of age and plasma adiponectin (Table 
3, models 1 and 3), plasma adiponectin contributed significantly to the discriminative accuracy for 
the presence of MetS. Including BMI in the model, this discriminative accuracy was even better 
(Table 3, model 4) and consistent between the genders and gender groups (AUC ≥ 0.84). Thus, the 
contribution of BMI in model 4 was substantial in the discriminative accuracy for the presence of 
MetS. Our findings further showed that age and BMI are more accurate in detecting the presence of 
MetS than age and adiponectin (Table 3, models 2 and 3). As measuring BMI is far more cost effective 
than measuring plasma adiponectin, the clinical utility of plasma adiponectin for the diagnosis MetS 
is questionable. Nevertheless, the logistic regression analyses indicated a high relative risk for MetS 
in particular in postmenopausal women with low plasma adiponectin. Since OR’s are frequently used 
Table 3: Discrimanative accuracy (AUC) of age, BMI and plasma adiponectin in the prediction of MetS.
       Model 1     Model 2       Model 3      Model 4
       age       age / BMI     age / adiponectin age / BMI / adiponectin
Premenopausal women  0.61 (0.56 – 0.67) 0.87 (0.84 – 0.90)  0.72 (0.68 – 0.78)  0.88 (0.85 – 0.91)
Postmenopausal women 0.60 (0.55 – 0.65) 0.80 (0.76 – 0.83)  0.76 (0.72 – 0.80)  0.84 (0.81 – 0.87)
Total women       0.71 (0.68 – 0.74) 0.85 (0.83 – 0.88)  0.87 (0.85 – 0.89)  0.87 (0.85 – 0.89)   
Younger men      0.66 (0.60 – 0.72) 0.92 (0.90 – 0.95)  0.71 (0.66 – 0.77)  0.92 (0.90 – 0.95)
Older men       0.55 (0.50 – 0.60) 0.84 (0.80 – 0.87)  0.65 (0.61 – 0.70)  0.85 (0.82 – 0.88)
Total men       0.67(0.64 – 0.71) 0.88 (0.86 – 0.90)  0.73 (0.69 – 0.76)  0.89 (0.87 – 0.91)
BMI: body mass index. Values presented as AUC (95% confidence interval). Detailed description of models see methods.
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in genetic studies, our data indicate that ignoring menopause may result in underestimation of effect 
size in genetic association analysis of plasma adiponectin. 
 The MetS can be diagnosed according to several different definitions34. In addition to the IDF MetS 
definition, a widely used MetS definition has been formulated by the National Cholesterol Education 
Pogram Adult Treatment Panel III (NCEP ATP III). The IDF and the NCEP ATPIII definitions differ 
slightly in MetS component threshold values19,34. Moreover, in contrast to the NCEP ATPIII, the 
obesity measure waist circumference is essential in the IDF definition. The Pearson correlation 
coefficient between IDF and NCEP ATPIII is 0.68 in our study cohort. To investigate whether the 
differences in MetS definitions affected the associations of plasma adiponectin with MetS or the 
discriminative accuracies for the presence the MetS, we recalculated all analyses using the NCEP 
ATPIII MetS definition. These analyses showed similar results obtained with regard to the IDF MetS 
definition. For example, postmenopausal women in the lower plasma adiponectin quartile showed 
for the IDF an OR of 18.6 (95% CI=7.9–44.0) and the NCEP ATPIII showed an OR of 16.8, (95% CI=7.8–
36.4). In addition, the AUC analyses showed highly similar results (data not shown). These analyses 
demonstrated that our calculation of OR and the discriminative accuracies for the presence the MetS 
associated with plasma adiponectin were not determined by the
IDF MetS definition. 
 In conclusion, the present study confirmed gender differences in the association of plasma 
adiponectin with MetS and demonstrated that this association was significantly affected by 
menopause. We showed that adiponectin per se was strongly associated with MetS, in particular in 
postmenopausal women, but then its discriminative accuracy was overruled by the obesity measure 
BMI. Nevertheless, the strong effect of menopause on the association of plasma adiponectin with 
MetS and MetS components indicates that inclusion of menopause in genetic association studies of 
plasma adiponectin will increase statistical power.
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Abstract 
Objective: Adiponectin, a hormone secreted by adipose tissue is of particular interest to metabolic 
syndrome (MetS), since it is inversely correlated with obesity and insulin sensitivity. However, it is 
unknown to what extent the genetics of plasma adiponectin and the genetics of obesity and insulin 
sensitivity are interrelated. We aimed to evaluate the heritability of plasma adiponectin and its 
genetic correlation with the MetS and MetS related traits and the association between these traits 
and ten ADIPOQ SNPs.
Research Design and Methods: We made use of a family-based population, the Erasmus Rucphen 
family (ERF) study (1258 women and 967 men). Heritability analysis was performed using a polygenic 
model. Genetic correlations were estimated using bivariate heritability analyses. Genetic association 
analysis was performed using a mixed model.
Results: Plasma adiponectin showed a heritability of 55.1%. Genetic correlation between plasma 
adiponectin HDL-C and plasma insulin ranged from 15% to 24% but were not significant for fasting 
glucose, TG, blood pressure, HOMA-IR and CRP. Significant association with plasma adiponectin was 
found for ADIPOQ variants rs17300539 and rs182052. Nominally significant association was found with 
plasma insulin and HOMA-IR and ADIPOQ variant rs17300539 after adjusting for plasma adiponectin.
Conclusions: The significant genetic correlation between plasma adiponectin and HDL-C, and plasma 
insulin should be taken into account in the interpretation of genome wide association studies. 
Association of ADIPOQ SNPs with plasma adiponectin was replicated and we showed association 
between one ADIPOQ SNP and plasma insulin and HOMA-IR. 
The dramatic increase in the prevalence of the metabolic syndrome (MetS) in countries with a 
western lifestyle is precipitated by environmental variables. However, the individual susceptibility 
to the obesogenic environment is largely determined by genetic susceptibility1. Central obesity, 
dyslipidemia, impaired glucose metabolism and hypertension are the key elements determining 
the expression of the MetS2 which is associated with an increased risk for type 2 diabetes (T2D) and 
cardiovascular disease (CVD)2.
 Adipose tissue is an active endocrine tissue which can respond to changes in metabolic conditions 
by secreting biologically active substances (adipokines). The adipokine family can be divided in two 
overlapping sets of signaling molecules, namely those with metabolic / immunologic function, which 
include interleukins 1ß, 6, 8, 10 or 18, tumor necrosis factor alpha and tumor growth factor beta, 
and those with endocrine function, which include leptin, retinol binding protein 4, adiponectin and 
resistin3. Human adiponectin is a protein of 247 amino acids (30-kDa), encoded by a gene (ADIPOQ) 
located on chromosome 3q274. Adiponectin is secreted and present in plasma in various multimeric 
forms of which the biological significance remains to be determined. Yamauchi et al showed that 
binding of adiponectin to adiponectin receptors (ADIPOR1 and ADIPOR2) in mice results in increased 
AMPK activity and PPAR-α activity. In humans, both receptors are mainly expressed in skeletal muscle 
and adiponectin could thus play a role in energy metabolism5.
 Limited data on the overall heritability of plasma adiponectin is available. Furthermore, it is not 
known whether the genetics of plasma adiponectin overlap with the genetics of body weight and 
insulin sensitivity/diabetes or other individual components of the MetS. Several studies showed 
convincing association of genetic variants near and in the promoter region of the ADIPOQ gene with 
plasma adiponectin and T2D or T2D related traits9,5,10. 
 In the present study, we set out to evaluate the heritability of plasma adiponectin and its genetic 
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correlation with the MetS and the MetS related traits BMI, insulin, HOMA-IR and plasma CRP. 
Research Design and Methods 
Study population
In the present study, we used data of the Erasmus Rucphen Family (ERF) study, which is embedded 
into a rural genetically isolated population (Genetic Research in Isolated Populations; GRIP). This 
young, genetic isolate from the southwest of the Netherlands was initiated by <400 founders in the 
middle of 18th century. Minimal immigration occurred between the surrounding settlements due to 
social and religious reasons. The population experienced a fast expansion and at the moment this 
region counts roughly 20.000 inhabitants. The ERF population is a cross-sectional cohort and includes 
3,000 individuals, who were not selected based on health information, but rather comprise living 
descendants of 22 couples who had at least 6 children baptized in the community church around 1850-
1900. Details about the genealogy of the population have been described elsewhere11,12. In the current 
study, we included 2256 individuals of the ERF population from whom all study parameters were 
known. We did not exclude participants based on health status. The study protocol was approved 
by the medical ethics board of the Erasmus MC Rotterdam, the Netherlands. All investigations were 
carried out in accordance with the Declaration of Helsinki. 
Data collection
Blood from participants was obtained in a fasted state. Total plasma insulin measurements were 
analyzed with the INS-Irma kit of Biosource (cat.#: KIP1254), total plasma adiponectin with the 
Human adiponectin RIA kit (cat#: HADP-61HK) of Linco Research and total plasma CRP with the 
US C-reactive protein ELISA (cat.# DSL-10-42100) of Diagnostic Systems Laboratories, Inc. All 
measurements were performed conform the manufactures protocol. Insulin sensitivity was based on 
the homeostasis model assessment insulin resistance (HOMA-IR; glucose * insulin divided by 22.5). 
Plasma CRP showed kurtosis, therefore, upper plasma CRP levels exceeding three times the standard 
deviation of the mean were removed from further analyses. Data on plasma adiponectin, insulin, 
HOMA-IR and CRP was available for 2256 individuals. MetS was assessed according to the criteria 
of the International Diabetes Federation (IDF- 2006, Europids), which requires a minimum waist 
circumference (WC,) and two of the following abnormalities: high fasting plasma glucose (glucose), 
low HDL-cholesterol (HDL-C), high total plasma triglycerides (TG), and high systolic and/or diastolic 
blood pressure (SBP/DBP), described in detail in supplemental table 1. Prevalence and heritability of 
MetS and related traits in ERF have been reported previously1,13. 
Statistical analyses
Analysis of mean differences between groups was tested using analysis of variance statistics 
(ANOVA, continuous variables) or chi squared statistics (Chi2, categorical variables). Correlations of 
plasma adiponectin with other traits were estimated in men and women separately adjusting for age 
and BMI. Heritability estimations were obtained using SOLAR software (version 2.05, http://solar.
sfbrgenetics.org11,1. Heritability and genetic association analyses were performed using normal-log 
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transformed trait values and SOLAR’s 
“tdist” function. The polygenic model 
(covariates: gender, age) was applied. 
Heritability estimations included 
a second variance component, the 
sibship effect (S), which is an estimate 
of phenotypic similarity, due to effects 
of a shared (early) environment and 
genetically dominant effects1. The effect 
of relevant medication use was assumed 
to be covered by the MetS definition 
(Models B). Inbreeding coefficients 
in heritability estimations were not 
significant and therefore excluded 
from further analyses. To determine 
the genetic correlations of plasma 
adiponectin with other traits we used 
bivariate heritability analysis. We also 
estimated gender-specific heritability 
using bivariate analysis of traits stratified 
by gender. Because the latter analysis is 
confined to one quantitative trait, the 
environmental correlation component 
is forced to be zero. Bivariate analysis 
was applied to plasma adiponectin with 
the MetS components and MetS related 
components using gender, age and BMI 
as covariates (Model A) or using gender, 
age and MetS as covariates (Model B). The bivariate heritability analysis yields estimates of the total 
overlapping genetic and environmental component (correlation) of these traits. 
 The following ADIPOQ variants were selected after literature review (9) and confirmed for tag 
property using Haploview ((r2 > 0.8; MAF >10%) and CEU HAPMAP data: rs864265, rs822387, rs17300539 
(-11391G/A), rs266729, rs182052, rs822396, rs2241766 (+45T/G), rs1501299 (+276G/T), rs3774262 and 
rs6773957. Selected variants were genotyped using Sequenom iPLEX (MALDITOF, Sequenom Inc. San 
Diego, USA). Genotypes were screened for Mendelian errors using the pedigree structure (14). All ten 
ADIPOQ variants achieved a call rate of >95% and all were in HWE (P>0.05). For ADIPOQ genotype-
association we assumed an additive model. Analysis of plasma adiponectin included covariates 
gender, age and BMI (Model A) or covariates gender, age and MetS (Model B). To investigate whether 
ADIPOQ SNPs were independently associated with plasma adiponectin, we applied a backward linear 
regression model containing all SNPs which were associated with plasma adiponectin at FDR < 0.05. 
The following model was used: rs822387, rs17300539, rs182052, rs1501299, rs6773957, gender, age and 
BMI as independent variables and plasma adiponectin as dependent variable. The independence of 
the associated SNPs was confirmed in HAPLOVIEW and these SNPs were used in association analysis 
with the MetS related traits. 
Table 1: Characteristics of the ERF population    
       Women   Men
       (n=1258)   (n=967)
Age (yr)       48.0 ± 14.3  49.4 ± 14.1 *
range (yr) / min-max   68.0 / 18-86  68.5 / 18-86  
Metabolic syndrome and its individual components
Metabolic Syndrome n(%) 369 (29.3)  359 (37.1) **
Waist circumference (cm)  81.9 ± 12.0  94.2 ± 11.5 **
Glucose (mmol/L)     4.4 ± 0.9   4.8 ± 1.0 **
HDL-cholesterol (mmol/L)  1.4 ± 0.4   1.1 ± 0.3 **
Triglycerides (mmol/L)   1.2 ± 0.7   1.5 ± 0.9 **
SBP (mm Hg)       136.1 ± 21.2  143.4 ± 18.0 **
DBP (mm Hg)       78.6 ± 9.8  81.7 ± 9.8 **
Metabolic syndrome related traits
Body mass index (kg/m2) 26.6 ± 5.0  27.3 ± 4.1 **
Insulin (_U/ml)      12.8 ± 5.8   13.9 ± 8.8 *
HOMA-IR      2.6 ± 1.6   3.0 ± 2.4 **
Adiponectin (mg/L)    12.4 ± 5.8   8.1 ± 4.1 **
CRP (mg/L)      11.1 ± 22.2  10.0 ± 28.5 **
Medication
Glucose lowering med. n (%) 26 (2.1)   27 (2.8)
Lipid lowering med. n (%) 132 (10.5)   144 (14.9) *
Anti-hypertension med. n (%) 237 (18.8)  201 (20.8)
SBP: systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: Homeostatic 
Model Assessment-Insulin Resistance; CRP: C-reactive protein; med.: medication. 
Values presented are mean ± SD for continuous traits and number (percent) for 
categorical traits. 
* Significant different from women (P-value < 0.05), ** (P-value < 0.01), continuous 
traits based on ANOVA, non- categorical traits based on Chi2 test.
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 Association analyses of ADIPOQ variants with MetS related traits was performed using two 
models with different covariates: (1) gender, age, BMI, (2) gender, age, BMI and plasma adiponectin. 
Adjustment for family structure of the association model was based on a pedigree matrix obtained 
using Illumina 6K linkage chip data. Analysis was performed using model residuals in score test 
accounting for pedigree structure as implemented in GenABEL software15 function “mmscore”16. The 
Bayesian information criterion (BIC) for plasma adiponectin was implemented on associated ADIPOQ 
SNPs, gender, age and BMI using R software. All other analyses were performed using SPSS 14.01 
(September 2005) software. 
results
Characteristics of the ERF 
cohort are presented in table 
1. The prevalence of the MetS, 
according to the IDF definition, 
was 29.3% in women and 37.1% 
in men. Virtually all mean values 
differed significantly (P<0.01) 
between genders. 
 To determine the association 
of plasma adiponectin with 
the MetS and related traits, 
we calculated the partial 
correlation coefficients of 
plasma adiponectin with each 
studied trait (supplemental 
table 2) adjusted for age and 
BMI. Plasma adiponectin 
showed a high correlation with 
the MetS (ρ= -0.20 and ρ= 
-0.13 in, respectively, women 
and men) and with the lipid 
components HDL-C and TG (all ρ 
≥ 0.15, P< 0.01). The correlation 
of plasma adiponectin with 
BMI (adjustment only for age), 
fasting plasma insulin, HOMA-
IR and plasma CRP showed 
correlations coefficients ranging 
from 0.10 to 0.29 (all P< 0.05). In 
men, we observed in general for 
all components lower correlation 
coefficients, with the exception 
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Table 2: Genetic and environmental correlation of plasma adiponectin 
with MetS, MetS components and MetS related traits
Model A     _G  SE  P     _E    SE  P 
Metabolic syndrome and its individual components
Metabolic Syndrome  -42.7 11.3 <10-04 -19.4  9.4     0.04
Waist circumference  -20.4  7.3  <10-03  -18.8  5.8  <10-04
Glucose        -2.6  8.7     0.76   -12.0  5.6     0.03
HDL-cholesterol    24.7  7.2  <10-04  35.6  5.5  <10-9
Triglycerides     -12.2  8.9     0.17   -26.0  5.2  <10-6
SBP      -10.3  9.1     0.26     -7.1   5.3     0.18
DBP        -9.5  9.2     0.31      6.0   5.4     0.27
Metabolic syndrome related traits
Body mass index ¥  -32.4  7.2  <10-05  -20.7  5.9  <10-04
Insulin      -20.0  9.9     0.04  -18.8  5.1  <10-04
HOMA-IR    -18.6  9.9     0.06  -19.6  5.1  <10-04
CRP     -11.6 12.3 0.34   -13.4  5.4     0.01
Model B     _G  SE  P     _E    SE  P 
Metabolic syndrome individual components
Waist circumference  -15.0 8.9  0.092  -22.6  5.6  < 10-04
Glucose        0.5 8.9  0.955  -11.3  5.5  0.040
HDL-cholesterol     15.2 7.7  0.048  37.2   5.4  < 10-11
Triglycerides     -11.9 9.8  0.225  -26.0  5.1  < 10-06
SBP      -6.3 9.3  0.498  8.5   5.3  0.100
DBP      -7.1 9.6  0.459  4.0   5.3  0.450
Metabolic syndrome related traits
Body mass index ¥  -12.9 7.9  0.103  -14.6  6.1  0.017
Insulin      -19.1 10  0.056  -19.1  5.1  < 10-03
HOMA-IR    -16.4 10  0.101 -20.4  5.1  < 10-04
CRP     -12.3 11.7  0.293  -14.4  5.5  0.009
Model A: included covariates – gender, age and body mass index; Model B: covariates – gender, 
age and metabolic syndrome. _G: genetic correlation (%); _E: environmental correlation (%).  
SBP: systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: Homeostatic Model 
Assessment-Insulin Resistance; CRP: C-reactive protein. P: P-values were derived using Chi2 
test, covariates gender, age and body mass index  ¥ covariate gender and age only. 
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of diastolic blood pressure. 
 We next estimated the heritability of plasma adiponectin and MetS related traits. Heritability 
estimates of the MetS and its individual components and BMI in ERF have been described earlier1,13. All 
heritability estimates were highly significant and none of the MetS related traits showed a significant 
sibship effect estimate (S). The heritability estimate of plasma insulin was 21.4 %, SE=5.2%, P=<10-05 
(S=6.1%, SE=4.2%, P=0.07), of HOMA-IR 22.0 %, SE=5.3%, P=<10-05 (S=5.8%, SE=4.3%, P=0.08) and of 
plasma CRP level 21.0 %, SE=4.9%, P=<10-05 (S=nihil). The highest heritability estimate was found for 
plasma adiponectin 55.1%, SE= 4.7, P< 10-6 (S=nihil). 
 Next, we performed bivariate analysis of gender-stratified age-adjusted traits. We observed no 
significant difference in the heritability between the genders and found a high correlation (ρ =100%) 
between the heritability of plasma adiponectin in men (h2 =59.6%, SE = 9.4) and women (h2 =52.9%, 
SE = 7.7). Details on gender specific heritability of plasma insulin, HOMA-IR and plasma CRP are 
presented detail in supplemental table 3. Gender-stratified bivariate heritability estimates of the 
MetS and its individual components and BMI have been described earlier1,13.
 Bivariate heritability analyses were performed using trait by trait analyses on plasma adiponectin 
combined with the MetS and the MetS related traits. To investigate whether the interrelation between 
Table 3: Association of variants in and around ADIPOQ with plasma adiponectin 
Model A          Alleles   Frequency Effect  
SNP  Position  n    M/m   (m)     (m)    SE      P
Prs864265 Pr     1918   G/T    0.19     -0.012   -0.023   0.601
rs822387 Pr     1917    C/T    0.95    0.146   0.040   3.0 10-4
rs17300539 Pr     1919   A/G    0.95    0.155   0.040   9.3 10-5
rs266729 Pr     1934   G/C    0.74     -0.025  -0.021   0.230
rs182052  Ex-1    1916   A/G    0.68    -0.070  -0.020   3.0 10-4
rs822396 Ex-1    1925   A/G    0.22    0.043   0.021    0.049
rs2241766 In-1    1939   G/T    0.93    0.037   0.036    0.303
rs1501299 Ex-2    1921    T/G    0.73     0.057   0.021    0.006
rs3774262 Ex-2    1937   A/G    0.93    0.035   0.036    0.330
rs6773957 3’-UTR  1914   A/G    0.67    0.061   0.020   0.002
Model B           Alleles   Frequency Effect  
SNP  Position  n    M/m   (m)     (m)    SE      P
rs864265 Pr     1904   G/T    0.19     -0.006  -0.023   0.788
rs822387 Pr     1904   C/T    0.95    0.143   0.040   3.6 10-4
rs17300539 Pr     1905   A/G    0.95    0.166   0.040   2.7 10-5
rs266729 Pr     1920   G/C    0.74     -0.017   -0.020   0.400
rs182052  Ex-1    1902   A/G    0.68    -0.066  -0.019   6.7 10-4
rs822396 Ex-1    1911    A/G    0.22    0.043   0.022    0.047
rs2241766 In-1    1924   G/T    0.93    0.046   0.036    0.202
rs1501299 Ex-2    1907   T/G    0.73     0.055   0.021    0.007
rs3774262 Ex-2    1923   A/G    0.93    0.046   0.036    0.200
rs6773957 3’-UTR  1900   A/G    0.67    0.063   0.020   0.001
Model A: included covariates – gender, age and body mass index; Model B: covariates – gender, age and metabolic syndrome. m; effect allele. Pr; 
promoter, Ex; exon, In; intron, UTR; untranslated region. P: P-values based on Chi2 test. P-values printed in bold were selected for analysis in a 
backward linear regression model and were evaluated on linkage disequilibrium using Haploview (HAPMAP CEU).  
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the traits affected their genetic correlations, we used two statistical models: Model A included BMI 
as covariate and Model B included MetS as covariate in addition to age and gender in the trait by trait 
analyses. The outcomes of the bivariate heritability analysis of plasma adiponectin and the MetS and 
the MetS related traits are presented in table 2. 
 According to Model A, MetS, WC and HDL-C demonstrated a significant (P<10-3) shared genetic 
component with plasma adiponectin (-42.7%, -32.4% and +24.7% respectively). TG, FPG and both 
SBP and DBP showed a low and insignificant shared genetic component with plasma adiponectin. 
BMI and plasma insulin showed a significant (P< 0.04) shared genetic component with plasma 
adiponectin of respectively -32.4%, -20.0%, while our finding for HOMA-IR was borderline significant 
(ρ G=-18.6%, P=0.06). The genetic correlation of plasma adiponectin and plasma CRP was found to be 
not significant. The environmental correlations of plasma adiponectin with plasma glucose (-12.0%), 
HDL-C (+35.6%), TG ( -26.0%) and plasma CRP (-13.4%) exceeded their shared genetic component 
value. In contrast, the genetic correlation of plasma adiponectin and MetS was twice as high as 
their environmental correlation (ρ G = -42.7% and ρ E = -19.4%). According to Model B (covariates 
gender, age and MetS), HDL-C shares a significant (15.2%, P< 0.05) genetic component with plasma 
adiponectin. Plasma insulin shared a borderline significant (19.1%, P = 0.056) genetic component 
with plasma adiponectin. All observed environmental correlations obtained according to Model B 
exceeded their genetic correlations (Table 2).
 To investigate to what extend the high heritability of plasma adiponectin is due to variants located 
in the ADIPOQ gene, we performed genetic association analysis. Table 3 presents association of ten 
ADIPOQ SNPs with plasma adiponectin, adjusted for gender, age and BMI (Model A) and adjusted 
for gender, age and MetS (Model B) . According to both Model A and B, nominally significant 
associations with plasma adiponectin were found for two promoter SNPs (rs822387 and rs17300539), 
one SNP located in exon 1 (rs182052), one SNP locate in exon 2 (rs1501299) and one SNP (rs6773957) 
located in the 3’ untranslated region of the ADIPOQ gene. Four of these SNPs (except rs822396 and 
rs1501299) remained significant after conservative Bonferroni correction (P<0.005). The effect size of 
the promoter SNPs was substantially higher than the other significantly associated SNPs. 
 To determine the best model explaining plasma adiponectin we used the Bayesian information 
criterion (BIC)17. The parameters used in the BIC analysis for plasma adiponectin were gender, age, 
BMI and the ADIPOQ SNPs: rs822387, rs17300539, rs182052, rs1501299 and rs6773957 (N=1914). BIC 
values are presented in supplemental table 4. The lowest BIC value was found for the model including 
four ADIPOQ SNPs (rs822387, rs17300539, rs182052, and rs6773957). 
 Backward linear regression analysis of the five associated SNPs indicated that rs17300539 and 
rs182052 were independently associated with plasma adiponectin (P<0.001 and P<0.004, respectively, 
in the joint model). Evaluation of r2 between the SNPs using Haploview, confirmed the independency 
of the two ADIPOQ SNPs (r2 = 0.2, plot not shown). Next, we analyzed whether the two significant SNPs, 
ADIPOQ rs17300539 and rs182052, were also associated with the MetS and MetS related traits using 
two models. The first model included gender, age and BMI as covariates. The second model included 
gender, age BMI and plasma adiponectin as covariates. The second model was used to investigate 
whether MetS related traits were associated independently of plasma adiponectin. No significant 
associations were found for rs182052. ADIPOQ rs17300539 showed an significant association with 
plasma insulin (N= 1919, ß=0.072, SE=0.031, P= 0.022) and with HOMA-IR (N=1892, ß=0.084, SE=0.036, 
P= 0.021), according to model 2. 
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Conclusions
Here, we report a high heritability of plasma adiponectin (55.1%) and a similar genetic architecture 
between men and women. We also demonstrated that the genetic component of the HDL-C and 
plasma insulin overlap significantly with that of plasma adiponectin. The ADIPOQ rs17300539 and 
rs182052 were both found to contribute independently to the heritability of plasma adiponectin. Of 
these two SNPs, rs17300539 was also associated with plasma insulin and HOMA-IR illustrating their 
genetic overlap with adiponectin.
 Our estimate of the heritability of plasma adiponectin is similar to heritability reported by Patel 
et al. (62%)18. Furthermore, our heritability estimates of the MetS related traits (plasma insulin, 
HOMA-IR and plasma CRP) are in agreement with earlier reports19,20,21. In our previous study1 on the 
heritability of MetS and its individual components, heritability varied from 10.6% (MetS) to 42.9% 
(HDL-C). The heritability of plasma adiponectin is higher than the heritability of MetS or of its 
individual components, making it an attractive trait for genome wide association studies. 
 We did not find evidence for a gender-specific genetic component for plasma adiponectin1,13. Patel 
et al18 studied in a large longitudinal family based cohort, the genetic correlation between plasma 
adiponectin and obesity traits and found that the genetic correlation (ρ G) of plasma adiponectin with 
BMI and WC was for both approximately -40%. This matches well with our estimate of the genetic 
correlation between adiponectin and BMI of -32.4% using gender, age and BMI as covariates (Model 
A). Furthermore, we found, using Model A, a high and significant shared genetic component between 
plasma adiponectin and the MetS (-42.7%). Moreover, this genetic correlation was twice as large as 
the environmental correlation. Furthermore, according to Model A, WC (-20.4%), HDL-C (+24.7%) 
and plasma insulin (-20.0%) shared a significant genetic component with plasma adiponectin. Since 
many of the study parameters are strongly associated with each other, we also studied the genetic 
correlations adjusting for MetS (Model B). Applying this conservative model, the genetic correlations 
found according to Model A were consistent, again revealing the genetic correlations between 
plasma adiponectin and HDL-C and plasma insulin. Our findings imply that genetic studies of plasma 
adiponectin might also lead to the identification of genes associated with HDL-C and plasma insulin. 
 The ADIPOQ gene has been found to be consistently and significantly associated with plasma 
adiponectin in genetic association studies or GWA22,9. To investigate the role of the ADIPOQ gene in 
the genetic overlap between plasma adiponectin and MetS traits, we performed association analysis 
using 10 ADIPOQ SNPs. Hivert et al9 showed significant association of the ADIPOQ SNP rs17300539 with 
plasma adiponectin. Our study of 10 ADOPOQ SNPs showed that plasma adiponectin was significantly 
and consistently associated with six ADIPOQ variants using adjustment for gender, age and BMI 
(Model A) or adjustment for gender, age and MetS (Model B). Moreover, our study of 10 ADOPOQ 
SNPs showed that plasma adiponectin was significantly and independently associated with both 
ADIPOQ rs17300539 and rs182052 variants. ADIPOQ rs17300539 is located in the promoter region of the 
ADIPOQ gene whereas ADIPOQ rs182052 is located in exon 1 of the ADIPOQ gene. Whether these two 
variants are actually causal remains to be determined. Since our heritability and association analyses 
on plasma adiponectin and associated traits are in concert with findings of other studies in general 
cohorts or other genetically isolated populations, it seems unlikely that our findings are specific for 
the genetically isolated ERF cohort.
 Plasma adiponectin is strongly associated with MetS, obesity, and in particular with plasma 
insulin and insulin sensitivity. There is evidence indicating that insulin directly affects plasma 
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adiponectin23,24,25. Thus it is likely that the genetics of plasma adiponectin and insulin overlap. Hivert 
et al reported that rs173766743 was associated with the incidence of T2D9. Our analyses showed that 
rs17300539 was also associated with plasma insulin and HOMA, independently of plasma adiponectin. 
We did not observed any effect on this association using MetS instead of BMI as covariate (data not 
shown). Since HOMA-IR is a measure for insulin resistance which reflects a pre-diabetic state, we 
analyzed the r2 between ADIPOQ rs17300539 and rs173766743 in Haploview using HAPMAP CEU data. 
This analysis did not show any evidence of linkage disequilibrium between these variants (r2 =0). An 
explanation for this apparent discrepancy may be the adjustment for plasma adiponectin levels in 
our association analyses. Whether the association of rs173766743 with T2D is independent of plasma 
adiponectin was not reported. Since the association of rs17300539 with plasma insulin and HOMA-IR 
is independent of plasma adiponectin in our analyses, this implies a direct effect of this SNP on plasma 
insulin and insulin sensitivity. One explanation could be that ADIPOQ rs17300539 is associated with 
a functional variation of the adiponectin protein affecting insulin sensitivity independent of plasma 
levels of the protein. However, this association would have to be replicated in independent analyses 
before further investigation. 
 In conclusion, the present study confirms and extends the correlation of plasma adiponectin with 
HDL-C and plasma insulin. The high heritability of plasma adiponectin is promising for GWAS. The 
genetics of plasma adiponectin is similar between genders. The genetics of plasma adiponectin 
showed a significant and consistent overlap with the genetics of HDL-C and plasma insulin, which 
implies that GWAS of plasma adiponectin might also result in the detection of genetic variation 
associated with HDL-C , plasma insulin.
 Genetic association analyses indicated that ADIPOQ variation is strongly associated with plasma 
adiponectin and indicated that ADIPOQ rs17300539 is associated with plasma insulin and HOMA-
IR independently of plasma adiponectin. These genetic association data are thus in line with the 
observed genetic overlap between plasma adiponectin and plasma insulin. 
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Supplementary Material
Supplemental table 1: Metabolic syndrome 
definition according to the International Dia-
betes Federation (IDF, 2006)a    
_ Waist circumference (cm)   ≥ 94  
_ Waist circumference (cm)   ≥ 80 
Fasting plasma glucose (mmol/L) ≥ 5.6b,c
Systolic bloodpressure (mm Hg)  ≥ 130c
Diastolic blood pressure (mm Hg) ≥ 85c
_ HDL-Cholesterol (mmol/L)   < 1.03c
_ HDL-Cholesterol (mmol/L)   < 1.29c
Triglycerides (mmol/L)    ≥ 1.7c
a Europids
b included previously diagnosed type 2 diabetes patients
c included treatment patients.
Supplemental table 2: Partial correlation coefficients of 
plasma adiponectin with the MetS, its individual compo-
nents and MetS related traits. 
      Women   Men
      (n=1258)  (n=967) 
Metabolic syndrome and its individual components
Metabolic Syndrome       -0.20 **      -0.13 **
Waist circumference      -0.23 **      -0.12 *
Glucose           -0.10 **    -0.04
HDL-cholesterol         0.35 **       0.27 **
Triglycerides          -0.21 **       -0.15 **
SBP       -0.03       0.01
DBP        0.03     -0.04
Metabolic syndrome related traits
Body mass index ¥      -0.29 **       -0.20 ** 
Insulin          -0.17 **       -0.10 **
HOMA-IR         -0.18 **       -0.10 **
CRP           -0.12 **      -0.08 *
SBP: systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: 
Homeostatic Model Assessment-Insulin Resistance; CRP: C-reactive 
protein. Partial correlation coefficient: * P-value < 0.05; ** P-value < 0.01, 
covariates age and body mass index,  ¥ covariate age only. 
Supplemental table 3: Gender specific heritability of the MetS related traits
  Women         Men   
  h2 (%)   SE   P     h2 (%)   SE   P     _G    SE  P 
Adiponectin 52.9    6.5   <10-15  59.6    7.5   <10-14  100.0  -   -
Insulin  28.2    7.4   <10-03  21.6    7.3   <10-03  100.0  -   -
HOMA-IR 28.1    7.7   <10-03  24.5    9.4   <10-03  100.0  -   -
CRP  32.2    8.1   <10-04  17.1     9.8      0.08     91.7   28.6 0.77
_G: genetic correlation (%); _E : environmental correlation (%).  HOMA: Homeostatic Model Assessment-Insulin Resistance; CRP: C-reactive 
protein. P: P-values were derived using the Chi2 test. 
97
The genetic architecture of plasma adiponectin overlaps with the genetics of metabolic syndrome related traits
Supplemental table 4: Bayesian information criterion for 5 ADIPOQ SNPS with plasma adiponectin
nr rs822387 rs17300539  rs182052 rs1501299 rs6773957   BIC/1000
1 0  0 0 0 0 2.567
2 1  0 0 0 0 2.491
3 0  1 0 0 0 2.498
4 0  0 1 0 0 2.505
5 0  0 0 1 0 2.510
6 0  0 0 0 1 2.498
7 1  1 0 0 0 2.463
8 0  0 0 1 1 2.452
9 1  0 1 0 0 2.460
10 1  0 0 1 0 2.446
11 1  0 0 0 1 2.453
12 0  1 1 0 0 2.463
13 0  1 0 1 0 2.454
14 0  1 0 0 1 2.493
15 0  0 1 1 0 2.482
16 0  0 1 0 1 2.501
17 1  1 1 0 0 2.424
18 1  0 1 1 0 2.433
19 1  1 0 1 0 2.422
20 1  1 0 0 1 2.449
21 0  1 1 1 0 2.439
22 0  1 1 0 1 2.485
23 0  0 1 1 1 2.457
24 1  0 0 1 1 2.450
25 0  1 0 1 1 2.435
26 1  0 1 0 1 2.448
27 1  1 1 1 0 2.420
28 1  1 1 0 1 2.410
29 0  1 1 1 1 2.441
30 1  1 0 1 1 2.426
31 1  0 1 1 1 2.439
32 1  1 1 1 1 2.413
Thirty two Bayesian information criterion (BIC) models based on the log-likelihood estimates, calculated using the parameters gender, age, BMI 
and SNP(s). N=1914. BIC presented as BIC/1000. 
genetics of metabolic syndrome and related traits
98
99
Clear detection of ADIPOQ locus as the major gene 
for plasma adiponectin: results of genome-wide 
association analyses including 4659 European 
individuals
Iris M. Heid1,2*, Peter Henneman3*, Andrew Hicks4*, Stefan Coassin5, Thomas Winkler1, Yurii S. 
Aulchenko6, Christian Fuchsberger4, Kijoung Song7, Marie-France Hivert8, Dawn M. Waterworth7, 
Nicholas J. Timpson9, J. Brent Richards10,11, John R.B. Perry12, Toshiko Tanaka13,14, Najaf Amin3, Barbara 
Kollerits5, Irene Pichler4, Ben A. Oostra6, Barbara Thorand2, Rune R. Frants3, Thomas Illig2, Josée 
Dupuis15, Beate Glaser9, Tim Spector11, Jack Guralnik16, Josephine M. Egan17, Jose C. Florez18,19,20, 
David M. Evans9, Nicole Soranzo11,21, Stefania Bandinelli22, Olga D. Carlson17, Timothy M. Frayling12, 
Keith Burling23, George Davey Smith9, Vincent Mooser7, Luigi Ferrucci14, James B. Meigs18,24, Peter 
Vollenweider25, Ko Willems van Dijk3,26, Peter Pramstaller4,27,28*, Florian Kronenberg5#*, Cornelia M. v. 
Dujn3* (* authors contributed equally)
1 Department of Epidemiology and Preventive Medicine, Regensburg University Medical Center, Regensburg, Germany 
2 Institute of Epidemiology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany 
3 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
4 Institute of Genetics Medicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy. Affiliated Institute of the University 
of Luebeck, Germany.
5 Division of Genetic Epidemiology; Department of Medical Genetics, Molecular and Clinical Pharmacology; Innsbruck Medical 
University, Innsbruck, Austria
6 Department of Epidemiology, Erasmus MC Rotterdam, The Netherlands
7 Genetics Division, GlaxoSmithKline, King of Prussia, Pennsylvania, USA
8 Service d’Endocrinologie, Département de Médecine, Université de Sherbrooke, Quebec, Canada
9 MRC Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Bristol BS8 
2BN, UK
10 Departments of Medicine and Human Genetics, McGill University, Montréal, H3T 1E2, Canada
11 Twin Research and Genetic Epidemiology, King’s College London, London, SE1 7EH, UK
12 Genetics of Complex Traits, Peninsula Medical School, Magdalen Road, Exeter, UK
13 Medstar Research Institute, Baltimore, MD, USA
14 Clinical Research Branch, National Institute of Aging, Baltimore, MD, USA
15 Department of Biostatistics, Boston University School of Public Health, Boston, MA, and National Heart, Lung, and Blood 
Institute’s Framingham Heart Study, Framingham, USA
16 Laboratory of Epidemiology, Demography and Biometry, National Institute on Aging, Bethesda, Maryland, USA
17 Laboratory of Clinical Investigation, National Institute of Aging, Baltimore, MD, USA
18 Department of Medicine, Harvard Medical School, Boston, MA, USA
19 Center for Human Genetic Research and Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
20 Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA
Chapter 8
Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association 
analyses including 4659 European individuals
genetics of metabolic syndrome and related traits
100
21 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK
22 Geriatric Rehabilitation Unit, Azienda Sanitaria Firenze (ASF), Florence, Italy
23 University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrookes’ Hospital, University of 
Cambridge, Cambridge CB2 0QQ, UK
24 General Medicine Division, Massachusetts General Hospital, Boston, MA, USA
25 Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
26 Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
27 Department of Neurology, General Central Hospital, Bolzano, Italy




Objective. Plasma adiponectin is strongly associated with various components of metabolic 
syndrome, type 2 diabetes and cardiovascular outcomes. Concentrations are highly heritable and 
differ between men and women. We therefore aimed to investigate the genetics of plasma adiponectin 
in men and women. 
Methods. We combined genome-wide association scans of three population-based studies including 
4659 persons. For the replication stage in 13795 subjects, we selected the 20 top signals of the 
combined analysis, as well as the 10 top signals with p-values less than 1.0*10-4 for each the men- 
and the women-specific analyses. We further selected 73 SNPs that were consistently associated 
with metabolic syndrome parameters in previous genome-wide association studies to check for their 
association with plasma adiponectin. 
Results. The ADIPOQ locus showed genome-wide significant p-values in the combined (p=4.3*10-24) 
as well as in both women- and men-specific analyses (p=8.7*10-17 and p=2.5*10-11, respectively). None 
of the other 39 top signal SNPs showed evidence for association in the replication analysis. None 
of 73 SNPs from metabolic syndrome loci exhibited association with plasma adiponectin (p>0.01). 
Conclusions. We demonstrated the ADIPOQ gene as the only major gene for plasma adiponectin, 
which explains 8.7% of the phenotypic variance. We further found that neither this gene nor any of 
the metabolic syndrome loci explained the sex differences observed for plasma adiponectin. Larger 
studies are needed to identify more moderate genetic determinants of plasma adiponectin. 
101
Introduction
Plasma adiponectin is a quantitative parameter, which has a strong role in modulating insulin 
sensitivity and glucose homeostasis. It has been found to be decreased in humans with type 2 diabetes 
and cardiovascular disease (CVD)1,2 and decreased plasma adiponectin was found to be associated 
with deteriorated levels of virtually all parameters of the metabolic syndrome3-5. Experiments in mice 
transgenic or deficient for the adiponectin gene have underscored the functional role of adiponectin 
on various components of the metabolic syndrome and diabetes mellitus3,6,7.
 Concerning CVD outcomes the observations on adiponectin are heterogeneous as recently 
reviewed extensively8: experimental data demonstrate that adiponectin stimulates the production 
of nitric oxide, positively affects inflammatory mechanisms, has anti-apoptotic properties and is 
involved in vascular remodeling. Clinical data are diverse depending mainly on the disease stage 
when investigated. Low levels seem to be associated with worse outcomes when measured in 
healthy conditions. However, there is accumulating data that in diseased states such as chronic 
heart failure or existing CVD high rather than low levels predict CVD and non-CVD mortality. Knowing 
the genes which affect plasma adiponectin might be helpful to disentangle adiponectin as cause or 
consequence of disease states using a Mendelian randomization approach9. 
 Plasma adiponectin shows pronounced differences between men and women with about 1.5 times 
higher concentrations in women10. An explanation for these differences is lacking as plasma adiponectin 
is only moderately influenced by nutritional behavior, physical activity or other environmental 
components5,8,11. However, there is clear evidence for a high heritability of about 50%4,12-14 which one 
study even suggested to be sex-dependent14. In line with lower plasma adiponectin in men, higher 
prevalences of type 2 diabetes and impaired fasting glucose were also reported in men15.
 Recent genome-wide association (GWA) scans have highlighted the potential of genetic factors 
with differential sex effects on concentrations of uric acid16-18 and lipids19, waist circumference20 or 
schizophrenia21. Many of these phenotypes show pronounced sex-specific differences in plasma 
concentrations or prevalence. A sex-differential SNP association with a quantitative phenotype can 
even mask a real association if data are analyzed without stratification. One example is a SNP near 
the LYPLAL1 gene which recently showed a strong association with waist-hip-ratio in women but not 
in men and would have been missed in the sex-combined analysis20. To our knowledge, sex-specific 
differences for genetic effects on plasma adiponectin have not been investigated so far.
 In the study at hand, we aimed to identify not only novel genes modulating plasma adiponectin 
but also whether genetic effects are differential between men and women. We combined this meta-
analysis with a candidate gene approach considering all genes which have recently been associated 
with singular components of the metabolic syndrome in GWA studies.
 
Methods
Study cohorts and Genotyping
Our gene discovery included 4659 subjects (women=2562, men=2097) derived from three population-
based studies, the Erasmus Rucphen Family Study (ERF, n=1820)22, the follow-up of the third survey 
from the “Kooperative Gesundheitsforschung in der Region Augsburg” Study (KORA-F3, n=1644)23, 
and the MICROS Study (n=1195)24. The replication contained 13795 subjects (women=7673, men=6122 
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from the study cohorts CoLaus (n=5381), Framingham (n=2228), GEMS (n=1780), ALSPAC (n=1415), 
TWINS UK (n=1399), InChianti (n=1027) and BLSA (n=565). 
 All studies had genotypes available from genome-wide SNPs imputed based on the HapMap 
Ceu r22 reference sample after quality control. Measurement of adiponectin was made by ELISAs 
(from Mercodia, BioVendor and R&D Systems) or RIA (Linco). Details on study cohorts including 
the phenotyping for adiponectin measurements, genotyping methods, statistical analysis, and 
descriptive statistics are provided in the Supplementary Material and Supplementary Table S1.
Study design and statistical analysis
The study design is summarized in Figure 1. GWA analyses (stage 1): GWA analyses were conducted 
using a standardized protocol in each of the three stage 1 studies. For each of the 2,585,854 SNPs, 
linear regression using an additive genetic model was performed for log-transformed adiponectin 
values adjusting for age, sex, and BMI and accounting for the uncertainty in the inferred genotype 
from the imputation by utilizing the estimated genotype probabilities (implemented in MACH2QTL 
and GenABEL/ProABEL, respectively). All analyses were repeated for men and women separately. 
Relatedness between study participants was accounted for where appropriate (ERF, MICROS). 
Genomic control was applied when appropriate with study-specific lambda factors being 1.05, 1.05, 
and 0.99 for ERF, KORA, and MICROS, respectively. The beta-estimates of the three cohorts were 
combined using a fixed effect model. Also, a scaling-invariant p-value pooling meta-analysis using a 
weighted Z-score method was applied. For each SNP, we tested for significant differences between 
pooled men-specific beta-estimates across the three GWA studies as well as women-specific beta-
estimates (see Supplementary Material for details).
 GWA SNP selection: We selected three types of interesting regions to identify potentially novel 
signals for plasma adiponectin: (1) from the sex-combined sample (20 loci), (2) from the analysis in 
women (10 loci) and (3) in men (10 loci). Loci were considered as interesting and one SNP per locus 
was selected, if the combined p-values were less than 1*10-4 and if study-specific MAF was greater 
than 5% and imputation quality r² greater than 0.2. 
 Replication analysis (stage 2): For the selected 40 SNPs, we attempted replication based on 7 
studies with the same study-specific SNP analysis as for stage 1 studies. A stage 2 only and a joint 
analysis of stage 1 and 2 (n=18454) was performed using the scaling-invariant weighted Z-score 
method. 
 Further statistical issues: In stage 1, we had 92% power to detect a variant that explains 1% of the 
variance of plasma adiponectin with genome-wide significance (alpha=5*10-8). In the stage 1 and 
stage 2 combined analysis, we had 99% power to yield genome-wide significant evidence for the 40 
selected SNPs if they explained 1% of more of the variance in plasma adiponectin.
 Candidate gene approach: From the literature, we identified loci associated with metabolic 
syndrome parameters in large GWA studies to obtain a list of candidate gene SNPs for adiponectin 
levels. We examined the association of these SNPs with plasma adiponectin from our stage 1 sex-
combined and sex-stratified meta-analyses. For this candidate gene approach, we had 92% power 
to detect a SNP association that explains 0.5% of the variance accounting for the 73 SNPs tested 
(alpha=0.0007).
 Percentage of variance explained: The general population design of KORA enabled computation 
of the proportion of the adiponectin variance explained by all analyzable ADIPOQ SNPs (i.e. SNPs 
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available in all three GWA studies in the 50kb region of the ADIPOQ locus with MAF>5%), by an 
independent SNP set of these (i.e. selecting the SNP with the lowest p-value in the meta-analysis 
for each bin of SNPs with pairwise r²>0.2; r² information was taken from HapMap), or by the top 
SNP alone. Computations were performed by linear regression on the standardized residuals (log of 
adiponectin concentrations adjusted for age, BMI and – if appropriate – for sex) and computing the 
R² measure of the model adjusting for the SNP(s) using PROC REG by SAS. 
 Heritability: The family-based design of MICROS allowed us to compute heritability of plasma 
adiponectin using a polygenic model for standardized residuals of plasma adiponectin (adjusted 
for age and BMI - and sex 
if applicable). Heritability 
was also computed with 
additional adjustment of 
the top ADIPOQ SNP, with 
the independent SNP set 
as described above (see 
above). Computations 
were performed using the R 
library GenABEL25.
 Bioinformatic analysis: 
Bioinformatic analysis for 
potential functional SNPs 
was done in two stages, 
using bioinformatic tools 




GWA analysis (stage 1)
Figure 2 shows the p-value, ADIPOQ-region and q-q-plots from the meta-analysis results of plasma 
adiponectin of the three GWA studies, ERF, KORA and MICROS cohorts. Results are presented for 
the sex-combined (n=4659) analysis as well as stratified for women (n=2562) and men (n=2097). 
The combined analysis yielded one genome-wide significant locus (Figure 2A), the ADIPOQ locus 
(p=4.3*10-24), which was consistent in women (p=8.7*10-17) and men (p=2.5*10-11) (Figure 2B). The q-q 
plot did not show evidence for bias due to population stratification in any of the analyses (Figure 2C). 
The top ADIPOQ SNP rs17366568 (Table 1) exhibited low imputation quality in ERF and MICROS that 
was genotyped using the Illumina platform in contrast to high imputation quality in KORA genotyped 
using the Affymetrix platform. However, other SNPs in this region such as rs3774261 reached genome-
wide significance in the combined analysis (p=3.0*10-16) and had good imputation quality in all three 
stage 1 samples (0.82<r²<0.97).





























Fig.1. Study design illustrating the genome-wide association (GWA) study approach and the candidate 
gene approach.
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Replication analysis (stage 2)
Characteristics of the 40 SNPs taken forward for replication are provided in Supplementary Table S2. 
From the combined, women-, and men-specific GWA-analyses (n=13795, 7673, and 6122, respectively), 
only the ADIPOQ SNP remained significant in the combined analyses (Supplementary Table S3). 
P-values for rs17366568 were 1.09*10-41, 2.8*10-22 and 7.8*10-23 for the combined and the analysis 
stratified for women and men, respectively (Table 1).
Fig.2. The analyses in panel A-C are provided for the combined sex analysis as well as the analysis stratified for women and men. A. Manhattan plots 
showing p-values of association of each SNPs in the meta-analysis with plasma adiponectin levels. SNPs are plotted on the X-axis to their position 
on each chromosome against association with plasma adiponectin on the Y-axis (shown as –log10 P-value). B. Regional Manhattan plots showing 
significance of association of all SNPs in the ADIPOQ region (3q27). SNPs are plotted on the X-axis to their position on chromosome 3 against association 
with plasma adiponectin on the Y-axis (shown as –log10 P-value). In each panel, the top-SNP rs17366568 is shown as red diamond. The SNPs surrounding 
this top-SNP are color-coded (see inset) to reflect their LD with the top-SNP using pair-wise r_ values from the KORA study. Estimated recombination 
rates from HapMap-CEU are plotted in blue to illustrate the local LD structure on a secondary Y-axis. Genes and their direction of transcription are 
provided below the plots using data from the UCSC genome browser. C. Quantile-quantile (QQ) plots of SNPs. Expected p-values are plotted on X-axis 
against the observed p-values plotted on the Y-axis.
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Sex-specific analyses
In line with previous reports, plasma adiponectin in women was approximately 1.5 times higher than 
in men in each of the three stage 1 studies (Supplementary Table S1). Heritability computations in the 
family-based MICROS study showed slightly higher estimates of 65.1% for women and 54.0% for men 
(Table 2). 
 For each SNP, we evaluated whether the sex-specific beta-estimates combined across the three 
stage 1 studies were significantly different between men and women pointing towards a gender-SNP 
interaction. The q-q plot for the p-values of sex differences indicated some observed sex difference of 
genetic effects beyond that expected by chance (Supplementary Figure S1A), but not due to differences 
in the ADIPOQ region. For none of the SNPs in the GWA studies, the sex-specific beta-estimates were 
significantly different between men and women on a genome-wide level (Supplementary Figure S1B). 
For the ADIPOQ top SNP rs17366568 the p-value for sex difference was 0.62. 
Association of metabolic syndrome candidate gene SNPs with adiponectin
From the literature, we identified loci associated with metabolic syndrome parameters in large 
GWA studies to obtain a list of candidate gene SNPs for adiponectin levels (Figure 1). These were 
partially overlapping for the various metabolic syndrome components and included 21 SNPs for HDL 
cholesterol, 17 for triglycerides (7 of them were also found for HDL cholesterol and were therefore only 
Table 1: Genome-wide significant association of the rs17366568 (G>A) SNP in the ADIPOQ locus
                   Combined                           Women                                  Men                
Population EAF* Rsqr† n Beta‡ P n   Beta‡  P    n  Beta‡ P
Stage 1
ERF  0.91 0.37 1817 0.103 2.7E-07 1052 0.115  1.0E-05  765 0.088 0.004
KORA  0.89 0.91 1643 0.173 1.7E-15 830  0.204  1.9E-11  813 0.142 5.8E-06
MICROS  0.90 0.27 1195 0.114 3.0E-06 678  0.102  4.1E-04  517  0.182 1.6E-05
Combined** 0.90 - 4655  4.3E-24 2560     8.7E-17  2095   2.5E-11
Stage 
Colaus  0.88 1.00 5261 0.132 3.0E-13 2759 0.119  1.1E-06  2502 0.146 5.1E-08
Framingham 0.88 1.00 2220 0.072 0.003 1213  0.050 0.108   1007 0.094 0.012
GEMS  0.87 1.00 1780 0.149 2.9E-06 732  0.084 0.095   1048 0.194 2.1E-06
ALSPAC  0.92 0.37 1415 0.395 2.9E-14 691  0.453  9.4E-09  724 0.351 3.5E-07
TWINS UK 0.998 NA 1399 0.154 0.078 1399 0.154  0.078   -  -  -
InChianti 0.94 NA 1027 -0.056 0.481 562  -0.130  0.268  465 0.007 0.95
BLSA  0.92 0.61 565 0.263 0.004 266  -0.028 0.822   299 0.488 2.5E-04
Combined** 0.89 - 13667 - 5.2E-22 7622 -    2.7E-10  6045 -  8.1E-14
Stage 1 + 2
Combined** 0.89 - 18322  1.1E-41 10182     2.8E-22  8140   7.8E-23
* EAF = effect allele frequency (i.e. frequency of G) for sex-combined analysis
† Rsqr = imputation certainty
‡ Beta estimate from linear regression adjusted for age, BMI, and (if appropriate) for sex per unit change [log(µg/mL)] for the risk allele G
** Results are provided for a beta-pooling meta-analysis using the fixed effect model weighting for the inverse variance. When a scaling-invariant 
p-value pooling meta-analysis using the sample size weighted z-score method was applied for sensitivity analysis, we found no major differences 
between both methods.
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counted once), 12 for BMI and/or waist circumference, 18 for type 2 diabetes and/or glucose levels (one 
of them was already mentioned for BMI and is therefore only counted once), and 13 for hypertension 
and blood pressure. Details on these SNPs are given in Supplementary Table S4.
 Only 3 out of the 73 SNPs showed p-values between 0.01 and 0.05 for example for the gender-
combined analysis (with 3.65 expected under the assumption of no association). No p-value was 
below the Bonferroni-adjusted significance level of 0.007. Thus, our data indicated no association of 
these metabolic syndrome parameter SNPs with plasma adiponectin. 
Sensitivity analyses
Sensitivity analyses repeating all analyses without the adjustment for BMI showed the same results 
regarding the ADIPOQ genome-wide significant results, the lack of sex difference, the lack of other 
SNPs in the replication stage to show replication, and the lack of metabolic syndrome SNPs to show 
association with plasma adiponectin. 
ADIPOQ region
A closer look at 
the ADIPOQ region 
revealed that the 
top SNP rs17366568 
was completely 
independent of all other 
SNPs in that region. A 
linkage disequilibrium 
(LD) plot depicting 
D’ and r² measures 
(Figure 3) revealed 
that for many SNPs 
in the ADIPOQ region 
the r² was weak even 
if they were located 
in the same LD block 
(as defined by D’). At 





The percentage of plasma adiponectin variance explained by the top hit was 3.8% and increased to 
5.9% when including an independent SNP set (selecting the SNP with the smallest p-value in each 
bin of pairwise r²<0.2) and peaked at 6.7% when including all SNPs with MAF>5% in the 50 kb region 
covering the three LD blocks (Table 2).
 Table 2: Heritability and percentage of variance explained by the ADIPOQ locus 
SNPs: Heritability of plasma adiponectin in the family-based study MICROS and 
percentage of plasma adiponectin variance (KORA) explained by the ADIPOQ locus 
SNPs in KORA (region on chr 3, position 188.030 – 188.080kb).                        
             Combined     Women      Men                
Heritability (%) in MICROS   
no SNP adjustment           59.6      65.1     54.0
adjusted for top hit rs17366568       58.4      64.6    51.5
adjusted for “independent “SNPs (n=9)a   52.9      55.1     48.1
% of variance of plasma adiponectin in KORA explained by
top hit rs17366568            3.8       5.3     2.4
for “independent“ SNPs (n=9)a       5.9       6.3     5.1
all SNPs with MAF >5% (n=33)b       6.7       6.4     5.5
Computations were based on standardized sex-combined or sex-specific residuals of plasma adiponectin 
adjusted for age (and sex if applicable) and BMI without and with additional SNP adjustment; includes only 
SNPs with MAF>5% available in all three studies. 
a Among the SNPS of the ADIPOQ region with MAF > 5% and available in all three GWA studies: selecting the 
SNP with the smallest p-value from each bin of SNPs with pairwise r_>0.2: rs1063539, rs16861194, rs17300539, 
rs17366568, rs17366743, rs3774261, rs6810075, rs7615090, rs822394
b All SNPS of the ADIPOQ region with MAF > 5% and available in all three GWA studies: rs6810075, rs10937273, 
rs12637534, rs1648707, rs864265, rs822387, rs16861194,  rs17300539, rs266729, rs182052, rs16861205, rs16861209, 
rs822391, rs16861210, rs822394, rs822396, rs12495941, rs7649121, rs17366568, rs2241767, rs3821799, rs3774261, 
rs3774262, rs17366743, rs6773957, rs1063537, rs2082940, rs1063539, rs7639352, rs6444175, rs7628649, 
rs17373414, rs9860747, rs1501296, rs7615090
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Fig.3. Linkage disequilibrium (LD) plot of SNPs in the ADIPOQ region spanning 50kb (positions 188030-188080kb). The grey shading of the diamonds 
represent the pair-wise D' and the numbers in the diamonds represent the pair-wise r_ between the two SNPs defined by the top left and the top right 
sides of the diamond. The figure clearly shows that the top-hit rs17366568 is located within an own LD block and shows virtually no correlations with any 
other SNP in the entire 50kb region. The columns on the right side of the Figure show i) whether a particular SNP is genotyped by the Affymetrix 500K 
chip (A) or the Illumina HumanHap300 chip (I); all other SNPs are imputed; ii) the z-scores and iii) the p-values for each SNP-adiponection association 







































































































































































































































































































































































Block 1 (14 kb)
Block 2 (3 kb)
Block 3 (19 kb)
A/I   z-score P-value   group
 6.30  3.0e-10 3
I     4.30  1.7e-05 4
A    3.32  0.0009 5
I     6.24  4.3e-10 3
A   -2.46  0.014
I    -7.48  7.7e-14 2
 3.50  0.0005 5
 7.97  1.6e-15 2
 5.17  2.4e-07 3
A   -6.29  3.1e-10 3
A   -3.37  0.0007 5
 7.91  2.5e-15 2
 -0.83  0.41
 7.54  4.7e-14 2
 2.70  0.007
I    -1.45  0.15
A  -10.13  4.3e-24 1
A   -2.99  0.003 7
A   4.23  2.4e-05 6
A    8.17  3.0e-16 6
I     3.03  0.002 7
 1.65  0.1
A    8.17  3.2e-16 6
 3.04  0.002 7
 3.03  0.002 7
 2.92  0.003 7
 6.70  2.1e-11 6
I    6.70  2.0e-11 6
 6.78  1.3e-11 8
I    5.02  5.3e-07 9
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Bioinformatic analysis revealed two main putative functional elements located in the second and 
the third LD block as depicted in Figure 3. Three SNPs located immediately up- and downstream of 
rs17366568 (for details see Supplementary Table S5) are predicted to affect 10, 6 or 4, respectively, 
transcription factor binding sites (using adipose tissue-specifi c analysis). No transcription factor 
binding sites or splicing regulation elements were detected for rs17366568 itself. Therefore, it is 
likely that rs17366568 is not the functional variant, but relates to a functional element located in the 
immediate vicinity (although regulatory potential was very low throughout the region). 
Analysis of LD block 3 (encompassing exon 3 and a large intergenic region downstream of the ADIPOQ 
locus) revealed three putative regulatory promoter regions located approximately 5.1 kb, 6.3 kb and 
15.8 kb downstream of the ADIPOQ locus. Interestingly, especially the proximal two regulatory regions 
are known to be affected by several copy number regions (see Figure 4 and Supplementary Table S6). 
However, no SNP in our data set was located directly in these CNVs, whose functional relevance may 
therefore require further investigation. More generally, the whole genomic region of ADIPOQ seems 
to be highly affected by copy number variations (Figure 4).
Discussion
In the meta-analysis of genome-wide SNP association with plasma adiponectin in three population-
based studies including a total of 4655 subjects, we found genome-wide signifi cant evidence for the 
association with the ADIPOQ locus, which is a known locus for plasma adiponectin10,27. Furthermore, 
we did not identify any genome-wide signifi cant evidence for association in any other locus when 
replicating the other 39 most strongly associated loci in 13795 independent samples. Despite the 
clear sex difference in plasma adiponectin, there was no sex difference observed for the ADIPOQ SNP 
associations. Finally, we found, despite the strong association between plasma adiponectin and 
Fig.4. Predicted regulatory regions in the ADIPOQ downstream region and their affection by copy number variations. Panel A: Genomatix Software 
Suite: Position of the regulatory promoter regions predicted by PromoterInspector (red boxes) and their position relative the ADIPOQ gene region (green 
box). Panel B: UCSC Browser: Position of the predicted regulatory regions (red boxes) relative to known copy number variations in the ADIPOQ gene 
region (represented by bold blue lines). The numbers on the left side correspond to the accession number of the respective copy number variation in the 
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the metabolic syndrome, no significant association with adiponectin for any of the chosen variants 
within reported loci for metabolic syndrome parameters.
 Our GWA study identified only one major locus for plasma adiponectin, the ADIPOQ gene region. 
The only other GWA study on adiponectin was performed in 1845 individuals of the GEMS Study and 
identified also only the ADIPOQ locus with genome-wide significance28. The other top seven hits from 
that study could not be replicated in our GWA study, neither in the combined (all p-values >0.28) nor 
in the sex-specific analysis (p>0.16). In our GWA discovery stage, the power was more than 90% to 
detect novel loci which explain 1% of the adiponectin variance, and, including the replication stage, 
over 99% to show genome-wide significant evidence of the 40 SNPs in the 18454 subjects. Therefore, 
our data suggests a lack of a major gene locus other than ADIPOQ. 
 ADIPOQ was studied earlier as a candidate gene and the relationship to plasma levels has long 
been recognized. The SNP rs17366568 showing the strongest association in our GWA study explained 
3.8% of the variance and this number increased to 6.7% if all analyzable SNPs in the ADIPOQ region 
were included into the model. This pronounced difference of the explained variance between the two 
models can be explained by a large number of SNPs independently contributing to adiponectin levels. 
The SNPs contributing most to the explained variance are not only located in the three different LD 
blocks but also several genetic variants within each of at least two of the three blocks contribute to 
the explained variance. In total, the explained variance was very similar to the 8% reported earlier (10). 
Functional studies within the promoter of the ADIPOQ gene revealed a pronounced influence of three 
SNPs also investigated in our study and the corresponding haplotypes on the promoter activity which 
was accompanied by changes in the DNA binding activity interfering with transcription factor bindings 
sites29. Other studies showed that histone acetylation might influence the transcriptional regulation 
of the ADIPOQ gene30 and that pioglitazone increases plasma adiponectin by posttranscriptional 
regulation31. Finally, an extensive bioinformatic analysis revealed that the ADIPOQ region might be a 
highly copy number variable region. It remains to be determined how strong the effect of these CNVs 
on plasma adiponectin is.
 Since adiponectin has been viewed as a marker for the metabolic syndrome, we have also studied 
73 SNPs that have been associated with any of the major determinants of metabolic syndrome in 
previous GWA studies. This candidate gene-based analysis did not yield any convincing associations 
with plasma adiponectin. This was surprising due to the strong link between plasma adiponectin 
and the metabolic syndrome or any of its components3-5, but in-line with previous reports on a 
lack of association of the ADIPOQ SNPs with metabolic syndrome parameters10. Whether plasma 
adiponectin affects metabolic syndrome parameters or metabolic syndrome parameters modulate 
adiponectin is highly debated as illustrated in Supplementary Figure S2. If the association of any of 
these 73 SNPs had been very strong with adiponectin - stronger than with the metabolic syndrome 
parameters - this would have pointed towards a gene locus primarily affecting plasma adiponectin 
and consecutively modulating the metabolic syndrome parameters. This is not suggested by our 
data (panel A of Supplementary Figure S2). Our data on these 73 metabolic syndrome SNPs lacks 
association with adiponectin beyond that expected by chance. This would rather support the idea that 
genetic pathways for plasma adiponectin are different from the pathways depicted by these 73 loci 
(panel B), or, alternatively, that pathways depicted by these 73 loci affect plasma adiponectin via the 
metabolic syndrome parameter and the lack of association was due to loss of power for a parameter 
further down the road (panel C). Both ideas (panel B and C) would point towards the hypothesis that 
genetically determined adiponectin does not modulate metabolic syndrome parameters directly. 
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 The present data suggests that the sex differences in plasma adiponectin can not be explained 
by any major gene. The GWA approach yielded no genome-wide significant difference between men 
and women for any SNP, not even the ADIPOQ locus. In fact, none of the variants studied in the 
replication or in our candidate gene approach based on metabolic syndrome loci showed a significant 
sex difference. Therefore, the sex-difference in plasma adiponectin might rather be explained by 
sex hormones5 or sex-specific epigenetic programming that could be transmitted to subsequent 
generations in a sex-specific manner leading to transgenerational effects as recently suggested32.
 The heritability estimates of plasma adiponectin are high with roughly 50-60%4,12-14. The ADIPOQ 
locus accounts for 6.7% of the variance in our populations-based KORA Study, which is in-line with 
previous reports10. This is also in-line with 6.6% of the heritability accounted for by this locus in our 
family-based MICROS Study. While the ADIPOQ locus association with plasma adiponectin is thus 
among the strongest associations for quantitative phenotypes in genetic epidemiology, it explains 
only a small proportion of the overall heritability, a puzzle observed for many other phenotypes (e.g. 
lipids or obesity measures)19,20,33. Potential explanations of this gap between explained and estimated 
heritability are unknown rare variants with strong effects on adiponectin34, unknown common loci 
influencing adiponectin with small effects, or deflation of association estimates due to heterogeneity 
between studies, uncertainties in the genotypes from imputation or uncertainties in the phenotype 
assessment. Our study suggests that these other genetic variants influencing plasma adiponectin 
are variants that explain less than 1% of the phenotypic variance. To localize these loci and to build 
up gene networks which identify even trans-acting quantitative trait loci, will require substantially 
larger data sets in combination with gene expression analysis. 
Strengths and Limitations of the Study
A limitation of our study is the limited sample size for gene discovery for small genetic effects, in 
particular when conducting stratified analyses. Furthermore, our top hit in the ADIPOQ locus had 
limited imputation quality in two of the included GWA studies, which can be explained by the fact 
that KORA used a different SNP-panel (Affymetrix 500K chip) for GWAs genotyping than ERF and 
MICROS (Illumina HumanHap300). For most of the other SNPs followed in replication samples, the 
imputation quality was quite high. The relatively low imputation quality of our top-hit in two of the 
studies explains the lower (but still genome-wide significant) p-values in these two studies compared 
to KORA. This is entirely in-line with measurement error theory: a ”measurement error” (like the 
uncertainty induced by the imputation) that does not depend on the phenotype (as the case here 
assuming that genotyping does not depend on adiponectin in the plasma) is expected to attenuate 
the precision of an underlying association yielding larger p-values. Therefore, the association in ERF 
and MICROS was rather underestimated than false positive. Finally, it can be considered a limitation of 
most GWAs studies that gonsomes are not analyzed due to technical issues not yet solved concerning 
the imputation of SNPs which, however, is a prerequisite to allow meta-analysis of data over various 
genotyping platforms used.
 The strong point of our study is the population-based design, in which the participants have 
not been ascertained based on the presence of pathology. Hypothesizing a genetic basis of sex 
differences in plasma adiponectin, a further advantage is the sex-stratified analysis since a sex-
combined analysis would otherwise mask an association. Further, the family-based MICROS study 
enables us to estimate heritability. 
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Conclusions
We present a genome-wide association study on adiponectin which the first time attempts to explain 
adiponectin sex difference by the underlying genetics. We conclude that there is no major gene 
involved in modulating plasma adiponectin other than the known ADIPOQ locus and that there is no 
major gene explaining the differences of plasma adiponectin between men and women. 
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All participants in all studies gave informed consent and each study was approved by the appropriate 
Research Ethics Committees. Body-mass-index (BMI, weight divided by height²) was assessed 
measuring weight and height in the study-center or by self-report. Details on adiponectin assays 
used for phenotyping and descriptive statistics are provided in Supplementary Table S1. 
Genome-wide association study cohorts
Erasmus Rucphen Family study (ERF): The Erasmus Rucphen Family (ERF) study is comprised of a 
family-based cohort embedded in the Genetic Research in Isolated Populations (GRIP) program 
in the Southwest of the Netherlands. Descriptions of ERF’s design have been previously published 
(Aulchenko et al., 2004). Briefly, twenty-two families that had a minimum of five children baptized in 
the community church between 1850 and 1900 were identified with the help of detailed genealogical 
records. All living descendants of these couples, and their spouses, were invited to take part in 
the study. Participants included in the current study total 2079 individuals for whom complete 
phenotypic and genotypic information was available. Covariates were obtained during the baseline 
examination.
 KORA studies: The KORA cohorts (Cooperative Health Research in the Region of Augsburg, 
KOoperative Gesundheitsforschung in der Region Augsburg) are several cohorts representative of 
the general population in Augsburg und two surrounding counties that were initiated as part of the 
WHO MONICA Study. The KORA S3 is a survey examined in 1994/95 with standardized examinations 
described in detail elsewhere (Löwel et al., 2005). Ten years age-sex strata have been sampled from 
the 25 to 74 year old population with a stratum size of 640 subjects. 3,006 individuals participated in 
a follow-up examination of S3 in 2004/05 which is called KORA F3. All study participants underwent a 
standardized face-to-face interview by certified medical staff and a standardized medical examination 
including blood draw and anthropometric measurements. The 1644 subjects for the KORA GWA 
analysis (the KORA S3/F3 500K study) were chosen from KORA F3. 
 Microisolates in South Tyrol Study (MICROS): The MICROS study is part of the genomic health care 
program ‘GenNova’ and was carried out in three villages of the Val Venosta, South Tyrol (Italy), in 
2001-03. It comprised members of the populations of Stelvio, Vallelunga and Martello. A detailed 
description of the MICROS study is available elsewhere (Pattaro et al., 2007). Information on the 
participant’s health status was collected through a standardized questionnaire. Laboratory data 
were obtained from standard blood analyses. Covariates were obtained during the interview phase.
 Genome-wide genotyping had been performed using the Illumina 300K array of the HumanHap300 
(ERF, MICROS) or the Affymetrix 500k array (KORA-F3). 
Replication study cohorts
CoLaus (Caucasian Cohorte Lausannoise) Study: The CoLaus study investigates the epidemiology and 
genetic determinants of cardiovascular risk factors and metabolic syndrome. The 3251 females and 
2937 males Caucasian participants, aged between 35 and 75 years, were selected using a simple 
115
non-stratified random sample of the population registry of the city of Lausanne, Switzerland, as 
previously described (Firmann et al., 2008). Participation rate was 41%. Recruitment began in June 
2003 and ended in May 2006. All participants attended the outpatient clinic of the University Hospital 
of Lausanne in the morning after an overnight fast. From 5435 participants genotypes are available 
from genotyping with Affymetrix chips (GeneChip Human Mapping 500K array and the BRLMM calling 
algorithm). Adiponectin levels were available for 5381 study participants and were measured by ELISA 
assay (R&D systems, Minneapolis, MN). Statistical analyses was conducted using Quicktest v0.94.
 Framingham: The Framingham Heart Study has investigated risk factor determinants of CVD 
over decades in a general population (Dawber et al., 1966). It began in 1948 with the recruitment of 
5209 residents aged 28-62 years in about two-thirds of the households in the town of Framingham, 
Massachusetts. Participants have undergone biennial examinations since the study began. In 1971, 
the Framingham Offspring Study (Kannel et al., 1979) was started, in part, to evaluate the role of 
genetic components in CVD etiology. In total, there were 5124 subjects aged 5-70 years at entry 
including the children of the original cohort and their spouses. The Framingham Heart Study consists 
almost entirely of subjects of European descent from England, Ireland, France, and Italy. Genotyping 
was performed using Affymetrix 500K array supplemented by the MIPS 50K array. Total adiponectin 
levels were available for 2228 genotyped study participants from the Offspring cohort and were 
measured by ELISA (R&D Systems, Minneapolis, MN) (Hivert et al., 2008). Statistical GWA analysis 
was performed using linear mixed effect models implemented in the function lmekin from the R 
kinship package (www.r-project.org), where the SNP is incorporated in the model as a fixed covariate 
while a familial random effect component is included to account for familial correlation.
 GEMS (Genetic Epidemiology of Metabolic Syndrome): The study population of the Genetic 
Epidemiology of Metabolic Syndrome (GEMS) study consisted of dyslipidaemic cases (age 20-65 
years, n=1025) matched with normolipidaemic controls (n=1008) by sex and recruitment site. Detailed 
information on the GEMS study design, sampling frame, and recruitment procedures has been 
published (Stirnadel et al., 2008). Genotyping was performed using Affymetrix GeneChip Human 
Mapping 500K array and the BRLMM calling algorithm. Adiponectin levels were available for 1780 
study participants and were measured by ELISA assay (R&D systems, Minneapolis, MN). Statistical 
analyses was performed using Quicktest v0.94.
 ALSPAC: The Avon Longitudinal Study of Parents and their Children (ALSPAC) is a population-based 
birth cohort study consisting initially of over 13000 women and their children recruited in the county 
of Avon, U.K in the early 1990s (http://www.bristol.ac.uk/alspac/). Both mothers and children have 
been extensively followed from the 8th gestational week onwards using a combination of self-reported 
questionnaires, medical records and physical examinations. Biological samples including DNA have 
been collected for ~10,500 of the children from this cohort. Ethical approval was obtained from the 
ALSPAC Law and Ethics committee and relevant local ethics committees, and written informed consent 
provided by all parents (Golding et al., 2001). 1518 ALSPAC individuals were genotyped using the Illumina 
HumanHap317K SNP chip. This chip contains 317504 SNPs and provides approximately 75% genomic 
coverage of the Utah CEPH (CEU) HapMap samples for common SNPs at r2 >0.8. Markers with minor 
allele frequency <1%, SNPs with >5% missing genotypes and, any marker that failed an exact test of 
Hardy-Weinberg equilibrium (p <10-7) were excluded from further analyses and before imputation. After 
data cleaning, 315807 SNPs were left in the ALSPAC genome-wide association analysis (Timpson et al., 
2009). Plasma adiponectin concentrations were determined in samples from 1415 individuals using 
ELISA (R&D Systems) with inter-assay CV being 7%. Analyses were performed using STATA and PLINK.
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 TwinsUK: The TwinsUK cohort (www.twinsuk.ac.uk) is an adult twin registry shown to be 
representative of the UK singleton population (Andrew et al., 2001). A total of 1399 (women were 
included in the analysis, Genotyping was performed using the Illumina HumanHap 300 Illumina 
HumanCNV370 Duo chips (Richards et al., 2008). Adiponectin levels were available for 1399 study 
participants and were measured with an in-house two-site ELISA assay using antibodies and 
standards from R&D Systems Europe (Abingdon, Oxford UK). The day-to-day coefficients of variation 
for adiponectin were 5.4% at a concentration of 3.6 µg/ml, 5.2% at 9.2 µg/ml and 5.8% at 15.5 µg/ml. 
Statistical analysis was conducted applying Merlin software package (Abecasis et al., 2002).
 InCHIANTI: InCHIANTI is an epidemiological study of risk factors contributing to the decline in 
physical functioning in late life (Ferrucci et al., 2000). Individuals were selected from the population 
registries of two small towns in Tuscany, Italy. Participants, all of white European origin, were invited 
to a clinic visit for evaluation of health status as described in detail previously (Bartali et al., 2002). 
SNPs were genotyped on the Illumina 550k array (Melzer et al., 2008), with missing SNPs imputed 
using IMPUTE software. Adiponectin levels were available for 1027 study participants and were 
measured by RIA assay (Human Adiponectin RIA Kit, Linco Research, Inc, Missouri, USA) Statistical 
analyses were conducted using SNPTEST.
 Baltimore Longitudinal Study of Aging (BLSA): The Baltimore Longitudinal Study of Aging (BLSA) is an 
observational study that began in 1958 to investigate normative aging in community dwelling adults 
who were healthy at study entry (Shock et al., 1984). Participants are examined every one to four 
years depending on their age. Currently there are approximately 1100 active participants enrolled in 
the study. The analysis was restricted to subjects with European ancestry. Genotyping was performed 
using Illumina HumanHap 550K. Adiponectin levels were available for 565 study participants and 
were measured by RIA (LINCO) having intra-assay and inter-assay variation of 1.8-6.2% and 6.9-9.3% 
respectively. Each analysis was further adjusted for the top two principal components derived from 
an EIGENSTRAT analysis utilizing ~10,000 randomly selected SNPs from the 550K SNP panel. 
Additional information on statistical methods
Metal-software: All combined analysis were performed using the METAL software (Abecasis and Willer, 
2007, http://www.sph.umich.edu/csg/abecasis/metal). We used the METAL implemented study-wise 
genomic control correction as well as genomic control correction of the METAL results. 
 To combine the three GWA studies (stage 1), we performed a beta-pooling meta-analysis using the 
fixed effect model (inverse variance weighted) and a scaling-invariant p-value pooling meta-analysis 
(using the weighted z-score method). We found no major difference between both methods in this 
GWA stage. For the replication stage (stage 2) and stage 1 and stage 2 combined, we conducted the 
scaling-invariant p-value pooling as there were greater differences between adiponectin assays in 
the full set of studies. We present the weighted Z-score method results throughout the manuscript. 
Test to compare gender-stratified beta-estimates from GWA analyses: Each study has provided SNP-
association results for men and women separately. For each SNP, we pooled the men-specific beta-
estimates across all studies (beta_men and its standard error se_beta_men) as well as the women-
specific beta-estimates (beta_women and se_beta_women) using the fixed effect model. For each SNP, 
significant difference between gender-specific pooled beta estimates, beta_men and beta_women, 
was obtained by using the approximately normally distributed test statistics of beta_men – beta_
women divided by the sum of their variance estimates minus the covariance of the beta-estimates 
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(i.e. se_beta_men² + se_beta_women² + 2 x corr (beta_men, beta_women) x se_beta_men x se_beta_
women). The correlation of the beta_men and beta_women was obtained by using the empirical 
distribution of the beta-estimates across all SNPs under the assumption that the abundance of these 
SNP-associations are under the null hypothesis of no association. 
Bioinformatic analysis
Bioinformatic analysis for potential functional SNPs was done in two stages, using bioinformatic 
tools outlined in (Coassin et al., 2009). Firstly, all SNPs of the imputed data set in the ADIPOQ 
gene region have been analyzed for potential functional effects using SNPseek (http://snp.wustl.
edu/cgi-bin/SNPseek/index.cgi) and SNPnexus (http://www.snp-nexus.org/) as well as FASTSNP 
(http://fastsnp.ibms.sinica.edu.tw/). In the second stage attempting to find potential functional 
variants not included in Hapmap, all SNPs reported by Ensembl Variation v.56 in the region between 
rs6810075 and rs7615090 (see Supplementary Figure S2) were submitted to FASTSNP. SNPs which 
were predicted to affect any kind of functional element were then further investigated using the 
Genomatix Software Suite (Genomatix Software GmbH, Munich, Germany) and the PupaSuite for 
transcription factor binding site analysis as well as F-SNP (http://compbio.cs.queensu.ca/F-SNP/) 
for further refinement of splicing regulation effects and other kinds of functional elements. Since 
FASTSNP recognizes only SNPs in gene regions, all intergenic SNP both up- and downstream of the 
ADIPOQ locus were analyzed for transcription factor binding sites using the Genomatix Software Suite. 
All analyses in the Genomatix Software Suite were done using only transcription factors specifically 
expressed in the adipose tissue as well as ubiquitous ones. Additionally, the presence of general 
functional elements and regulatory potential (ESPERR) in the intergenic region was investigated in 
the UCSC Genome browser and intergenic regions were scanned for regulatory promoter elements 
using PromoterInspector from Genomatix. Known copy number variations were retrieved from the 
Database of Genomic Variants (http://projects.tcag.ca/variation/).
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Supplementary Table S1: Characteristics of Study Samples
 # of subjects  Age (yrs)       BMI (kg/m_)        Adiponectin (µg/ml)   Adiponectin
Study  (% Women)  Combined Women Men  Combined Women Men   Combined Women Men   Assay
Genomewide association study samples
KORA  1644 (50.5) 62.5±10.1 62.1±10.1 63.0±10.1 28.1±4.5  28.0±5.1 28.2±3.8 10.6±4.7  12.3±4.9 9.9±3.7  ELISA a
ERF  1820 (57.9) 48.7± 4.4 48.0±14.4 49.6±14.4 26.9±4.6  26.5±4.9 27.4±4.2 10.7±5.7  12.5±5.9 8.1±4.2  RIA b
MICROS 1195 (56.7) 44.8 ± 16.7 44.8±17.1 44.9±16.1 25.4±4.8  25.0±5.3 25.8±3.9 13.5±8.4  15.6±9.6 10.7±5.3 ELISA c
Replication study samples
CoLaus 5381 (52.2) 53.2±10.8 53.6±10.7 52.7±10.8 25.8±4.6  25.1±4.9 26.6±4.2 10.1±8.1 12.4±9.4 7.4±5.4   ELISA d
Framingham 2228 (54.6) 60.4±9.5 60.4±9.5 60.3±9.5 27.8±5.0  27.2±5.4 28.4±4.3 10.5±6.4 13.0±6.8 7.6±4.5   ELISA d
GEMS  1780 (41.1) 52.5±9.5 52.4±9.6 52.7±9.4 28.5±3.6  28.7±4.0 28.3±3.4 6.8±4.8 8.3±5.5  5.8±4.0   ELISA d
ALSPAC 1415 (48.8) 9.9 ±0.3 9.8 ±0.2 9.9 ±0.3 17.2±3.5  17.2±4.1 17.2±2.7 13.0±5.3 13.3±5.5  12.8±5.1   ELISA d
TwinsUK 1399 (100)  48.5±13.1 48.5±13.1 -   25.1±4.7  25.1±4.7 -    8.1±3.9  8.1±3.9  -     ELISAd
InCHIANTI 1027 (54.7) 67.6±15.3 68.5±15.4 66.6±15.1 27.1±4.1  27.1±4.6 27.1±3.4 13.5±9.8 15.9±10.8 10.5±7.6   RIA b
BLSA  565 (47.1)  67.9±13.8 65.5+14.6 69.9+12.7 26.8±4.5  26.0+4.9 27.6+4.1 13.4±8.5 15.4±8.9 11.5±7.7   RIA b
Values stated are n (%) or mean ± SD
Assays used for measurement of adiponectin: a Mercodia; b Linco; c BioVendor; d R&D Systems
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Supplementary Table S2: SNP characteristics for the SNPs selected for replication. Numbers stated are the 
minor allele frequencies and the imputation certainties (R_) for each of the three stage 1 studies KORA (n=1817), 
ERF (n=1195), or MICROS (n=1643). 
                Allele       Minor allele frequency Rsqr                  
SNP   Chr Pos (bp)  Major Minor KORA ERF MICROS KORA ERF MICROS
Combined          
rs17366568 3  188053155  G  A 0.11 0.09 0.10 0.91* 0.37 0.27
rs8058648  16  25736408  G  C 0.38 0.37 0.36 0.64 0.74 0.73
rs7735993  5  140659543  A  G 0.21 0.32 0.16 0.98 0.98* 1.00*
rs6433017  2  151554095  C  T 0.15 0.15 0.13 0.29 0.44 0.41
rs936524  19  43924986  G  A 0.25 0.25 0.20 0.98 0.96 0.95
rs17554694 19  22108988  G  A 0.21 0.17 0.14 1.00* 0.91 0.85
rs1426438  12  114024489  A  G 0.18 0.22 0.20 0.98 0.98* 1.00*
rs2804441  10  128306965  T   C 0.48 0.50 0.46 0.88 0.90 0.92
rs1272041  9  114935061  G  C 0.38 0.43 0.44 1.00* 0.99 1.00
rs13201655  6  6295138  G  T 0.38 0.41 0.42 0.96 0.91 0.83
rs7235989  18  8726346  T   G 0.45 0.50 0.37 0.61 0.85 0.89
rs2460620  15  44085750  C  T 0.26 0.23 0.20 0.96* 0.80* 0.97*
rs6448895  4  12122006  C  G 0.10 0.09 0.08 0.64 0.58 0.75
rs7221927  17  76479722  T   C 0.33 0.34 0.30 0.96* 0.68 0.62
rs476546  11  132593133  A  G 0.33 0.30 0.26 0.96 0.99 0.99
rs10041164  5  103071961  C  T 0.40 0.41 0.49 0.96* 0.99* 0.99*
rs17810558  4  147342325  G  A 0.10 0.10 0.07 0.93 0.97 0.99
rs418410  5  31722785  T   G 0.48 0.45 0.46 0.75 0.96* 0.93*
rs7128545  11  32488991  G  A 0.09 0.12 0.13 0.76 0.78 0.81
rs7921500  10  10372106  C  T 0.34 0.39 0.31 0.73 0.87 0.87
Women           
rs7544470  1  212468592  T   A 0.38 0.42 0.35 0.90 0.99 1.00
rs12617829  2  55812968  C  T 0.10 0.13 0.10 0.85 0.91 0.83
rs9928327  16  2190234  G  T 0.12 0.09 0.03 0.17 0.94* 1.00*
rs1868521  3  42268266  G  A 0.06 0.06 0.06 0.38 0.46 0.34
rs2272439  16  87474262  G  A 0.17 0.12 0.15 0.40 0.91* 0.99*
rs2271265  4  48138173  T   A 0.05 0.07 0.07 0.98 0.98 1.00
rs12206888 6  167297384  G  A 0.08 0.08 0.08 0.67 0.45 0.36
rs11599120  10  132866667  T   G 0.25 0.32 0.24 0.65 0.97 0.99
rs17332108  5  60167641  T   C 0.26 0.20 0.25 1.00 0.99 0.98
rs2005029  17  2201888  A  C 0.39 0.49 0.38 0.80 0.95 0.97
Men          
rs2169877  15  83886806  A  G 0.25 0.29 0.18 0.93* 0.75 0.68
rs13073708 3  59443394  A  G 0.19 0.17 0.28 0.83 0.84 0.79
rs6495001  15  31339385  T   G 0.12 0.20 0.17 0.67 0.97* 0.97*
rs12598394 16  9945733  T   A 0.12 0.11 0.11 0.84 0.90 0.82
rs11767869  7  22823528  T   C 0.19 0.20 0.10 0.98* 0.97 1.00
rs17310106  14  96200749  C  T 0.34 0.36 0.31 0.91 0.90 0.94
rs8096456  18  13986751  G  A 0.23 0.18 0.21 0.99* 0.80 0.91
rs2328878  6  25405664  A  G 0.50 0.45 0.47 0.84 0.98* 1.00*
rs10879888 12  73877027  A  G 0.30 0.31 0.29 0.99* 0.97 0.97
rs6811805  4  184856851  A  G 0.07 0.07 0.07 0.22 0.59 0.67
* SNPs marked were genotyped, all other SNPs were imputed as described.
Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association 
analyses including 4659 European individuals
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Supplementary Table S6: Position of the predicted promoter regions downstream of 
ADIPOQ gene region. 
                   Position 
  Size [bp]  Start    End      Distance from ADIPOQ 
Region 1  331    188.063.725  188.064.056 4.779 bp
Region 2  379    188.064.893  188.065.272  5.947 bp
Region 3  319    188.074.441  188.074.760  15.495 bp
Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association 






































































































Supplementary Figure S1: Differences between the gender-specific beta-estimates. Panel A: the quantile-quantile (QQ) plot 
of SNPs for the respective p-values shows some observed gender difference of SNP effects beyond the expected by chance. 
Expected p-values are plotted on X-axis against the observed p-values plotted on the Y-axis. P-values derived from the 200 
kB region around ADIPOQ (position ranging from 187950 to 188150 Kb) are depicted as red dots. Panel B: Manhattan plot 
showing p-values for the difference between men and women of association of each SNPs in the meta-analysis with plasma 
adiponectin levels. SNPs are plotted on the X-axis to their position on each chromosome against p-values for the gender 
difference in the SNP association with plasma adiponectin on the Y-axis (shown as –log10 P-value).
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Supplementary Figure S2: Illustration on the debate whether plasma adiponectin affects metabolic syndrome parameters or metabolic syndrome 
parameters modulate adiponectin (for explanation, see Discussion section of the main paper). The 73 SNPs refer to the SNPs selected from previous 
genome-wide association studies on metabolic syndrome parameter loci (see Supplementary Table S4).
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Clinical relevance of MetS
The first MetS definition was formulated in the 1920s, based on the observation that several 
individual CVD/T2D risk factors tend to cluster. As is the case with every syndrome, it is difficult to 
determine boundaries. Currently, four MetS definitions are commonly used. These are the definitions 
formulated by (1) the World Health Organization (WHO) (2) the European Group for the study of 
Insulin Resistance (EGSIR) (3) the National Cholesterol Education Program-Adult Panel III (NCEP 
ATPIII) and (4) the International Diabetes Federation (IDF). 
 These various definitions overlap with regard to individual risk factors and threshold values. 
However, the overlap of diagnoses between the different MetS definitions is far from absolute. For 
example, Figure 1 illustrates the overlap of MetS diagnoses using the NCEP ATP III and the IDF MetS 
definition in the ERF population (see chapter 2). The overlap between individuals diagnosed according 
to the IDF and ATP III MetS criteria was 65.4% in women and 61.5% in men. This overlap is unexpectedly 
small, since the NCEP ATP III and IDF definition use exactly the same components. However, an 
important difference between the two definitions is the obligatory minimal waist circumference in 
the IDF definition. In addition, the two definitions differ with regard to inclusion of participants using 
medication and in the slightly lower threshold values for each component in the IDF definition. This 
threshold difference also contributes to the substantial non-overlap between the IDF and NCEP ATPIII 
definition. An attempt to unify MetS criteria was recently presented by the IDF, the American Heart 
Association (AHA), National Heart, Lung and Blood institute (NHLBI), the World Heard Federation 
(WHF) and the International Atherosclerosis Society (IAS)2. The harmonizing measures involved 
that three abnormal findings out of five should qualify a person for the MetS. Furthermore, it was 
proposed to use single cutoff points 
for all components, with the exception 
of obesity for which further research 
is required. In addition, obligatory 
minimal waist circumference was 
rejected. Whether this definition will 
be uniformly adopted by the scientific 
and clinical communities remains to be 
observed.
Threshold values for the individual trait abnormalities in the various MetS definitions are lower 
than the threshold values used by clinicians as indication for treatment. For example, the fasting 
plasma glucose threshold value in the IDF MetS definition is far below the threshold defining T2D 
(Table 1). Similarly, the treatment threshold values for hypertension and hypertriglyceridemia are 
higher than the threshold values of hypertension and hypertriglyceridemia according to MetS. Thus, 
MetS diagnosis per se is not an indication for pharmaceutical intervention, but does reveal that the 
metabolic homeostasis is in misbalance.
Once specific components of the MetS have exceeded the treatment values, the general strategy 
used by clinicians is the prescription of individual drugs for each clinical outcome. T2D is treated with 
plasma glucose lowering medication like metformin, sulfonylurea derivates (SU) and thiazolidinedione 
MenWomen
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Fig. 1: Overlap in diagnosis between two commonly used MetS definitions, NCEP ATP III 
and IDF in Erasmus Rucphen Family (ERF) study. 
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(TZD). An elevated plasma level of TG is 
treated with fibrates. Hypertension is a 
complicated disorder to treat, which is also 
reflected by the great number of different 
types of medication which are available 
(diuretics, β-blockers, ACE-inhibitors, 
calcium antagonists). Although life style 
advice on weight control and physical 
activity is generally also given, it is the 
most difficult intervention for patients to 
embrace. Perhaps it should be emphasized 
more specifically that lifestyle intervention 
trials have shown that many patients can drastically reduce and even discard their medication once 
weight loss is achieved6. 
 The predictive value of diagnosing an individual as having MetS is limited8. Several studies have 
shown that multiple variable prediction analyses of the individual MetS components perform 
much better in the accuracy of prognosis for CVD and diabetes than the diagnosis MetS does9. The 
development of quantitative risk scores, like the Framingham risk scores (CVD and stroke www.
framinghamheartstudy.org), are based on such multiple variable prediction analysis. These particular 
scores are focused on dyslipidemia and include age and smoking as predictors. In contrast to MetS, 
these risk scores are used by clinicians for the indication of pharmaceutical treatment (predominantly 
statins). Since hypercholesterolemia is particularly resistant to lifestyle intervention, statin treatment 
has proven its clinical value. Thus, although the diagnosis MetS per se may not predict outcome, it 
is at the same time an opportunity for the patient to modify his or her lifestyle to prevent an ever 
increasing risk of CVD and diabetes10,8. 
 Information about the prevalence of MetS in the general population can provide information 
about public health perspectives. Such information can contribute to an alternative governmental 
policy. For example, many countries, indeed promote exercise and reduction of caloric intake to limit 
the increase of MetS prevalence. 
Scientific relevance of the MetS
The most important finding in chapter 2 was the limited heritability of MetS as compared to the 
heritability of the individual MetS components. MetS may thus not be a promising trait for finding 
novel loci in genetic research. The limited heritability of MetS is likely to be associated with the fact 
that the MetS is a heterogeneous disorder that encompasses multiple sets of different abnormalities 
with different etiologies. This is illustrated by the observation of specific clusters of components 
within the MetS. For example, low HDL-cholesterol and high TG versus low HDL-cholesterol and 
hypertension are both distinct clusters within MetS, but these two clusters may represent a different 
origin of metabolic impairment. The combination of low HDL and high TG indicates an impaired 
lipoprotein metabolism11 that may be due to increased VLDL production and increased cholesterol-
ester transfer activity (that reduces HDL). In contrast, the combination of low HDL and hypertension 
indicates an impaired vascular function12. The genetics of susceptibility for each of these two clusters 
within the MetS will be distinct. At the same time there is increasing evidence for genetic overlap 
Table 1 Threshold values individual MetS components versus 
indication clinical intervention
    IDF (2006)a  Clinical threshold  
FPG (mmol/L)   > 5.6  > 7.0
SBP (mm Hg)   ≥ 130  > 140
DBP (mm Hg)   ≥ 85  > 100
    HDL-C (mmol/L)  < 1.03  na
   HDL-C (mmol/L)  < 1.29  na
TG (mmol/L)   ≥ 1.7  > 5.0
IDF; International diabetes federation. a Europids. FPG; fasting plasma glucose, 
SBP; systolic blood pressure, DBP; diastolic blood pressure, HDL-C; HDL-
cholesterol, TG; total plasma triglycerides. na: no clear threshold available.
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between TG and HDL genes, as shown by recently reported genome wide studies, involving the lipid 
metabolism and including over 100,000 persons13. Since the MetS is likely to include many more sub 
clusters of specific components, this implies that the genetics of the entity MetS is complex. 
 Despite the fact that the MetS as a singular trait has little value in gene discovery research, it can 
still contribute to the search for novel loci involved in metabolic impairments. By recognizing the fact 
that MetS involves a collection of multiple impaired pathways, the challenge lies in the recognition 
of the clusters that define these specific pathways. MetS therefore serves as an umbrella or starting 
point for further research into sub-phenotyping or defining sub clusters within MetS. Genetic 
research of novel traits or endo-phenotypes associated with particular clusters of MetS will provide 
insight into the pathology of MetS. 
 An example of genetic correlation between all MetS components and the related trait adiponectin 
was described in chapters 7 and 8. Chapter 7 described a significant genetic overlap between 
adiponectin and plasma insulin and insulin sensitivity which was confirmed by genetic association 
using genetic variants in the adiponectin gene conform a mendelian randomization approach. 
Chapter 8 described a genome wide association analysis of plasma adiponectin. This study concluded 
that the adiponectin gene is the major gene in explaining variation in plasma adiponectin. Larger 
studies will be necessary to detect the remaining genes with only a small effect.
 It is clear that the MetS is the consequence of interaction between genes and the environment. 
Thus, it is imperative to gain insight into the role of specific genes or loci in the context of specific 
environments. Examples of the intricate relationship between MetS and environmental factors 
such as female hormone status and menopause were described in chapters 4, 6 and 7. Chapter 4 
showed that female hormonal status interacts with genetic variants in the APOC3/A5 cluster causing 
hypertriglyceridemia. In chapter 6 it was shown that postmenopausal women have a high risk of 
MetS, independently of age and body mass index. Chapter 7 concluded that although plasma 
adiponectin levels differ considerably between the genders, the genetic component explaining the 
plasma adiponectin variance is similar in men and women.
Association of MetS with other common diseases
Interestingly, MetS or particular MetS components have been associated with several common 
disorders, other than CVD and T2D. Examples of such association are the common disorders: 
obstructive sleep apnea (OSA), addiction, migraine and dementia.
 OSA is characterized by pauses in breathing during sleep due to low muscle tone or soft tissue 
around the airway, which is often caused by obesity. This form of apnea causes a disturbance in 
diurnal rhythm, which in itself may be associated with aggravation of the MetS. Thus, apnea may 
be a consequence of obesity, while at the same time aggravating the MetS by disturbing the diurnal 
rhythm. Also other sleep disturbances may lead to MetS. For example, some disturbed diurnal 
rhythm derivates are associated with shift work and, interestingly, also with the MetS14. Genome wide 
significance was reported recently with regard to plasma glucose and a SNP in the Melatonin Receptor 
1B (MTNR1B) gene. This gene is involved in the melatonin related diurnal rhythm mechanism15, which 
implicates that the genetics of diurnal rhythm is involved in the MetS.
 Compulsive overeating is an addiction that is obviously strongly associated with obesity and 
the MetS. Compulsive overeating may be caused by specific sociological and psychological factors, 
which are poorly understood. It has also been shown that alcohol dependency and obesity are well 
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correlated16. In addition, compelling similarities between compulsive overeating and drug addiction 
were recently reviewed17. Furthermore, compulsive overeating clearly has a genetic component, 
since it has recently been shown that BMI is associated with genes involved in the susceptibility to 
addiction18. 
 Migraine is a common neurological disorder that occurs in 35% of adult women and 20% of adult 
men of the general population. Migraine is characterized by attacks of severe headache and can 
be accompanied by visual distortions that are called auras. The current view is that the headache 
component of migraine has a neurovascular origin. Vasodilatation in specific brain regions indirectly 
triggers the higher order pain centers. The auras are thought to be caused by a slowly spreading 
depolarization over the cortex19. Hypertension, hyperglycemia and, in particular, obesity overlap with 
both migraine-susceptibility and MetS. A common link may be systemic inflammation, which could 
also affect the brain. This meningual inflammation may result in impaired vascular function in the 
brain and subsequent susceptibility to migraine20,21. 
 A common form of dementia is Alzheimer’s disease (AD). AD is a progressive neurological 
degenerative disease and mainly diagnosed in the elderly. AD is characterized by the deposition of 
amyloid-β plaques in the brain. Animal studies it has been shown that high fat diet promoted the 
AD-type of amyloidosis, while caloric restriction showed the opposite22. Even more intriguing is the 
role of insulin on cognitive function and AD. Not only can T2D lead secondary to dementia but there is 
also increasing evidence for increased insulin levels leading to AD23. Thus, AD may be a co-morbidity 
of the MetS caused by unfavorable dietary habits.
 The second most common form of dementia is vascular dementia caused by multiple cerebral 
infarcts. The MetS is associated with the development of premature atherosclerosis which is a common 
mechanism underlying both (multiple) cerebral and cardiovascular infarcts. Unstable atherosclerotic 
plaques might rupture which in turn, triggers the development of a clinical sequence leading to 
thrombosis. When thrombi resulting from plaque rupture are not cleared, they will be transported 
down stream, which results in the temporary or permanent obstruction of blood vessels in the heart 
or the brain. This results in an infarct that is characterized by damaged or necrotic tissue24. 
 To conclude, the application of the complex entity MetS as a single disease in genetic research for 
finding novel susceptible loci is unlikely to be successful. Despite its complexity, MetS functions as a 
common denominator in the search for connections between distinct traits.
Genetics of dyslipidemia
The MetS lipid components hypertriglyceridemia and low HDL-cholesterol are clearly associated and 
their co-occurrence has been termed metabolic dyslipidemia (ref). Thus far, this specific abnormality 
has not been recognized by the traditional classification of different types of dyslipidemia that is 
used in the lipid clinic25. The so-called Frederickson classification is presented in Table 2 and involves 
6 different types of hyperlipoproteinemia (HLP). The sub-classification of dyslipidemias or HLPs is 
relatively strict. However, it can be hypothesized that for example the hypertriglyceridemia that is 
observed in Type III, which involves an APOE2 homozygote background, and Type IV is affected by 
the same proteins and, thus by the same genetic variants26. 
An example of a shared modifier between HLP types III and IV was described in chapters 3 and 
5. The HTG patients described in chapter 3 suffer from elevated plasma triglyceride levels. The 
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clearance of TG from the plasma is primarily due to the action of lipoprotein lipase (LPL), which itself 
is subject to complex regulation by multiple cofactor and modifi er proteins. Chapter 3 described the 
association analysis of genetic variants in the apolipoprotein A5 (APOA5) which is a modifi er of LPL. 
The contribution of these genetic variants was found to be relatively small, but signifi cant. 
 Recently it has been described that APOE2 homozygosity can explain up to 30% of the genetic 
component for the expression of HLP Type III. Other genetic factors should explain a substantial 
part of the genetics of HLP Type III27. The HTG patients described in chapter 5 suffer from HLP Type 
III. We hypothesized that the genetic 
modifi ers found in chapter 3 play a role in the 
expression of HLP type III (chapter 5). The 
main fi nding of chapter 5 was that genetic 
variation in LPL and two LPL modulators, 
APOC3 and APOA5, indeed contributed to the 
expression of HLP III. 
 The hypertriglyceridemia that is part of 
the MetS defi nition is undoubtedly affected 
by the same proteins that affect the TG 
component of HLP type III and type IV (Figure 
2). The challenge lies in the recognition and 
sub-clustering of the MetS patients that 
suffer from HTG and are carriers of specifi c 
genetic variants in TG metabolism. More 
detailed phenotyping of MetS patients in 
combination with the analysis of a panel of 
candidate genes could provide the basis for 
this sub-clustering. 
Genetics and gender in MetS 
Gender plays an important role in the expression of the MetS. This is illustrated by the well 
documented observation that women, especially before menopause, are in some way protected from 
the expression of MetS or related metabolic impairments28,29,30,31,32,33. In this thesis, this is illustrated 
in chapter 2 by the signifi cant difference in prevalence of MetS between men and women in the age 
range of 30 to 50 years old. Furthermore, in chapter 6, an increased risk of MetS in post menopausal 
women was shown. Interestingly, other disorders also show gender differences with regard to 
their prevalence. For example, migraine is more prevalent in women than in men34 and obstructive 
Table 2 Frederickson classifi cation of hyperlipoproteinemia (HLP) / dyslipidemia. 
Phenotype  Involved (lipo)proteins     Total plasma cholesterol  Total plasma triglycerides 
Type I   LPL defi cient / chylomicrons   na     ↑↑↑↑
Type IIa   LDL             ↑↑    na
Type IIb   LDL / VLDL          ↑↑    ↑↑
Type III   IDL            ↑↑    ↑↑↑
Type IV   VLDL           na     ↑↑
Type V   VLDL / chylomicrons      ↑↑    ↑↑↑↑















Fig. 2: Schematic overview of a genetic overlap between HLP type IV –and type 
III with regard to the MetS and its dyslipidemic cluster. Both HLP type IV –and 
III share the triglyceride phenotype and both HLP types were associated with 
genetic variants in the LPL modifying apoAV.
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sleep apnea is more prevalent in men than in women35. In general, gender should be included as 
covariate in the epidemiological studies of MetS, MetS components or MetS related traits. However, 
chapter 4 clearly showed that the susceptibility to high TG levels is strongly influenced not only 
by oral contraceptives use but also by pregnancy. In this context, one could argue that also oral 
contraceptives use and menopause should also be included as covariates in statistical analysis, while 
pregnant women should be excluded from studies in the general population.  
 However, the inclusion of gender, menopause and oral contraceptives use as covariates in genetic 
epidemiological studies results in ignoring gender specific genetics and thus, by definition, cannot 
explain the gender specific variance of the trait. Information on gender specific genetics can only be 
obtained by stratification of the cohort with regard to gender and/or with regard to female hormonal 
parameters. 
 Although differences in prevalence of disease across sexes do not imply that the genes involved 
are different for men than for women, the role of sex specific hormones in disease, such as MetS, 
asks for sex specific gene discovery. Since gender is a standard parameter in genetic epidemiological 
studies, stratification according to gender is not an issue. However, age at menopause and the life 
time exposure to contraceptives are difficult to determine at retrospect. Unfortunately, the major 
problem with stratification is the loss of statistical power. Table 3 illustrates a hypothetical power 
estimation for applying gender stratification in a study involving MetS (http://pngu.mgh.harvard.
edu/~purcell/gpc). The stratification results in a strong reduction of the sample size in each statistical 
test and, thus, a reduction of statistical power of the study. The recessive model illustrated in Table 3 
is strongly simplified and assumes certain genotypic risks for MetS of the alleles. Table 3 illustrates, 
that in the total group, with a relatively small sample size of 1000, the power to detect a genetic variant 
(minor allele frequency 25%, genotypic risk Aa=1.3, genotypic risk AA=1.8) within P=5% is 90%. In the 
stratified group however, of which the sample size is reduced by a half, the power is only 63%. Such 
stratified design allows the detection of gender-specific and not-gender-specific associations, but 
lacks, in this example, sufficient statistical power for both associations. Therefore, in genetic analyses 
stratified for gender, it is essential that the sample size is large enough. Fortunately, the present day 
genome wide association studies do involve large sample sizes. Gender specific loci can be located on 
the X and Y chromosome, 
but, it is also possible 
that autosomal loci 
show a gender-specific 
association. 
Genetic associations in MetS
In this thesis, considerable attention is paid to the adipocyte hormone adiponectin. The association 
of plasma adiponectin levels with obesity and insulin sensitivity is well established. This has led to the 
detailed investigation of the genetic architecture of adiponectin (Figure 3). A variety of associations 
between plasma adiponectin, adiponectin SNPs, the MetS and MetS traits were described in chapters 
6, 7 and 8. 
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Table 3: Statistical power estimation of MetS, N=1000
            PhenotypeTotal Gender stratified
Case-control ratio          333 : 999     166 : 333
80% Power recessive model α=0.05 (%)  0.90        0.63
Power estimation model (80%) based on the following assumptions: Prevalence MetS: 35%; Minor allele 
frequency = 25%; genotypic risk Aa=1.3, genotypic risk AA=1.8. 
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The genetic epidemiological studies 
described in chapters 7 and 8 showed 
that the heritability of adiponectin 
is high, ranging between 55% and 
60%. Similar estimates were found, 
considering women and men together, 
but also stratified by gender. Chapter 
7 replicated findings of others with 
regard to the association of genetic 
variants in the adiponectin gene (ADIPOQ) with plasma adiponectin levels. This ADIPOQ is one of the 
genes that were successfully identified by candidate gene approach and was replicated by two sets 
GWAS. The GWAS described in chapter 8 did not reveal any other locus than ADIPOQ to be strongly 
associated with plasma adiponectin. As discussed above, the detection of more loci affecting 
plasma adiponectin, will require larger collaborative studies, using pooled results from the present 
consortia. 
 Many of the ADIPOQ associated variants described in chapter 8 were also covered by the variants 
described in chapter 7. Although the genetic part of the studies in chapters 7 and 8 involved 
association analysis of plasma adiponectin and MetS traits, they differed in design. The study in 
chapter 7 primarily questioned whether genetic variants in ADIPOQ affect MetS and related traits, 
while the study in chapter 8 questioned whether a series of loci associated with MetS traits affected 
plasma adiponectin. The meta -and replication analyses described in chapter 8 are discussed in more 
detail in the next section. 
 In chapter 7 the study of genetic overlap between adiponectin and MetS, MetS components and 
MetS related traits was described. The estimates of genetic overlap indicated that waist circumference, 
HDL-C, plasma insulin, HOMA-IR and BMI share a genetic component with plasma adiponectin. The 
association of an ADIPOQ SNP with plasma insulin and HOMA-IR was described in chapter 7 and 
partly confirmed this genetic overlap. However, in chapter 8 no associations were found between 
SNPs known to affect MetS traits and plasma adiponectin. This lack of association may be explained 
by the long chain of metabolic steps and interactions between genes affecting MetS traits, which 
indirectly affect adiponectin. Moreover, despite the large sample size, the statistical power was still 
too low to be able to detect such MetS related genetic variants involved in plasma adiponectin.
 Further research into the overlap and thus exact mechanism, between adiponectin and MetS (traits) 
is necessary. This research could focus on the association of novel endo-phenotypes of obesity and the 
reverse cholesterol pathway. However, since adiponectin has already been thoroughly investigated 
in both mechanistic directions using association analysis without much success, it seems likely that 
alternative approaches may be more successful. Such approaches could involve in vitro and in vivo 
research to determine the exact mechanism of action of adiponectin in metabolic pathways. 
Genome wide association in MetS
Genome wide association studies on a wide range of traits have been designed in accordance with 
the “Common Disease Common Variant” (CDCV) hypothesis. In this hypothesis, common genetic 
variation is usually defined as individual variants with a minor allele frequency (MAF) of more than 
5%. Study designs in association analyses of MetS and related traits have involved quantitative 
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traits such as WC4 and qualitative traits such as diabetes36. Thus far, the CDCV approach has yielded 
some 20 loci that are associated with the binary trait T2D and 15 loci that are associated with the 
quantitative trait body mass index4. Furthermore, the genes that were found to be associated with 
lipid levels, jointly, also determined which person end up in the extreme13. However, the effect sizes of 
the genetic variants in these loci were found to be small. In addition, even when the genetic variants 
of such loci were used in a combined analysis, such as a “risk allele score analysis”, generally, a very 
small increase of total effect size was observed. 
 Thus far, for most traits only a small percentage of the variance can be genetically explained3,4,5,7. 
The extent of variance of plasma adiponectin which can be explained by the SNPs in the adiponectin 
gene itself ranges from 2% explained by the strongest ADIPOQ SNP to 8% explained by 9 ADIPOQ 
associated SNPs (chapter 8). Even though this percentage of explained variance seems low, it is high 
compared to the values for other traits (Figure 
4). For example, the heritability of human 
stature is estimated to be approximately 80% 
of which only 6% can be explained by genetic 
variants in multiple genes. 
 Interestingly, the ADIPOQ SNPs, described in 
chapter 8, that were associated with plasma 
adiponectin, were not similar to the findings 
of others. Moreover, the recently reported 
association of the ARL15 gene, influencing 
plasma adiponectin levels, was not observed in 
the study described in chapter 837.
The relatively limited contribution of the CDCV GWAS approach to gaining insight in the genetics 
of complex diseases has resulted in the questioning of the relevance of the CDCV hypothesis itself. 
First, it is questioned whether common variance itself is not subject to epigenetic, gene-gene and/
or environmental interactions. However, for each of these explanations no experimental proof has 
been found, but neither these explanations can be excluded. Second, it is hypothesized that common 
disorders may not be caused by common genetic variation, but by large amounts of more or less rare 
variation present in the general population38. Finally, it is questioned whether the use of binary traits, 
which have their origin in the clinic, is the most appropriate approach in genetic epidemiology. Figure 
5 illustrates such binary stratification in “healthy” and “diseased” using a threshold value or cut off 
point in association analysis according to the “common disease common variant” (CDCV) hypothesis. 
Such threshold values are based on clinical cut off points and/or threshold values determined by 
means of epidemiological studies. However, it is unlikely that these threshold values define the exact 
biological relevant set point of impairment, which definitely compromises the statistical power of 
association analyses. 
The hypothesis that quantitative traits are determined by multiple forms of regulation is currently 
being addressed in various ways. The role of epigenetics and especially parental imprinting is 
being investigated by parent-of-origin specific association analyses. This technique addresses 
the question whether a specific genetic variant has different effects depending on the parent who 
Fig. 4: Overview of percentages of the genetic component explaining the 
variance of Adiponectin (chapter 8), glucose and Type II diabetes1, plasma 
lipid3, BMI4. Height5, schizophrenia and bipolar disorder7. 
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donated the allele39,40. Genome wide gene-gene interaction 
analyses are being performed, but are computationally 
challenging41,42,43. However, gene-gene interaction studies 
using a limited number of genetic variants are feasible. 
For example, the interaction between the two candidate 
genes cholesteryl ester transferase protein (CETP) and 
hepatic lipase (HL) was shown to be associated with HDL-
cholesterol44. 
 The second question with regard to the validity of the 
CDCV hypothesis is addressed by the common disease 
rare variant (CDRV) hypothesis38,1. Two types of rare 
variation are thought to play a role in the genetic basis of 
disease. The first type of rare genetic variants includes coding SNPs, promoter SNPs or SNPs affecting 
microRNAs. The latter two variants are involved in transcriptional regulation. The currently used 
genotyping platforms were not designed to include such rare variants but, contain as many common 
tagging SNPs as possible. The second type of variation involves rare or de novo copy number variation 
(CNV) in the form of duplications or deletions of relatively large regions of a chromosome38,1. Thus 
far, rare genetic variants covered by the first category can only be discovered using linkage analysis 
followed by sequencing. Deep sequencing will be discussed in section 9.6 below. CNVs, however, 
can be detected with the current platforms using the intensities of the genotypes of each individual. 
Large association analyses of CNV and MetS traits are, at present, still limited in number and size.
 Finally, the question with regard to the appropriateness of binary traits in GWAS is addressed 
by simply banishing binary traits. This approach is covered by the infinitesimal hypothesis38. The 
infinitesimal hypothesis poses that the use of threshold values defining the disorder precludes the 
finding of thousands of common variants with minor effect size. It was estimated that redefining 
traits like T2D towards a more continuous trait for particular genetic epidemiological studies would 
instrumentally improve the power to detect novel loci. However, it should be recognized that the 
infinitesimal approach implies that a disease like T2D is a continuum, and does not fully take into 
account the possibility that multiple distinct underlying disease mechanisms may have the same 
outcome. 
Future perspectives
Steady state versus dynamic phenotypical parameters
Thus far, GWAS have been predominantly performed on static plasma parameters such as glucose, 
lipids and hormones. Plasma levels are, however, the net result of production and clearance and 
these processes may be affected without a net effect on plasma levels. Moreover, plasma levels of for 
example glucose and lipids are generally measured after an overnight fast, whereas it may actually 
be the response to feeding (and not fasting) that is different for a specific parameter. 
 Thus, a more promising alternative to improve the discovery of novel loci in GWAS is to define 
dynamic phenotypes. For example, studies on T2D or insulin sensitivity could be more successful 
when using parameters from hyperglycemic clamp and hyperinsulinemic euglycemic clamp 
analysis45. Both clamping methods provide specific data on the sensitivity and flux with regard to 
Fig. 5: Schematic illustration of stratification towards 
healthy and diseased using a threshold value or cut off 
point in binary association analysis.
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glucose metabolism. Using both these specific insulin sensitivity parameters would definitely reduce 
the heterogeneity in GWAS with regard to traits like plasma glucose or T2D. The reduction of the 
heterogeneity of the fasting plasma glucose trait has recently been described46. This report described 
the inclusion of HOMA-B, which is a measure for pancreatic β-cell function, and HOMA-IR, which is a 
measure for peripheral insulin sensitivity, in GWA and meta-analysis. The levels of insulin sensitivity 
and β-cell function both affect plasma glucose levels but, through distinct biological pathways. The 
authors clearly showed that the inclusion of the heterogeneity lowering traits HOMA-B and HOMA-IR 
indeed contributed to the detection of 9 novel loci which were not detected by GWAS using fasting 
glucose. The determination of dynamic parameters other than HOMA-B and HOMA-IR is, however 
expensive, time-consuming and often more burdening for the participants.
 Thus, the challenge for the generation of dynamic parameters lies in the development of novel less 
time consuming and less expensive methods.
Sex chromosomal and mitochondrial DNA
The currently reported GWAS have largely ignored the X and Y chromosomes in their analyses. In 
addition, the mitochondrial DNA is also absent in virtually all GWAS reported over the last years. 
Since the MetS and several of its individual components show large differences in prevalence or 
level between genders, the absence of both sex chromosomes is a missed opportunity to discover 
novel loci. Mitochondria play a key role in energy metabolism and thus the inclusion of mitochondrial 
genetic variants in GWA could contribute to the discovery of new loci. The absence of both the sex 
chromosomes and mitochondrial variants in present GWAS is, however, not without reason. 
 For the X chromosome, one reason is that recombination occurs in females and only partly in 
males. This latter partial recombination involves the pseudo-autosomal regions (PARs) and is 
described below. All genotyping platforms cover the X chromosome well. Nevertheless, inclusion of 
the X chromosome in GWAS is not yet standard. 
 For the Y chromosome, one reason is that recombination can only occur at the PARs. Thus, with 
the exception of these PARs, the main part of this chromosome shows very strong LD. The region 
PAR1 is localized on the short arm of the X or Y chromosome and the PAR2 region is located on the 
long arm of X or Y chromosome. To date, 24 genes have been reported in the PAR1 region and only 
5 genes have been reported to be located in the PAR2 region. The limited number of genes and the 
fact that the remaining part of the Y chromosome is in strong LD, might explain why companies like 
Affymetrix and Illumina have virtually ignored the Y chromosome in their SNP array platforms. The 
Illumina arrays in particular, only included none or a small amount of genetic PAR variation on their 
arrays. It should be noted, though, that the most recently released arrays of both companies show an 
improved PAR and Y chromosome coverage. Nevertheless, the GWAS which are now or have recently 
been reported are, in many cases, based on the older SNP array versions47,48. 
 Similar to the Y chromosomes, with the exception of the PARs, the mitochondrial DNA also shows 
no recombination. Mitochondria are passed down maternally, completely unchanged except for 
occasional spontaneous mutations. Thus, when mutations occur, they are in complete linkage with 
all other present variants in that mitochondrial DNA. Therefore, mitochondrial haplotypes are an 
important resource for studying the maternal history of populations49,50. In the course of evolution, 
the mitochondria have donated several genes to the autosomes. This group of mitochondrial genes is 
thus covered by all genotyping platforms. However, the formerly used Illumina and Affymetrix arrays 
General Discussion & Future Perspectives
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did not properly cover the mitochondria themselves. In particular Illumina 300K did not include any 
mitochondrial variants. To conclude, the limited coverage or absence of the X, Y and mitochondrial 
genetic variation on the former versions of, in particular the Illumina, SNP arrays is a missed 
opportunity to discover novel loci associated with gender specific traits like MetS or some of its 
components and related traits. Re-genotyping of the whole genome using more recently developed 
arrays is not cost-effective, because, it would involve mainly redundant genotypic information. 
Therefore, genetic information on the PARS, Y chromosome and mitochondria should rather be 
obtained by genotyping on other platforms, such as the Sequenom using MALDITOF technology 
(http://www.sequenom.com)50 or sequencing. 
 
Common Disease, Common Variants vs. Common Disease, Rare Variants
Since the CDRV hypothesis requires the identification of rare mutations in many individuals, this calls 
for a totally different genotyping technique than the one used in the CDCV hypothesis, namely large 
scale DNA sequencing. Ideally, the whole genome sequence of each individual of a particular cohort 
is determined.
 Over the last decades, the sequencing technique based on the DNA chain terminating method, 
developed by Frederick Sanger has been most extensively used51. However, this method is not suitable 
for genome wide sequencing of whole cohorts. Recently, several companies have developed novel 
methods for large scale and high throughput sequencing, which is illustrated in Table 452. These novel 
sequencing techniques are called second or next generation sequencing. In theory, these techniques 
are capable of determining whole genome sequences with a high throughput. 
 However, there are problems with regard to cost, storage and analysis of next generation 
sequencing data, which makes the implementation of these new techniques more challenging. 
First, the next generation sequencing techniques are not flawless in nucleotide calling. Therefore, 
sequences have to be retyped several times, which means that the analysis will consume more time 
and, importantly, increase the expenses. In addition, the coverage -or reading length- of all next 
generation sequencing techniques is limited. Furthermore, sequencing whole genomes of each 
individual in a particular cohort will generate an enormous amount of data. Even for a small cohort, 
analyzing such an amount of data is a challenging task. More importantly, genome wide association 
scans using rare variants obtained from whole genome sequence analysis will result in a tremendous 
increase in the number of variables to test. The normal controls, computational methods and 
technical power necessary for such complex analyses are simply not yet available and this is not 
likely to change in the near future. To date, only genome wide sequencing of coding regions, called 
exome sequencing, can be performed and implemented in association analysis. Thus, on the short 
term, the proper testing of the CDRV hypothesis on a large and truly genome wide scale requires 
novel approaches that remain to be developed. 
 Thus far, a limited test of the CDRV hypothesis has been performed by analyzing the coding regions 
of candidate genes, which were identified using CDCV techniques. This approach has yielded some 
interesting results. For example, it was recently shown that rare mutations in two novel T2D CDCV 
associated loci, the KCNJ11 and ABCG8 genes, were associated with an increased risk of T2D53. These 
mutations were shown to be in strong linkage disequilibrium with the common variants formerly 
discovered in a genome wide association of T2D. In addition, this report proposed a clear biological 
mechanism which may lead to the expression of T2D.  However, for other disease associated loci, 
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rare causal variants might be located in regions far apart from their coding region or even on distinct 
chromosomes. Thus, whether this limited implementation of next generation sequencing is a fruitful 
approach in general is not clear yet.
Application of bioinformatics and systems biology
The technology to measure a large number of biological components with very high throughput 
is covered by the term “omics” and has boomed over the past decade. The current SNP and DNA 
sequence assays technologies are examples of such omic approach and is covered by the term 
“genomics”. More or less simultaneously, technologies to perform genome-wide analyses of mRNA 
levels, proteins and metabolites have been developed. Obviously, the handling, storage and analyses 
of these often very large data sets require biostatistics and bioinformatics expertise. 
 At present, the tools to analyze single data sets, for example, sets of SNP or gene-expression data, 
are well developed. Moreover, SNP and gene expression data sets can be relatively easily combined, 
because they share a common reference; genomic position54. A polymorphism in a gene associated 
with its own expression is called a cis association, while a polymorphism that explains an altered 
mRNA expression of a distinct chromosomal region is called a trans association. This method in an 
extended form, using full omic data sets, is called eQTL analysis55,56,57. Recently, several tissue specific 
eQTL data sets have been made publicly available. This public availability makes the eQTL analysis a 
feasible approach, since the tissue specific determination of expression levels in the currently used 
epidemiological study cohorts is unrealistic (http://eqtl.uchicago.edu).
 The major challenge in the combination of different “omics” data sets lies in the data sets where 
the common reference (i.e. the gene) is more difficult to define. For example, metabolites are 
notoriously difficult to assign to a single specific enzyme or gene and combining metabolomics and 
transcriptomics therefore requires an alternative approach. A suitable approach could be the mapping 
of the up or down regulated genes and metabolites to a common literature-based concept database58. 
Finding the overlap between the data sets then requires finding the overlap in the common reference 
concepts. No matter what approaches are taken to combine data sets, an essential requirement for 
further development of this field, is the availability of data sets that are publicly available. 
 It should also be recognized that some of the “omic” technologies may not be developed far enough 
for implementation in bioinformatics and biostatistics approaches. For example, a reproducible and 
qualitative “protein fingerprint” method59,60,61 is currently in development, while others, such as 
epigenomics and metabolomics approaches, are likely to become available at a much later stage. 
General Discussion & Future Perspectives
Table 4: Overview of 2nd (next) generation sequence technology 
Company      Technique        Maximum length / strain  Maximum Strains / run
Illumina - SOLEXA     Array based -       100 bp   8 * 15.106
       parallel sequencing 
Applied Biosystems -SOLiD Array / bead based -   100 bp   16 * 15.106
       Multiplex polony 
       sequencing 
Roche - 454      Single bead / well based - 500 bp   16 * 5.105
       pyro sequencing  
Helicos       Array based -       35 bp   50 * 15.106
Single molecule sequencing  Single molecule 
       incorporation 
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It should be clear that, similar to the full scale testing of the CDRV hypothesis, combinatorial 
genomics analysis is a challenge for the computational power of the currently used bioinformatics 
platforms62,63.
The bioinformatics toolbox has been extended to so-called pathway analyses which determine 
whether specific biological components that belong to a pathway are enriched under the one 
condition rather than under the other64,65. The origins of these pathways are found in often manually 
cured databases (KEGG: www.genome.jp/kegg/pathway.html). The current pathway analyses 
generally make calls based on the expected/observed number of components of a specific pathway 
and do not take into account that some steps in a pathway may be rate limiting. The novel field of 
mathematical Systems Biology aims to quantify the role of components in pathways. This requires 
the development and analysis of mathematical models that describe pathways and, eventually, 
the biological systems in cells, organs and organisms. The ultimate goal would be an analysis that 
combines all omic approaches, using genome-wide mathematical models, in order to describe the 
patho-physiology of the system under study.
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Summary
The primary causes of death among both males and females in developed countries with a western 
lifestyle are vascular diseases including CVD and stroke. In the last decade, approximately 30% of 
all deaths in the Netherlands were due to stroke, CVD or related vascular diseases. Metabolic risk 
factors for CVD, stroke and T2D are obesity, hyperglycemia, dyslipidemia and hypertension. These risk 
factors often cluster together. The metabolic syndrome (MetS) takes into account such clustering. 
Chapter 1 introduces the MetS definition and its individual components and their corresponding 
morbidities, prevalence and suggested biological mechanisms. In addition, several feasible genetic 
epidemiological study approaches for finding novel loci for the MetS or related traits are described.
The main question in the study described in chapter 2 was whether MetS is a promising feasible 
phenotype in itself or that its individual components are more promising phenotypes to find novel loci 
in future genetic association studies. To answer this question, we used the Erasmus Rucphen Family 
(ERF) study. The ERF population is a genetically isolated population and involves large interrelated 
families. The latter made it possible to obtain extended pedigree information about this population. 
The power of such pedigree information is that the heritability of complex diseases, like MetS, can 
be easily estimated without genotyping. In chapter 2 a study of heritability estimates of MetS and 
of the individual MetS components is described. This study found that the individual components of 
MetS, in particular waist circumference and HDL-cholesterol, are markedly more heritable than MetS 
itself. It was therefore concluded that the individual components of MetS are more promising with 
regard to finding novel loci.
The studies described in chapters 3 and 4 were focused on the genetics of plasma triglyceride. 
Hypertriglyceridemia (HTG) is a component of the MetS. In general, HTG involves an impairment 
of VLDL and/or chylomicron production or clearance. Lipoprotein lipase (LPL) is involved in the 
clearance of VLDL and chylomicrons. The apoAV is thought to be a modulator of LPL and is present on 
chylomicrons and VLDL. ApoAV is thought to have a stimulatory effect on the clearance of TG by LPL. 
The main question in the study described in Chapter 3 was whether genetic variants in the APOA5 
gene contributed to the HTG phenotype. This study concluded that two genetic variants located in 
the APOA5 gene, S19W and SNP3 did indeed contribute to the expression of HTG. 
In the survey of the genetic association between APOA5 variants  and HTG, described in chapter 3, we 
found one individual who lacked apoAV. Interestingly, during an extended period of time, plasma TG 
levels in this female individual showed to be highly variable. In the study described in Chapter 4, we 
aimed to determine the genetic variant causing this particular apoAV deficiency and to elucidate the 
interrelationship between apoAV, female hormones and plasma TG. From this study it was concluded 
that the apoAV deficiency involved a novel discovered splice variant which resulted in impaired splicing 
causing the complete absence of the apoAV protein on chylomicrons and VLDL. In addition, it was 
shown that pregnancy or oral contraceptive in combination with this apoAV deficiency dramatically 
increased the plasma TG levels in this patient, whereas without pregnancy or oral contraceptive, diet 
intervention resulted in a normalized plasma TG level. 
The study described in chapter 5 involved a genetic association study  of HLP type III. This metabolic 
disease is characterized by elevated levels of both TG and (total) cholesterol, caused by inefficient 
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clearance of the LDL, VLDL and chylomicrons by the liver. This inefficient clearance is caused by 
the diminished binding capacity of the apoE2 variant to the LRP receptor. Patients suffering from 
HLP type III are homozygote carriers of the APOE2 genetic variant. However, the penetrance of 
this homozygosity to expression of HLP type III is low, which indicates that multiple genetic 
factors contribute to the expression of HLP type III. In this study we aimed to determine whether 
genetic variants in the Hepatic lipase (HL), lipoprotein lipase (LPL), apolipoprotein C3 (APOC3) and 
apolipoprotein A5 (APOA5) genes contribute to the manifestation of hyperlipidemia type III. HL and 
LPL are both involved in the clearance of TG from VLDL and chylomicrons to the liver or periphery. 
ApoCIII and apoAV are thought to be modulators of LPL. Genotypic -and allelic frequency differences 
as well as odds ratios between HLP type III patients and normolipidemic homozygote carriers of 
apoE2 were determined. The study concluded that genetic variation in the LPL, apoC3 and apoA5 
indeed contributed to the expression of HLP type III. 
Adiponectin is a hormone which is secreted by adipose tissue. It has been shown to be strongly 
associated with obesity and T2D and has been suggested as a biomarker for the MetS. MetS depends 
on factors like lifestyle, age and gender or related factors. The study described in chapter 6 was 
particularly aimed at elucidating the effect of menopause and low plasma adiponectin levels and the 
risk for MetS. In addition, we investigated whether plasma adiponectin shows a better discriminative 
accuracy for the presence of MetS than traits more easily obtained, such as BMI and age. This study 
concluded that, in particular, low levels of plasma adiponectin in postmenopausal women are a 
risk for MetS, independently of age and BMI. However, the discriminating accuracy of adiponectin 
for the presence of MetS is exceeded by BMI in men and pre -and postmenopausal women. These 
conclusions imply that the clinical value of adiponectin is limited.
The mechanisms and genetics underlying the correlations between adiponectin and MetS, obesity 
and T2D and related traits have not been explained yet. The study described in chapter 7 aimed to 
determine the genetic overlap between plasma adiponectin and MetS, its individual components and 
MetS related traits like BMI insulin resistance (HOMA-IR) and systemic inflammation. Furthermore, 
we aimed to validate such genetic overlap with regard to the adiponectin gene (ADIPOQ). In this 
study we used data from the ERF study. The genetic correlation was determined using bivariate 
heritability analyses and the genetic association study was performed with 10 ADIPOQ tagging 
variants. This study concluded that adiponectin shared a genetic component with HDL-cholesterol 
and plasma insulin. Furthermore, it was concluded that two ADIPOQ variants were independently 
associated with plasma adiponectin and that one of these variants was associated independently 
of plasma adiponectin with plasma insulin and HOMA-IR. The latter conclusion suggests there is 
indeed a genetic overlap between adiponectin and insulin and HOMA-IR with regard to the ADIPOQ 
gene itself.
Chapter 8 describes the search for novel loci associated with plasma adiponectin using genome-wide 
association (GWA) in the ERF cohort. These ERF results were used in a meta-analysis with two other 
cohorts: (1)  a German cohort - Kooperative Gesundsheidsforshung in der Region Ausburg (KORA) 
and (2) an Italian cohort - Microisolates in South Tyrol Study (MICROS). Since plasma adiponectin 
levels show large differences between the genders, the analyses were performed in a combined set 
and in women and men separately. Meta-analysis results were submitted for replication to 7 other 
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large cohorts. The study described in chapter 8 concluded that variants in ADIPOQ showed a highly 
significant association with plasma adiponectin in both the combined and the two gender stratified 
analyses. Other hits in the meta-analyses were found not to be genome wide significant, but were 
nevertheless submitted for replication (threshold P < 10-6). The ADIPOQ variants were found to explain 
a relative large percentage of the adiponectin variance.
Chapter 9 starts with a discussion of the relevance of MetS in a clinical setting, a social context and in 
research. Secondly, the chapters in this thesis are reviewed, both individually and in relation to each 
other. Thirdly, limitations of study methods and designs are discussed, in particular the study design 
concerning the common variants common disease (CVCD) hypothesis. Finally, suggestions are made 
for the improvement of existing methods and for alternative approaches for future analyses towards 
unraveling the genetic and environmental factors that play a role in metabolic risk factors. 
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Samenvatting
Vasculaire ziekten vormen de primaire doodsoorzaak bij mannen en vrouwen in ontwikkelde landen 
met een Westerse leefstijl. In de afgelopen tien jaar werden 30% van alle sterfgevallen veroorzaakt 
door beroerten, CVD of andere gerelateerde vasculaire ziekten. Metabole risicofactoren voor CVD, 
beroerte en TD2 zijn obesitas, hyperglycemia, dylipidemia en hypertensie. Deze risicofactoren zijn 
vaak geclusterd. De definitie van het Metabool Syndroom (MetS) is gebaseerd op zulke clustering. 
Hoofdstuk 1 introduceert de definitie van MetS en de individuele componenten en hun respectievelijke 
sterftecijfers, prevalentie en veronderstelde onderliggende biologische mechanismen. Vervolgens 
worden verschillende haalbare genetisch-epidemiologische onderzoeksbenaderingen om nieuwe 
loci voor Mets-gerelateerde eigenschappen te vinden beschreven.
De belangrijkste vraag in het onderzoek dat in hoofdstuk 2 wordt beschreven was of MetS op zichzelf 
een veelbelovend fenotype is of dat de afzonderlijke componenten van MetS geschikter zijn als 
fenotypen om nieuwe loci te vinden in toekomstige genetische associatiestudies. Om deze vraag te 
beantwoorden is gebruik gemaakt van het Erasmus Rucphen Familie (ERF) onderzoek. Deze ERF-
populatie is een genetisch geïsoleerde populatie met veel grote, nauw met elkaar verbonden families. 
Dit laatste gegeven maakte het mogelijk om uitgebreide stamboominformatie over deze populatie 
te verkrijgen. De kracht van dergelijke uitgebreide genealogische informatie is dat de erfelijkheid 
van complexe ziekten, zoals MetS, gemakkelijk kan worden geschat zonder dat daar genotypering 
voor nodig is. In het in hoofdstuk 2 beschreven onderzoek werd de erfelijkheid van zowel Mets 
als van de afzonderlijke componenten van Mets bekeken. Uit dit onderzoek kwam naar voren dat 
de erfelijkheid  van de afzonderlijke componenten van MetS, in het bijzonder middelomvang en 
HDL-cholesterol, aanzienlijk groter is dan die van MetS zelf. Hieruit werd geconcludeerd dat de 
afzonderlijke componenten van MetS veelbelovend zijn met betrekking tot Mets voor het vinden van 
nieuwe loci.
De onderzoeken die beschreven worden in hoofdstukken 3 en 4 waren beide gericht op de genetica 
van plasma triglyceride. Hypertriglyceridemia (HTG) is een afzonderlijke Mets component  In 
het algemeen wordt HTG gekenmerkt door een defect in de productie of de klaring van VLDL en/
of chylomicronen. Lipoproteine lipase (LPL) speelt een belangrijke rol in de klaring van VLDL en 
chylomicronen. Chylomicronen en VLDL bevatten beide apoAV, een proteïne dat wordt gezien als een 
modulator van LPL. Verondersteld wordt dat apoAV een stimulerend effect heeft op de klaring van TG 
door LPL. De hoofdvraag in het onderzoek dat beschreven wordt in hoofdstuk 3 was of genetische 
varianten in het APOA5-gen bijdroegen aan het HTG fenotype. De conclusie van dit onderzoek was 
dat twee genetische varianten in het APOA5 gen, te weten S19W en SNP3, inderdaad bijdragen aan 
de expressie van HTG.
In het onderzoek naar de genetische associatie tussen APOA5 varianten en HTG, zoals beschreven 
in hoofdstuk 3, werd 1 individu gevonden bij wie apoAV volledig ontbrak. Een interessant resultaat 
was dat, over een langere periode gemeten, de plasma TG niveaus van deze vrouw sterk varieerden. 
Het in hoofdstuk 4 beschreven onderzoek was erop gericht om vast te stellen welke genetische 
variant deze specifieke apoAV deficiëntie veroorzaakte en om het veronderstelde verband tussen 
apoAV, vrouwelijke hormonen en plasma TG te verhelderen. Uit dit onderzoek werd geconcludeerd 
dat de apoAV deficiëntie werd veroorzaakt door een nieuw ontdekte splice variant, resulterend in 
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gemankeerd mRNA waardoor het apoAV proteïne op chylomicronen en VLDL volledig ontbreekt. 
Bovendien werd aangetoond dat deze apoAV deficiëntie in combinatie met zwangerschap of gebruik 
van een oraal anticonceptiemiddel een dramatische toename in de plasma TG niveaus bij deze patiënt 
tot gevolg had, terwijl zonder zwangerschap of oraal anticonceptiemiddel aanpassingen in het dieet 
leidden tot een genormaliseerd plasma TG niveau.
Het onderzoek dat in hoofdstuk 5 beschreven wordt betrof een genetische associatiestudie van 
hyperlipoproteinemia type III (HLP type III). Deze metabole ziekte wordt gekenmerkt door verhoogde 
niveaus van zowel TG als (totaal) cholesterol welke veroorzaakt worden door de inefficiënte klaring 
door de lever van LDL, VLDL en chylomicronen. Deze inefficiënte klaring wordt veroorzaakt door een 
verminderde bindingscapaciteit van de apoE2 variant met de LRP receptor. Patiënten die lijden aan 
HLP type III zijn homozygote dragers van de APOE2 genetische variant. Echter, de penetrantie van 
deze homozygositeit naar expressie van HLP type III is laag, wat erop duidt dat meerdere genetische 
factoren bijdragen aan de expressie van HLP type III. In dit onderzoek werd getracht vast te stellen 
of de genetische varianten in de Hepatische lipase (HL), lipoproteine lipase (LPL), apolipoproteine C3 
(APOC3) en apolipoproteine A5 (APOA5) bijdragen aan de manifestatie van HLP type III. HL en PL zijn 
beide betrokken bij de klaring van TG uit VLDL en chylomicronen naar de lever of periferie. ApoCIII 
en apoAV worden beschouwd als modulators van LPL. Er werden zowel genotypische- en allelische 
frequentieverschillen als het genetisch risico tussen HLP type III patiënten en normolipidemische 
homozygote dragers van apoE2  vastgesteld. De conclusie van het onderzoek was dat genetische 
variatie in LPL, APOC3 en APOA5 inderdaad bijdraagt aan de expressie van HP type III. 
Adiponectine is een hormoon dat wordt uitgescheiden door vetweefsel. 
Adiponectine is sterk geassocieerd met obesitas and TD2 en is geopperd als een biomarker voor het 
MetS. MetS is afhankelijk van factoren als leefstijl, leeftijd, gender en gerelateerde factoren. Het 
onderzoek dat in hoofdstuk 6 wordt beschreven is vooral gericht op het ophelderen van het effect 
van de menopauze en lage adiponectine niveaus en het risico voor MetS. Daarnaast werd onderzocht 
of plasma adiponectine nauwkeuriger discrimineert voor de aanwezigheid van MetS dan eenvoudiger 
te meten kenmerken, zoals BMI en leeftijd. Dit onderzoek concludeerde dat vooral lage niveaus van 
plasma adiponectine in postmenopauzale vrouwen een risico op MetS vormen, onafhankelijk van 
leeftijd of BMI. Echter, de discriminerende nauwkeurigheid van adiponectine voor de aanwezigheid 
van MetS wordt overtroffen door BMI bij mannen en pre- en postmenopauzale vrouwen. Deze 
conclusies impliceren dat de klinische waarde van adiponectine beperkt is.
De onderliggende mechanismen en genetica van de correlaties tussen adiponectine en MetS, 
obesitas en TD2 en verwante kenmerken zijn nog niet verklaard. Het doel van het in hoofdstuk 
7 beschreven onderzoek was om de genetische overlap tussen plasma adiponectine en MetS, 
de afzonderlijke componenten van Mets en Mets-gerelateerde kenmerken zoals BMI, insuline 
resistentie (HOMA-IR) en systemische inflammatie vast te stellen. Daarnaast werd getracht een 
dergelijke genetische overlap te valideren voor wat betreft het adiponectine gen (ADIPOQ). Voor 
dit onderzoek zijn gegevens uit de ERF-studie gebruikt. De genetische correlatie werd bepaald door 
middel van bivariate erfelijkheidsanalyses en de genetische associatiestudie werd uitgevoerd met 
ADIPOQ ”tagging” varianten. De conclusie van dit onderzoek was dat adiponectine een genetische 
component deelt met HDL-cholesterol en plasma insuline. Bovendien bleek dat twee ADIPOQ 
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varianten onafhankelijk geassocieerd zijn met plasma adiponectine en dat één van deze varianten 
onafhankelijk geassocieerd is met plasma insuline en HOMA-IR. Deze laatste conclusie suggereert 
dat er inderdaad een genetische overlap bestaat tussen adiponectine en insuline en HOMA-IR in 
relatie tot het ADIPOQ gen zelf.      
In hoofdstuk 8 wordt de zoektocht beschreven naar nieuwe loci die geassocieerd zijn met plasma 
adiponectine middels “genome-wide association” (GWA) binnen het ERF-cohort. Deze resultaten 
werden gebruikt in een meta-analyse met twee andere cohorten: (1) een Duits cohort – Kooperative 
Gesundheidsforshung in der region Ausburg (KORA) en (2) een Italiaans cohort – Microisolates in 
South Tyrol Study (MICROS). Aangezien plasma adiponectine niveaus grote verschillen laten zien 
tussen de genders, werden de analyses zowel in een gecombineerde set als afzonderlijk in mannen 
en vrouwen uitgevoerd. De meta-analyse resultaten zijn vervolgens voor replicatie aangeboden 
aan 7 andere grote cohorten. Uit het in hoofdstuk 8 beschreven onderzoek werd geconcludeerd dat 
bepaalde varianten in ADIPOQ zeer significant waren geassocieerd met plasma adiponectine, zowel 
in de gecombineerde als in de twee gender gestratificeerde analyses. Andere hits in de meta-analyses 
bleken niet genoombreed significant te zijn, maar werden desondanks wel ter replicatie (drempel P 
< 10-6) aangeboden. De ADIPOQ varianten bleken een relatief groot percentage van de adiponectine 
variantie te verklaren.  
Hoofdstuk 9 begint met een discussie over de relevantie van het MetS in de context van de kliniek, 
maatschappelijk en in wetenschappelijk onderzoek . Vervolgens worden alle voorgaande hoofdstukken 
in dit proefschrift zowel afzonderlijk als in relatie tot elkaar in ogenschouw genomen. Daarna worden 
de beperkingen ten aanzien van onderzoeksmethoden en onderzoeksontwerp besproken, in het 
bijzonder voor het onderzoeksontwerp met betrekking tot de ”common variants common disease” 
(CVCD) hypothese. Ten slotte worden suggesties gedaan voor verbetering van bestaande methoden 
en ook voor alternatieve benaderingen van toekomstige analyses gericht op het ontrafelen van de 
genetische en omgevingsfactoren die een rol spelen in metabole risicofactoren. 
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AUC Area Under the receiver operating characteristic Curve
BC Body Composition
BMI Body Mass Index
CDCV Common Disease Common Variant (hypothesis)
CDRV Common Disease Rare Variant (hypothesis)
CRP C-Reactive Protein
CVA Cerebral Vascular Accident
CVD Cardio Vascular Disease
DBP Diastolic Blood Pressure
DNA DeoxyriboNucleic Acid
ERF Erasmus Rucphen Family (study)
FPG Fasting Plasma Glucose
GWA Genome Wide Association
h2 heritability
HDL-C High Density Lipoprotein Cholesterol
HL Hepatic Lipase
HLP HyperLipoProteinemia
HMW High Molecular Weight




LDL Low Density Lipoprotein
LPL LipoProtein Lipase
LUMC Leiden University Medical Center
MAF Minor Allele Frequency
MetS Metabolic Syndrome
mRNA messenger RiboNucleic Acid
OR Odds Ratio
S Sibship effect
SBP Systolic Blood Pressure
SNP Single Nucleotide Polymorphism
STR Short Tandem Repeat
T2D Type-2 Diabetes mellitus
TG Triglyceride
VLDL Very Low Density Lipoprotein
WC Waist Circumference
_E Environmental correlation estimate
_G Genetic correlation estimate
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